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1 Dendritic cells
Thirty years after their modern description [1], dendritic cells (DCs) have emerged 
as the principal cell type involved in naïve T cell activation and differentiation, 
effectively representing the controlling arm of the immune system [2]. DCs are 
bone marrow-derived leukocytes that are sparsely distributed in peripheral tis-
sues. The appreciation for the central role of this cell type in initiation and direc-
tion of adaptive immune responses was unraveled by some key discoveries in DC 
biology. First, it was recognized that DCs roughly exist in two states; a resting 
state in the peripheral tissues, that continuously samples the environment for 
pathogens, and an activated cell state in the draining lymph nodes (LNs), optimal 
to activate lymphocytes. Once DCs are activated they downregulate their antigen 
uptake and processing machinery, thereby ‘fixing’ the antigen repertoire from 
the pathogen on their cell surface, which in turn ensures antigen presentation in 
the lymph nodes that faithfully represents the antigen repertoire derived from 
the site of antigen acquisition.
A major breakthrough was the identification of toll-like receptors (TLRs) as a 
major group of pattern recognition receptors (PRRs) which are responsible for 
pathogen recognition by DCs [3, 4], which will be discussed in more detail be-
low.
Secondly, with the realization of the central role of DCs in regulation of the adap-
tive immune responses came the insight that DCs are also an important element 
in the maintenance of peripheral tolerance. It is currently believed that presenta-
tion of self-antigen by resting DCs may foster anergy or apoptosis of autoreactive 
T cells. In addition, these immature DCs may also promote the expansion and/or 
functionality of regulatory T cells [5-7]. 
Third, it should be mentioned that these advances in DC biology may not have 
been possible without the simultaneous development of techniques to generate 
large amounts of these otherwise rare cells [8-11].
1.1 DC subsets
Since the first description of DCs by Steinman and colleagues [1], a bewildering 
number of DC subsets have been described in humans as well as mouse [12, 13]. 
Several factors have added to the complexity of this field. First, considerable het-
erogeneity among different studies exist in the antibody panels used to charac-
terize DC subsets, especially in the mouse where the ready availability of tissues 
and reagents has led to numerous studies into this subject. In humans, the lack 
of expression of CD8α by any human DC subset makes comparison with mouse 
DC subsets difficult [12]. Furthermore, it is still a matter of debate whether the 
different phenotypes described represent different activation states or that the 
distinguishable DCs subsets represent separate developmental lineages [14-18].
1.1.1 Mature murine DC subsets
Despite the use of different antibody panels, several common markers have been 
used in most studies so far, enabling some comparison between the described 
subsets and has led to the identification of six distinct subsets[12].
Five subsets express high levels of CD11c, three of which are present in the 
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spleen and can be subdivided into CD8α+CD4-CD11b-CD205+ lymphoid DCs, 
CD8α-CD4+CD11b+CD205- myeloid DCs and another subset of myeloid DCs which 
is CD8α-CD4-CD11b+CD205- (also referred to as tissue interstitial DC). Two addi-
tional populations are present in lymph nodes. A CD8α-CD4-CD11b+ subset that 
has upregulated CD205, believed to be the mature form of the tissue interstitial 
DC, and only in skin-draining LNs, CD8αlowCD4lowCD11b+ DCs expressing langer-
in, which are believed to be the mature form of Langerhans cells [19, 20].
The DC subset expressing low to intermediate levels of CD11c and MHC class II 
and in addition stains positive for Ly-6G/C (GR-1) and B220 is called the plasma-
cytoid DC and was only recently describecd in the mouse [21].
Finally, several in vitro culture methods have been described to generate DCs 
from murine bone marrow, using GM-CSF and/or Flt-3L as the major differentia-
tion stimuli [8, 9, 22]. 
1.1.2 Mature human DCs subsets
Compared to mouse DC studies, relatively few studies have been performed on 
human DCs freshly isolated from tissues. Therefore, most of the data acquired 
about human DC subsets is derived from several in vitro culture systems [12]. 
Four different mature subsets have been identified so far. Analogous to the mu-
rine homologue, langerhans DC have been described, expressing in addition to 
CD11c also langerin, E-cadherin and contain Birbeck granules in their cytoplasm. 
Interstitial, or ‘dermal’ DC, are a second lineage which are CD11c+, and can be 
further identified by CD68 and the coagulation factor XIIIa. Blood monocytes are 
the  precursor cells for monocyte-derived DCs, termed DC1, and are generated 
during a six-day culture period  in the presence of GM-CSF and IL-4 [11]. These 
cells are positive for CD11c and upon maturation induced by proinflammatory 
cytokines such as TNF-α or microbial products (e.g. LPS), acquire a CD14-, CD83+, 
CD86+, MHCIIhi phenotype. The final subset described in humans is the plasma-
cytoid subset, termed pDC2, which is characterized by low levels of CD11c ex-
pression and the only DC subset to known to express IL-3Rα (CD123) [23, 24]. 
Recently, antibodies against certain proteins present on the cell surface of DCs 
subsets have been raised, with BDCA-2 appearing to be highly specific for plas-
macytoid DCs [25].
1.2 DC activation, migration and T cell activation
In all nonlymphoid tissues, DCs are in a immature state (alternatively named 
‘resting’ or quiescent) and continuously sample the environment via three major 
mechanisms; receptor-mediated endocytosis, macropinocytosis and phagocyto-
sis. Receptor-mediated uptake is accomplished via a myriad of receptors, includ-
ing C-type lectin receptors (such as langerin, DC-SIGN, dectin, DEC-205) or the 
mannose receptor for glycoproteins, and Fc-receptors for  immune complexes 
[26, 27]. 
A key aspect of DCs is their migration towards draining lymph nodes upon activa-
tion by pathogen derived signals. This activation process compromises a highly 
coordinate series of steps, including upregulation of costimulatory molecules, a 
switch in chemokine receptor expression, secretion of cytokines and chemokines 
and increased expression of antigen-loaded MHC molecules on the cell surface. 
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The importance of these innate immune system signals for directing adaptive 
immunity was first proposed by Charles Janeway, in an article proposing a hy-
pothesis for the need to use adjuvants to get effective immune responses [28]. 
It was subsequently shown that Toll-like receptors (TLRs) were a major group 
of receptors responsible for sensing pathogens (in the form of pathogen associ-
ated molecular patterns (PAMPs)) in the environment and initiating the adaptive 
immune response [29, 30]. The TLR family currently comprises of 11 members. 
TLR 1, 2, 4, 5 and 6 are expressed on the cell surface and seem to specialize in 
recognizing products unique to microbes.  TLR 3, 7, 8 and 9 detect different 
forms of nucleic acids [4, 31]. In the latter case, the recognition of ligands for this 
group of receptors is not only mediated by the molecular nature of the PAMP, but 
also by the location of the TLRs, in intracellular compartments, preventing acti-
vation of these TLRs by host nucleic acids. DCs express many of the known TLRs, 
with distinct expression patterns between different DC subsets, especially in hu-
man DCs [4]. It has been speculated that TLR expression profile correlates with 
the main DC subset function. For example, human plasmacytoid DCs is the sole 
DC subset expressing TLR9, which recognizes hypomethylated double-stranded 
DNA sequences (CpG motifs), in line with their efficient detection of bacterial and 
viral infections.
TLR mediated signaling leads to downregulation of the chemokine receptor 
CCR6 and upregulation of CCR7 [32], governing the migration to the draining 
lymph nodes. During this transition phase DCs also undergo a maturation pro-
gram which consists of upregulation of costimulatory molecules, notably B7-1 
(CD80) and B7-2 (CD86), but also CD40, OX40L, 4-1BBL, SLAM and high levels 
of MHC-peptide expression [33].
In the lymph node, DCs migrate to T cell areas and produce certain chemokines 
that attract naïve (MIP-3ß/CCL19) as well as memory T cells (MDC/CCL22 TARC/
CCL17) [34], thereby increasing the likelihood of interaction with antigen-specif-
ic T cells. The initial contact between DCs and T cells is antigen independent and 
results in partial activation of the T cell, necessary to mediate TCR recognition of 
peptide-MHC complexes on the DC surface [35]. Successful interaction between 
TCR and peptide-MHC complexes lead to the formation of immunological syn-
apses; concentrations of activated TCRs surrounded by co-stimulatory molecules, 
cytokine receptors, signal transduction molecules and integrins [36, 37]. Simi-
larly, DCs concentrate peptide-MHC and costimulatory molecules toward the site 
of T cell engagement [38]. Recent advances in the field of optical imaging, such 
as two-photon microscopy, permit visualization of this process in which three 
phases can be distinguished. The first phase consists of serial brief encounters 
between the T cell and DCs. The second phase, 8 hours after the initial start of 
the T cell activation and lasts for 12 hours, is characterized by prolonged stable 
DC-T cell interaction and coincides with the start of T cell IL-2 and IFN-γ pro-
duction. During the third phase, T cells resumed their rapid motility and brief 
DC contacts and this phase correlates with the onset of T cell proliferation [39, 
40]. The second phase seems of particular importance for generation of a effec-
tor T cell response, as immunization with tolerizing DCs is characterized by the 
absence of this phase [39]. The lifespan of the activated DC is regulated by innate 
(TLRs) and acquired immunity (CD40-CD40L and TRANCE-TRANCE-L pathways) 
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which induce a Bcl-XL survival pathway and a molecular timer consisting of the 
anti-apoptotic protein Bcl-2 and the pro-apoptotic molecule Bim. The ratio of Bim 
to Bcl-2 gradually increased during a four day culture period, eventually leading 
to DC death [41].
2 CD4+ T cells
2.1 Th1 & Th2 subsets
A major breakthrough was the classification of CD4+ T cells into T helper type 
1 (Th1) and T helper type 2 (Th2) subsets based on cytokine secretion in vitro, 
which correlated with effector function [42, 43]. Th1 cells are necessary for im-
mune responses against intracellular pathogens, promoting the production of 
opsonizing and complement-binding antibodies by plasma cells and activate mac-
rophages and neutrophils. Immune responses against helminths are dependent 
on Th2 cells, switching antibody production towards neutralizing IgG antibodies 
as well as IgE and lead to activation of eosinophils [43]. 
The prototypic cytokine for Th1 cells is IFN-γ. Besides increasing phagocytic ac-
tivity, IFN-γ also supports the development of cytotoxic CD8+ T cells that are re-
quired for killing virus-infected host cells. In contrast, Th2 cells produce mainly 
IL-4, IL-5 and IL-13. In particular IL-4 is important, generating an autocrine feed-
back loop for further Th2 development and essential for IgE antibody production 
by plasma cells [43] Another important feature of these two CD4+ T cell subsets is 
the ability to cross-regulate each others generation and function, although most 
evidence for this phenomenon is derived from in vitro experiments [43].
Although first identified by differences in cytokine production patterns, many 
more differentially expressed molecules have been described nowadays (Table 
1), some of which will be discussed in this section.
2.2 Regulatory T cells (Tregs) subset
A third group of CD4+ T cells, with immunosuppressing functions, has made a 
comeback and is now the focus of intense research [44]. The regulatory T cells 
(Tregs), or suppressor T cell, subset can be further subdivived in ‘naturally oc-
curring’ Tregs and inducible Tregs [7, 45]. Naturally occurring Tregs represent 
5-10% of the CD4+ T cell lymphocyte pool in healthy adult humans and mice 
and are thought to be important for keeping autoreactive T cells in check that 
have escaped negative selection in the thymus, but they have also been shown 
to downregulate Leishmania major mediated immune responses [46] and allergy 
[47]. These cells are phenotypically characterized by surface expression of the 
IL-2Rα chain (CD25) [48], and also express the forkhead/winged helix transcrip-
tion factor Foxp3 [49]. In addition, several markers have been described that 
were implicated to be molecules used by these CD4+CD25+ T cells to exert their 
suppressive function, such as CTLA-4 [50] and GITR [51]. Of note, except for 
foxp3, none of the phenotypic markers described so far (see table 1) is unique 
to regulatory T cells, limiting their description and isolation. IL-10 and TGF-ß 
are important effector molecules, suppressing disease pathology in experimental 
models of colitis as well as allergic and autoimmune diseases [52-54], but mecha-
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nisms requiring cell-cell contact have also been reported [55], presumably via 
membrane-bound TGF-ß [56, 57].
Another subset of regulatory T cells is not selected for in the thymus during T cell 
maturation, but is induced in the periphery during infection or can be induced 
by tolerance-inducing antigen administration regimens [7, 58]. Alternatively, this 
cell population can be derived from in vitro culture systems [59]. No characteris-
tic stable cell-surface markers have been described for this population, although 
the costimulatory molecule ICOS has been reported to be expressed on this sub-
set [53] They are currently best described by their cytokine signature consisting 
of IL-10 (Tr1 cells) or TGF-ß (Th3 cells) secretion [7]. It should be emphasized 
that both cytokines are not uniquely produced by this cell type, but that the clas-
sification of regulatory T cells is dependent on  the cytokine secretion profile. 
For example, Th2 cells also produce IL-10, but in less quantities while producing 
large amounts of IL-4. 
Furthermore, due to the lack of reliable (cell-surface) markers it is at present 
unclear what, if any, relationship there is between the natural and inducible Treg 
lineages. 
Regulatory T cells target multiple cell types of the immune system. Tregs  inhibit 
proliferation of and cytokine production by naïve CD4+ T cells as well as Th1 
or Th2 effector cells  in vitro and in vivo [46, 60], and have also been shown to 
inhibit activation of CD8+ T cells in vitro and in vivo [61, 62]. Indirect effects of 
IL-10 may also account for T cell inhibition, as IL-10 also acts on DCs by means of 
downregulating inflammatory cytokine production and MHC-peptide complexes 
on the cell surface, resulting in decreased effector T cell activation whilst pro-
moting the generation of  regulatory T cells [7]. Finally, a direct suppressive ef-
fect, independent of T cells, on cells of the innate immune system has also been 
described [63].
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Table 1: Molecules used to discriminate between CD4+ T cell subets 
Th1 Th2 Tregs*
secreted mediators
IFN-γ� IL-4 IL-10
TNF-ß IL-5 TGF-ß
IL-9
IL-13
cell surface molecules
CXCR3 T1/ST2 LAG-3
CCR5 CXCR4 GITR
TIM-3 CRTH2 CD25‡
IL-12Rß CCR3 CD38
TRANCE CCR4 CD62L
CD94 IFN-γ-R CTLA-4
ICOS† αEß7
CCR8 ICOS†
intracellular
SOCS-5 c-MAF Foxp3
T-bet SOCS-3
HLX GATA-3
NFATc
*: includes all described Treg populations
†: stable expression on Th2 cells, also on subset of inducible Tregs
‡: expressed on naïve naturally occurring Tregs, as well as activated CD4+ T cells
3 Lineage decisions of CD4+ T cells
Naïve CD4+ T cells polarize towards Th1/Th2 effector cells or regulatory T cells, 
dependent on the type of immune response that needs to be mounted in order to 
eradicate the pathogen. In recent years many details have been elucidated about 
the molecular processes involved in Th1/Th2 lineage decision but much less is 
known about Tregs development
3.1 Th1 development 
Th1 polarization is initiated in the presence of TCR signaling by IFN-γ mediated, 
STAT-1 dependent, expression of an essential transcription factor, T-bet. [64, 65].
This initial IFN-γ is provided by cells of the innate immune system, in particular 
NK cells which migrate to the lymph nodes under influence of mature DCs [66] 
The significance of T-bet is underscored by the observation that mice deficient 
in T-bet succumb to Leishmania major infection, a prototypic Th1 pathogen [64]. 
This activation of T-bet sets a cascade of events in motion. It induces expression 
of IFN-γ, and in addition leads to epigenetic remodeling of the ifng locus by 
rearrangement of chromatin regions allowing active gene transcription. Simulta-
neously, IL-12Rß2 gene expression  is induced and its own expression stabilized, 
either by intrinsic positive feedback loop or in an autocrine fashion via IFN-γ 
production [67]. In effector Th1 cells, IFN-γ production is rapidly upregulated 
via two independent signaling pathways; TCR signaling or (IL-12) cytokine stimu-
lation [65]. The latter pathway largely depends on STAT-4 signaling, although 
residual IFN-γ production has been noted in Stat4-/- animals [68]. In the absence 
of IL-12 however, no effective immune response can be generated against Th1 
pathogens [43]. Recently, IL-27 has also been implicated in Th1 differentiation, 
16
Ch
ap
te
r 
1
although subsequent studies have also revealed an suppressive role for this cy-
tokine [69, 70]. In addition, various non-cytokine instructive signals have been 
identified. The LFA-1-ICAM-1 pathway has been reported to favor Th1 develop-
ment, [71], as well as  members of the notch ligand family Delta [72].
3.2 Th2 development
A cardinal transcription factor, GATA-3, is involved in Th2 cell commitment [73]. 
Analogous to Th1 instruction, the best known and studied signal for Th2 devel-
opment is a cytokine, IL-4. IL-4 induces phosphorylation of  STAT6, which in turn 
increases GATA-3 expression [74]. In combination with TCR-mediated signals, 
GATA-3 remodels the chomosome region containing the Th2 cytokine cluster 
(consisting of IL-4, IL-5 and IL-13) [65, 75]. The remodeling of the Th2 cytokine 
cluster leads to a loop formation that brings a cis-acting enhancer sequence, the 
locus control region (LCR), in close distance of the promoters of the Th2 cytokine 
cluster genes [76]. GATA-3 not only induces IL-4 transcription, but also inhibits 
the expression of  IL-12Rß2, thereby suppressing IL-12-mediated Th1 develop-
ment [74].
Upon TCR triggering of terminally differentiated Th2 cells, acute Th2 cytokine 
transcription is mediated via Th2-specific (c-MAF, GATA-3) or general (NFAT fam-
ily members, AP-1) transcription factors [65]. 
A remaining paradox was the apparent need for IL-4 to induce GATA-3 expres-
sion, which in turn initiated IL-4 production. Although various cell types of the 
innate immune system, such as basophils, mast cells and NKT cells produce IL-4, 
Th2 polarization appears to be independent of these sources [77]. It might be 
that the absence of activation of the innate immune system removes inhibition 
of Th2-cell development by IFN-γ and IL-12, which allows Th2-cell development 
to be driven by positive feedback through IL-4 and GATA-3 [65]. Alternatively, 
several groups have reported that the notch ligand family Jagged has Th2 polar-
ization capabilities, inducing GATA-3 independent of STAT6/IL-4 signaling [72, 
78].
3.3 Treg development
Virtually nothing is known about molecular processes involved in regulatory T 
cell development. It is only known that CD4+CD25+ Treg development is depen-
dent on Foxp3, a member of the forkhead transcription-factor family[49]. The 
importance of this gene for Treg development is illustrated by the (auto)immune 
disorders humans or mice with mutations in this gene acquire due to a loss of 
regulatory T cells [79, 80]
4 DC mediated CD4+ T cell polarization
It has been well established that DCs have a pivotal role in the differentiation 
of naïve CD4+ T cells into Th1 and Th2 cells and evidence is accumulating that 
DCs are also able to direct the development of Tregs [2, 6]. The final outcome 
of the differentiation process is determined by several factors, with the type of 
pathogen and the subset of DC stimulated being the major determinants. Figure 
1 provides an overview of (microbial) stimuli that influence DC phenotype and 
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DC-derived mediators that subsequently modulate Th cell differentiation.
4.1 DC polarization stimuli
A myriad of molecules have been described that have the capability to direct 
helper T cell polarization via modulation of the DC phenotype (signal 3 hypoth-
esis; [81]). One of the first molecules reported for its potent Th1 polarizing ability 
was E.coli LPS [82]. Numerous molecules have been added to this Th1 list, includ-
ing, CpG motifs, poly I:C and undefined extracts of pathogens such as T. gondii 
and the unicellular form of several fungi [6, 83, 84].
In comparison to the number of known Th1-driving compounds, the number of 
selectively Th2-inducing molecules is relatively small, but this could be a conse-
quence of the original hypothesis that TLR-triggering unequivocally led to Th1 
polarization, thereby biasing the compound screening towards Th1 compounds. 
S. mansoni egg extract (SEA) and a glycoprotein of a filarial nematode (ES-62) are 
among the best described Th2-inducing compounds [83, 85]. Furthermore, Chol-
era toxin and LPS of the gram-negative bacteria P. gingivalis have been reported, 
although the latter remains controversial [83, 86, 87]. Interestingly, DC have also 
the capability to discriminate between different forms of the same pathogens. As 
mentioned before, Candida yeasts or Aspergillus condida evoke a Th1 promoting 
DC phenotype, while the hyphae form of the same organism induce Th2 promot-
ing DCs [84, 88]. As a consequence of the relatively recent (renewed) interest in 
regulatory T cells (Treg), microbial products that polarize DCs towards a Treg-in-
ducing phenotype are beginning to be identified. Well documented molecules are 
filamentous haemagglutinin (FHA) and adenylate cyclase toxin (CyaA), derived 
from B. pertussis, Cholera toxin ß-subunit, S. mansoni lysophosphatidylserine and 
hepatitis C virus glycoprotein NS4 (all reviewed in [7]).
An indirect, but potentially important source of DC polarization stimuli induced 
by pathogens originates from tissue or innate immune cells at the site of inflam-
mation. IFN-γ produced by NK cells supports type 1- inducing DCs, while mast 
cell-derived histamine and PGD2, and TSLP produced by epithelial cells, drive 
Th2 effector response via their effect on DC phenotype [6]. Analogue to factors 
driving Th1/Th2 DC phenotypes, IL-10 and TGF-ß from the environment stimu-
late the formation of DC with regulatory functions [6]. The importance of tissue 
derived stimuli induced by pathogens was also underscored by the ‘danger signal’ 
theory proposed by Matzinger who stated that endogenous signals derived from 
pathogen-induced necrotic cells indirectly activate DCs, as opposed to Janeway’s 
direct activation of DC by microbial signals [28, 89]. Acceptance of this model 
was hampered by the lack of mediators, although recently molecules that fulfill 
this role have been proposed [90]. 
4.2 DC-derived effector molecules
Various DC-derived molecules with Th-polarizing capacities have been identified. 
One of the most documented is IL-12, a powerful inducer of effector Th1 cells 
[91]. More recently, IL-23 and IL-27 which are closely related to IL-12, have also 
been implicated to drive Th1 differentiation [70, 91]. IL-18 also has a Th1-pro-
moting effect, amplifying the effects of IL-12, but not capable of Th1 differentia-
tion by itself [91]. Another group of important in Th1-driving factors humans, 
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but not in mice, are type I IFNs (e.g. IFN-α/ß) In both man and mice, type I IFN 
production is strongly associated with virus infection and may be crucial in the 
development of protective Th1 immunity [6]. Several cell-surface molecules have 
also been shown to have a Th1 polarizing effect, among them ICAM-1 and the 
notch-ligand family Delta [71, 72]. 
It was once postulated that MHC-peptide (signal 1) and costimulation (signal 2) 
signaling in the absence of Th1 inducing PAMP signal transduction (MYD88), 
leads to Th2 differentiation by default [92, 93]. However, careful examination 
of immune responses in mice deficient for IL-12 or immune responses gener-
ated through indirectly activated DCs do not confirm this hypothesis [94, 95] 
Furthermore, a number of molecules implicated in Th2 differentiation have been 
identified up till now, arguing against this hypothesis, although it should be em-
phasized that no clear-cut picture has emerged yet as seen with  Th1 driving 
cytokines such as IL-12. Some recently identified secreted mediators with Th2 
inducing properties include CCL2 (MCP-1), IL-25, IL-6 [84, 96], while IL-18 has 
been reported to be able to drive Th2 development in the absence of IL-12 [97]. 
Cell-surface molecules with Th2-driving properties are OX40L and Jagged fam-
ily members [6, 72]. Finally, DC-derived molecules that are important in Treg 
induction are IL-10 and TGF-ß (in the absence of IL-12) [6, 7], and one study also 
reported a role for the ICOS ligand B7-RP1 [53].
Besides identified distinct signal molecules, a poorly defined term, called ‘matura-
tion’ seems also important in T helper cell differentiation, in particular for Treg 
induction. The maturation status is commonly defined by the expression levels of 
costimulatory markers CD40, CD80 and CD86. High levels of all these molecules 
support Th1 induction . In agreement with this finding, IL-23 has been shown 
to enhance DC maturation and might via this route contribute to Th1 polariza-
tion [98]. It should be emphasized however, that other molecules besides the 
well-known DC maturation markers such as described here seem important. Reis 
e Sousa elegantly demonstrated that only direct activation of DCs with PAMPs 
resulted in IL-12 production and Th1 effector cell generation, while indirect ac-
tivation of antigen-presenting DCs does result in a similar activation status, but 
these DCs are not capable of generating bona fide Th1 cells.[95]
Low levels of MHCII and costimulatory molecules, in particular CD40L,have been 
associated with Treg induction [6, 7, 99]. Although nowadays the definition of 
regulatory DCs has been subtly refined from ‘immature’ towards ‘quiescent’ DCs, 
intended to indicate a specialized subset of mature DC, there is still evidence that 
some pathogens block DC maturation, leading to Treg development in order to 
protect itself of detrimental effects of the immune response [6]. Other evidence 
of the relationship between maturation state of DCs and tolerance induction was 
acquired with elegant mouse models, targeting antigen specifically to DCs and 
assess the immune response under steady state or inflammatory conditions. The 
results unequivocally showed that under non-inflammatory responses tolerance 
against the antigen was observed, while under inflammatory conditions a vigor-
ous response ensued [100, 101].
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4.3 DC subsets & CD4+ T helper priming.
Traditionally, it was thought that the different human DC subsets had fixed in-
structive capacities, hence the DC1/DC2 nomenclature [102]. Studies on lym-
phoid and myeloid DC populations in mouse confirmed the different priming ca-
pabilities [103, 104]. However, a conceptual problem arose from this model; how 
could different DC subsets discriminate between pathogens when simultaneously 
present at the site of infection and ensure a proper type of immune response? 
The identification of TLRs as the main family of PRRs could not entirely solve 
this theoretical flaw, as the distribution pattern of TLR members show partial 
overlap between different DC subsets [4]. Indeed, in recent years it has become 
increasingly clear that DC subsets exhibit flexibility with regard to their CD4+ T 
cell polarization capacity, based on microbial stimuli and local environmental 
factors [83, 105, 106]. Despite this plasticity, some DC subtypes seem to have a 
different functional bias. For example, freshly isolated human pDCs are the only 
group expressing TLR9, providing the ability to respond to viral DNA sequences, 
which is in line with the reported massive production of type 1 IFNs by these 
subset after viral infections [21]. 
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5 Atopic asthma
Asthma is a chronic inflammatory disease of the airways, characterized by inter-
mittent airway narrowing and variable symptoms of chest tightness, wheeze and 
shortness of breath. Asthma can roughly be divided in two groups; intrinsic (non-
atopic) asthma and allergic (atopic) asthma, which will be the focus of this thesis. 
Atopy and allergy are used almost synonymously  in English-speaking literature, 
and are now defined as the propensity to develop immediate-type hypersensi-
tivity reactions to common environmental proteins, known as allergens [107], 
although formally allergic reactions are only atopic when the observed immune 
response is IgE-mediated. 
The word ‘atopic’ is derived from the Greek ‘atopos’, meaning ‘strange, out of 
place’. Sadly, this is not the case for asthma nowadays, as incidence and preva-
lence of atopic asthma continue to rise in the First World countries and develop-
ing Second World countries. For example in the USA, the overall prevalence rate 
of asthma is about 5-8% and currently affects about 20 million persons including 
approximately 4.8 million children [108]. In Bangalore, India the prevalence of 
asthma in the pediatric population has risen from 9 % in 1979 to 29.5% in 1999 
and it is forecasted that the asthmatic population in total India will reach 250 
million by 2013. Likewise, in the same timeframe, the estimated population af-
fected by asthma in China will be around 150 million [109]. In the Netherlands, 
prevalence has increased to around 3% in 1999 [110]. Apart from the reduced 
quality of live, asthma also places a large burden on the healthcare system with 
respect to costs. In the USA, expenses have risen form an estimated US$6.2 bil-
lion in 1990 to US$ 12.7 billion in 1998 [111]. 
5.1 Pathology of asthma
The tell-tale symptoms of asthma, shortness of breath, coughing and wheezing, 
are caused by airway obstruction and airway hyperresponsiveness (AHR). AHR, 
which is defined as an increased bronchoconstrictor response to nonspecific 
stimuli such as smoke, cold air, exercise, amongst others [112]. These character-
istics of the asthmatic airways are in turn the result of inflammation and airway 
remodeling.
On a microscopic level, pulmonary inflammation is manifested by the infiltration 
of the airway wall with mononuclear cells, mostly CD4+ T cells, and eosinophils 
but depending on the severity, also plasma cells, neutrophils, macrophages, den-
dritic cells, and mast cells have been shown to be increased. In the airway lumen, 
goblet cell hyperplasia leads to increased mucus production and this mucus is 
mixed with activated macrophages, lymphocytes, eosinophils and shed epithelial 
cells [113, 114]. Further evidence of this inflammatory response is the presence 
of proinflammatory cytokines an chemokines [115]. 
Structural changes to the airways, collectively referred to as airway remodeling, 
is another hallmark of asthma. The accumulation of these changes lead to in-
creased thickness of the airway wall, varying between 10% to 300%. Besides the 
infiltration of inflammatory cells, mucous gland hypertrophy, smooth muscle cell 
hyperplasia and metaplasia of airway epithelium into mucus-secreting cells also 
contribute to the increase in thickness. In addition there is collagen deposition 
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(types I, III and V) beneath the basal membrane, leading to pseudo-thickening of 
the basement membrane [116]. 
In a temporal manner, the asthmatic reaction can be divided into an early phase 
and a late phase. The early phase reaction is maximal at 15-30 min after allergen 
inhalation and generally resolves within 1-2 hours. This phase is characterized 
by mast cell degranulation, leading to bronchoconstriction, vascular leakage and 
mucus production, which will be discussed in more detail below. In approximate-
ly 50% of patients, this reaction is followed by the so-called late phase, peaking 
at 6-12 hr after allergen challenge and usually resolves within a few days. During 
this phase, a massive infiltration of the airway wall with eosinophils and lympho-
cytes is observed [116].
5.2 The etiology of asthma 
5.2.1 Genetic factors
Although family and twin studies have provided evidence that asthma is a heri-
table disorder, identification of susceptibility genes has been hampered by sev-
eral factors. First, asthma is a multigenic disorder and evidence is accumulating 
that genetic heterogeneity exists across populations, i.e. a similar phenotype is 
produced by different genes. Second, the linkage of specific genes to asthma is 
difficult due to the lack of objective clinical benchmarks of the disease. For this 
reason objective, quantitative traits such as total IgE, AHR and skin prick tests 
have been used as surrogate markers for asthma. Using these markers to define 
asthma bears the risk that genes involved in asthma pathogenesis but not un-
derlying the intermediate phenotypes remain unidentified. For example, atopy is 
one of the strongest risk factors for asthma, but it alone is not sufficient to induce 
asthma, as many atopic individuals do not have asthmatic symptoms [117].
Although several approaches can be taken to identify asthma-susceptibility 
genes, they are all combinations of two basic methods; genome-wide screens 
and the candidate-gene approach. The genome-wide screening involves linkage 
analysis of markers that span the entire genome to map all loci with detectable 
effects on a phenotype of interest. The main advantage of this method is its unbi-
ased nature, which may more reliably identify susceptibility genes, in particular 
genes that were not previously implicated in asthma pathogenesis. However, due 
to the large number of independent variables, this study setup might suffer from 
lack of statistical power which in turn necessitates large study cohorts. In addi-
tion, the regions identified with this method are generally broad chromosomal 
regions containing many candidate genes, requiring labour-and cost intensive 
fine mapping to identify the particular gene. Genome-wide screens published so 
far have confirmed the linkage of regions to the asthma phenotype known to con-
tain genes that are involved in the pathogenesis of asthma such as the cytokine 
cluster located at the 5q chromosome region [117]. 
The candidate-gene approach analyses the linkage of polymorphisms in genes 
suspected to be involved in asthma pathogenesis to a particular phenotype. The 
rationale to select a particular gene is based on its biological activity (e.g. IL-13) 
or on previous associations of the region with the trait of interest. An overwhelm-
ing number of candidate genes has been proposed and studied, many of them 
Introduction 23
located in the 5q chromosome region where the cytokines genes are located, 
believed to play a principal role in the immunological processes underpinning 
atopic asthma [117]. 
A major recent breakthrough in asthma genetics is the progression from broad 
linkage regions to individual genes. In the last four years, six asthma-susceptibil-
ity genes have been identified. In 2002, the Adam33 gene was identified [118]. 
Adam33 is a member of a family of genes encoding membrane-anchored zinc-de-
pendent metalloproteinase which are implicated in cell-cell interactions, cytokine 
activation and cell signaling, but it’s exact function is not known. Using similar 
approaches, dpp10, phf11 and  gpra genes were identified [119-121]. Addition-
ally, using congenic or a combination of genetic and genomic approaches, two 
new susceptibility genes, tim1 and C5, have been identified using murine models 
of asthma [122, 123]. Although functional studies are awaited to confirm the role 
of these genes, the fact that none of them was previously implicated to be part of 
known pathways associated with asthma pathogenesis underscores the strength 
of hypothesis-independent genome-wide screening.
5.2.2 Environmental factors
Although it is undisputed that atopic asthma has a heritable component, the dra-
matic increase in prevalence of the disease seen over the past decades in the 
Western World occurs too fast to be explainable by a shift in genetic makeup. 
Therefore, the focus has been put on environmental factors. Although the pres-
ence of allergens is the primary prerequisite for development of atopic asthma, a 
strong correlation between in the intensity of exposure to such allergens and the 
development of allergic disease has yet to be found [124], resulting in alternative 
hypotheses.
The hypothesis that has gained most attention originated from the observation 
that an inverse relationship existed between the risk of atopic sensitization and 
family size; ‘the hygiene theory’ [125]. Similar correlations have been reported 
for other indicators of childhood infection, such as day-care attendance, low pa-
rental social-economic status and growing up on a farm [124]. However, although 
this hygiene hypothesis suggests that protection from allergy is associated with 
an increase in microbial exposure, direct evidence is scarce. The most promising 
data in support of this theory is the discovery of a tim-1 gene polymorphism that 
also acts as cellular receptor for hepatitis A virus. Patients carrying this particu-
lar polymorphism showed a correlation between hepatitis A virus seropositivity 
and protection against atopy [126]. Indirect epidemiological evidence that advo-
cates this relationship is provided by a study among Italian military recruits that 
revealed a similar significant relationship between the presence of antibodies 
to hepatitis A and various measures of atopy [127]. Other proposed protective 
stimuli such as measles infection, BCG vaccination or commensal gut flora have 
been under intensive scientific scrutiny, without yielding any convincing candi-
date that may be responsible for atopy protection [124]. 
The immune system of neonatal humans is thought to have a Th2 bias which 
gradually diminishes during the first 2 years of life in non-allergic individuals, but 
increases in allergic infants [128]. The hygiene hypothesis is explained from an 
immunological point of view that a Th1 stimulus is needed to avoid development 
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of atopy. However, several lines of epidemiological evidence argue against this 
Th1 switch hypothesis. First of all, not only the prevalence of allergic diseases 
has increased, also Th1-associated autoimmune diseases have also risen over the 
same time period [129]. Furthermore, populations with high rates of helminth 
infections, which induce strong Th2 responses, are also protected from allergic 
diseases [130]. It was shown by the authors that IL-10 was responsible for this 
protective effect. The important role for IL-10 was further underscored by recent 
findings that IL-10 protein levels in the BAL fluid of asthmatics are markedly 
lower compared to controls and an IL-10 promoter polymorphism more common 
in asthmatic individuals has been described as well [131, 132]. studies in mouse 
models support a protective role for IL-10 [133-135], although paradoxically IL-
10 is necessary for AHR induction [136].
Based on these data a refined immunological explanation of the hygiene hypoth-
esis was formulated, the ‘counter-regulatory’ hypothesis [124], which postulates 
that infections or colorizations with microbes during childhood results in upregu-
lation of IL-10 production which subsequently protects against the development 
of atopic diseases in susceptible individuals. Although it is unlikely that IL-10 is 
solely responsible for this protection, evidence is accumulating that regulatory 
CD4+ T cells are the principal source of IL-10. Strong microbial stimuli applied to 
the airways of rodents induce IL-10 producing regulatory CD4+ T cells [60, 137]. 
Subsequent studies in humans found lower numbers of IL-10-producing regula-
tory T cells in atopic individuals compared to non-atopic controls [138], as well 
as evidence for reduced function of these cells in  atopic individuals [47].
The differentiation of regulatory T cells in turns seems to be dependent on IL-
10 as well, at least in rodents were it is produced by pulmonary DC exposed to 
strong microbial stimuli [60, 139]. Clinical data in agreement with this hypoth-
esis is provided by the observation that monocyte-derived DCs from atopic chil-
dren produce less IL-10 upon LPS stimulation [140].
6 Immunological basis of asthma
Despite the fact that it has been known for almost 100 years  that eosinophilic 
infiltrates are present in the airways of asthmatic patients [141], it was not until 
the advent of use of flexible, fiberoptic bronchoscopy and biopsies that inflam-
mation was regarded to be the cause of asthma. In addition, it was also known 
for a long time that asthma was linked with high IgE serum levels, but the reason 
for this was not understood. In this section, we will discuss the various cell types 
of the immune system with respect to their function in the pathology of asthma. 
Figure 2 depicts a schematic overview of some of major immunological pathways 
involved during distinct phase of the immune response.
6.1 DCs
An adaptive immune response against any antigen, including aeroallergens, 
starts when antigen is provided in the right cellular context (mature APCs) to 
T-and/or B cells. DCs have emerged as the principal APC in priming naïve T cells, 
including T cells involved in atopic asthma [2]. The important role of these cells 
in allergy is mainly derived from animal studies. Adoptive transfer of antigen-
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pulsed DC into the airways is able to sensitize mice and rats for development 
of eosinophilic airway inflammation [142, 143], while conditional depletion of 
DCs before allergen challenge abrogates airway inflammation development [144, 
145]. In these models, airway DCs are rapidly recruited to the mucosal sites of 
inflammation during pulmonary inflammation [146, 147], and the quantity of 
myeloid dendritic cell precursors in the bone marrow expands [147]. These data 
derived from murine models are also supported by observations taken from the 
airways of atopic asthma patients, which reveal an active recruitment and in-
creased number of myeloid DCs in the mucosa accompanied by a concomitant 
decrease in numbers of myeloid DC in blood [114, 148, 149].
In the lung, aeroallergens first have to cross the lung epithelium to gain access 
to DCs lining the respiratory tract, Many allergens, such as derp1, the principal 
allergen of house dust mite, possess endogenous proteinase activity capable of 
breakdown of tight junctions of the epithelium [150]. Moreover, in the intestine, 
DCs are able to extend their cellular processes (dendrites) to the luminal side of 
the epithelium without disrupting epithelial integrity [151]. This phenomenon 
has not yet been formally demonstrated for DCs lining the respiratory tract, but 
evidence in support of this mechanism is illustrated by the reduced airway in-
flammation in mice deficient for matrix metalloproteinase 9, which is necessary 
for DC-mediated epithelium rearrangement [152, 153].
DCs, activated by either exposure to allergen or pathogens, migrate with acceler-
ated kinetics to the draining lymph nodes [154, 155] possibly due to upregula-
tion of CCR7, CXCR4 and CCR8, while simultaneously downregulating CCR5 and 
CCR6, as is the case for skin derived DCs [156-158], although not formally shown 
for lung DCs. 
6.2 Th2 cells  
It was found that both IgE production and specific recruitment of allergy as-
sociated immune cells was dependent on Th2 cells, putting these cells into the 
spotlight of asthma research. Th2 cells are now generally believed to initiate an 
perpetuate disease. Upon arrival in the draining lymph nodes of the lung, DCs 
migrate to the T cell areas and present antigen to naïve T lymphocytes, which in 
the case of allergic airway inflammation will differentiate into Th2 cells .
So what evidence comprises the claim that CD4+ Th2 cells are the main orches-
trators of allergic airway inflammation? First of all, Th2 cells are present in the 
airways of asthmatics [159] and possess an activated phenotype [160, 161]. 
Transcripts and protein of the Th2-associated cytokines IL-4, IL-5 and IL-13 are 
elevated in BAL fluid, BAL cells and airway biopsies [159, 162, 163]. At the mo-
lecular level, the Th2 phenotype of CD4+ T cells is confirmed by GATA-3,  which 
is expressed at high levels in CD4+ T cells isolated from the airways of asthmatic 
patients [164], whereas the Th1 master switch T-bet is reduced [165]. This cir-
cumstantial evidence has been strongly supported with data from animal studies. 
Mice deficient in IL-4 or STAT6 are not able to mount an allergic airway response 
[166, 167], while mice overexpression of Th2 cytokines in the airways such as 
IL-4, IL-5 and IL-13 exhibited characteristic features of asthma [168-170]. Mice 
expressing a dominant negative form of GATA-3 in T cells do not develop eosino-
philic airway inflammation [171], while mice deficient in T-bet spontaneously 
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develop asthma-like symptoms [165].
As mentioned before, the current paradigm of Th subsets is based mainly on their 
cytokine production, which is also their principal effector mechanism. Here we 
will briefly discuss the role of the different cytokines produced with regard to 
asthma.
6.2.1 IL-4
IL-4 is especially important during the sensitization phase, as mice deficient for 
IL-4 or any component of the IL-4 signaling pathway exhibit greatly reduced Th2 
responses and airway eosinophilia [26, 166, 167]. Its principal role is mediating 
B cell isotype switching to IgE. However, it also has some functions in the effec-
tor phase of asthma, and is involved in goblet cell hyperplasia, induces chemo-
kine production by activated respiratory epithelium and upregulates VCAM-1 on 
endothelial cells, thereby facilitating VLA-4 mediated eosinophil transmigration 
[26].
6.2.2 IL-5
The most important role of IL-5 in asthma is driving the differentiation of bone 
marrow progenitors into eosinophils [172]. In the absence of IL-5, lung tissue 
and BAL eosinophils are not increased in response to Th2 activation [173, 174]. 
Furthermore, IL-5, in collaboration with eotaxin, recruits eosinophils from the 
bone marrow during allergic inflammation [175].
6.2.3 IL-13
IL-13 is an essential cytokine for AHR development. Although it was first thought 
that IL-4 and IL-13 could have a complimentary roles in AHR induction [176], 
further research with IL-4/IL-13 double knockout mouse firmly established that 
IL-13 is necessary and sufficient for AHR [177]. Mucus hypersecretion has also 
shown to be dependent on IL-13 [178, 179].
6.2.4 IL-25
A recently described cytokine with potent Th2 inducing properties produced by 
Th2 cells is IL-25. IL-25 induces Th2-type cytokine production by accessory cells 
that are MHC class IIhigh, CD11cdull, and lineage negative [180]. Mice given intra-
nasal IL-25 developed marked eosinophilia in the BAL and lung tissue, epithelial 
cell hyperplasia, increased mucus secretion, and airway hyperreactivity [181].
6.3 B cells
Primed Th2 cells will subsequently migrate to the B cell follicles due to acquisi-
tion of the CXCR5 receptor [182]. Allergen-specific B cells will be activated upon 
allergen encounter and initiate immunoglobulin production. Two distinct signals 
are essential for isotype class switching towards IgE: IL-4/IL-13 and CD40-CD40L 
signaling [26]. In addition, the B7RP-1/ICOS pathway has also been shown to be 
important for IgE class switching [183].
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6.4 Mast cells
Mast cells are present in large numbers in the mucosa, submucosa and alveolar 
walls [184]. They are also seen to infiltrate smooth muscle layers and this infil-
tration is deemed essential for bronchial airway hyperreactivity [185]. Mast cells 
express the high affinity receptor for IgE, FcεR1 and will bind allergen-specific 
IgE (sensitization). Re-exposure to the same antigen (challenge)  will crosslink 
IgE on the mast cell surface leading to the release of preformed mediators such 
as histamines, neutral proteases (predominantly tryptase and chymase), leukot-
rienes and prostaglandins. 
These inflammatory components typically have a short half-life and are held re-
sponsible for the early phase reaction which consists of  bronchoconstriction and 
increased mucus secretion, leading to the general feeling of chest tightness and 
breathing difficulties. This phase usually resolves in a few hours and is followed 
by the late phase reactions; recruitment and activation of other effector cells 
such as Th2 lymphocytes, basophils and eosinophils. Chemokines, cytokines and 
leukotrienes produced by activated mast cells are primarily responsible for this 
late phase recruitment [26].
6.5 Eosinophils
One of the most prominent features of this disease is the presence of eosinophils 
in the airways of asthmatics, but their role in the pathophysiology is a matter of 
debate. In favor of a direct role are the observations that: 1) the number of acti-
vated eosinophils closely correlates with severity of disease [161], 2) eosinophils 
produce mediators  that damage airway epithelium (e.g. eosinophil peroxidase, 
major basic protein) or have bronchomodulatory  properties (e.g. leukotrienes) 
and 3) reducing the number of eosinophils mildly ameliorates the asthma symp-
toms [26]. However, in murine models pulmonary eosinophilia has often been 
separable of disease pathology. Neutralization of IL-13 reduced AHR and goblet 
cell hyperplasia, without affecting eosinophilia [186], while IL-5 deficiency has 
yielded conflicting results in both human and murine studies [173, 187-189]. 
Recently, two new transgenic mice strains have been constructed that are devoid 
of eosinophils [190]. Although results from these two mice strains are not totally 
consistent, possibly due to the way eosinophil eradication is achieved or differ-
ence in background strains, preliminary results point again to an essential role 
for eosinophils in airway remodeling but not in AHR or mucus production. 
6.6 Animal models of asthma 
Animal models have been, and are, invaluable to study the patholgenesis of 
asthma. Whereas human studies show associations between pathophysiological 
characteristics of the disease and biological systems such as the immune sys-
tem, animal models offer the possibility to study cause and effect. For example, 
mice deficient in IL-4 do not develop eosinophilic airway inflammation [191], 
establishing the crucial role of this cytokine for induction of asthma. Most ani-
mal models have evolved around the mice, due to the availability of a plethora 
of reagents, i.e. monoclonal antibodies, cytokines, chemokines. In addition, the 
technique to generate transgenic mice (either deletion of a gene, called ‘knock-
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out’, or insertion of a gene ) is more efficient in mice than other animal species. 
In spite of the universal choice for the mouse as experimental species, there is 
a bewildering variety in strains, antigens, adjuvants, route of sensitization and 
challenge, number of sensitizations and challenges, and the time frame used. A 
comprehensive review of the literature has distilled the minimum requirements 
necessary for the induction of eosinophilic airway inflammation characteristics, 
consisting of usage of the Balb/c strain, primed with two systemic antigen doses 
in adjuvant followed by multiple airway allergen challenges [192].
These murine models mimic many features of human asthma, including pulmo-
nary tissue and BAL eosinophilia, AHR, Th2 cytokine production and antigen-
specific IgE production. However, some pathological observations of asthma in 
humans are missing in murine models, questioning the relevance of these models 
to study the mechanisms behind asthma. Most notably are the lack of plasma 
extravasation and mucosal edema [193], and eosinophils fail to localize in the 
airway epithelium and do not degranulate [194], although a recent study did 
report degranulation of eosinophils in the airway lumen [195]. In addition, most 
mouse models are relatively short-term (up to two weeks) thus modeling the 
acute phase inflammation reactions, but not chronic events such as airway re-
modeling. Experimental setups using controlled exposure to low concentrations 
of aerosolized antigen for long periods of time have succeeded to elicit some of 
the features of airway wall remodeling, although persistency of the characteris-
tics is debatable [196, 197].
Despite the drawbacks, mouse models have provided functional evidence for 
many cells and mediators identified from clinical studies and likely will be of 
paramount importance to screen for and test new therapeutic compounds.
7 Therapy
7.1 Current therapy
Current asthma therapy is highly effective in controlling symptoms of asthma, 
although the mechanisms of action are incompletely understood. Many patients 
are treated according to international agreed guidelines [198], which are based 
on the use of inhaled corticosteroids to control inflammation as first-line therapy, 
in combination with long-acting ß2 agonists (a bronchodilator), and antileukotri-
enes to fine-tune symptom control, For short term relief, short-acting ß2 agonists 
are prescribed [26]. Although current treatment is adequate and safe, corticoste-
roids do not affect TGF-ß levels and collagen deposition, important for remodel-
ing events [199] It is therefore still unknown if inhaled steroids alter the natural 
history of its disease.
Furthermore, although there is no doubt that the benefits of current corticoste-
roid therapy vastly outweigh the potential risk, some concerns remain, in par-
ticular about long-term effects as a trend is observed towards earlier use of cor-
ticosteroids among children. Some known corticosteroid associated side-effects 
include adrenal suppression, increased risk of osteoporosis and fracture, ocular 
problems, such as ocular hypertension and posterior subcapsular cataracts, and 
skin effects (thinning and bruising) [200].
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7.2 Immunotherapy
A commonly accepted definition of immunotherapy is ‘treatment of a disease with 
therapeutic agents that promote or inhibit immune responses’. Strictly speak-
ing, corticosteroid treatment should be considered immunotherapy according to 
this classification, but due to the non-specific immunosuppressive mechanism of 
these agents, we define immunotherapy here as modulation of the CD4+ T cell 
response in order to prevent or suppress an allergen-specific Th2 response. 
7.2.1 Counterbalancing the Th2 response
One of the first approaches to specifically target the Th2 nature of eosinophilic 
airway inflammation consisted of either stimulation of Th1 development, (based 
on the observation that Th1 effector cytokines (in particular IFN-γ) antagonize 
the development and function of Th2 cells [43]), or direct administration of the 
Th1 effector cytokine IFN-γ.
In experimental mouse models, treatment with IFN-γ during sensitization or 
challenge showed promising results [201, 202]. Clinical trials with inhaled or 
subcutaneously administered IFN-γ however, disappointingly showed no benefi-
cial effects on symptom scores or lung function [203, 204]. A more indirect way 
to establish an allergen-specific Th1 response uses IL-12, which directs the differ-
entiation of naïve CD4+ T cells strongly towards Th1. Similar to IFN-γ, treatment 
of eosinophilic airway inflammation with recombinant IL-12 in mouse models 
showed beneficial effects, even when given during the challenge phase [205]. Un-
fortunately, a clinical trial with recombinant IL-12 given subcutaneously to mild 
asthmatics showed no signs of lung function improvement despite a reduction in 
blood and sputum eosinophils [206]. Moreover, there were serious side-effects 
reported in this trial and others, including deaths [206, 207]. Along similar lines, 
Th1 promoting immunotherapies have been studied using bacteria (e.g. BCG) or 
CpG motifs with comparable results (for a review see [205] and [26]). 
Apart from the effectiveness of the strategies described above, the question re-
mains whether induction of an allergen-specific Th1 response has any adverse 
effects. Studies using adoptive transfer of Th1 cells in mice with eosinophilic air-
way inflammation report conflicting results, with the majority of studies showing 
lack of suppression or even enhancement of inflammation  [129, 192]. Further-
more, it was shown that IFN-γ prevented the migration of eosinophils into the 
airway lumen but not to the lung parenchyma [208], providing an explanation 
for the observed decrease in BAL eosinophilia whilst histological examination 
showed similar numbers of eosinophils in the lung parenchyma of the adoptive 
transfer experiments mentioned above. These mouse model data corroborate 
with an IFN-γ inhalation safety study, revealing an increase in lymphocytes in 
the BAL of healthy volunteers [209]. 
To summarize, despite the numerous possibilities to direct the allergen-specific 
Th2 response towards Th1, the results of experiments performed so far raise 
considerable doubt whether this strategy should be further pursued as an inter-
vention strategy. Nonetheless, this therapy may still hold prophylactic value, as 
shown in chapter 4. 
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7.2.2 Suppressing the Th-2 response
The advancements in understanding the immunological processes underlying 
the pathological features of asthma has led to strategies targeting Th2-specific 
effector molecules. Depletion of IL-5 with two different monoclonal antibodies 
against IL-5 resulted in a dramatic reduction of circulating eosinophils, but did 
not alter asthma symptoms or AHR, fuelling the debate about the exact role of 
eosinophils in asthma etiology. Antibodies or soluble receptor antagonists in-
tervening with IL-4 or IL-13 signaling are also at various stages of development 
or in clinical trial [210]. Antibodies against IgE prevent binding of free IgE to 
its receptors, thereby preventing basophil and mast cell degranulation. Indeed, 
clinical trials have shown reductions in serum free IgE levels up to 1% of baseline 
levels. More importantly, clinical trials have shown to reduce both the EAR and 
LAR and symptoms of IgE-mediated allergy. Clinical studies have shown that the 
patients who benefit most from omalizumab therapy are those at high risk of ex-
acerbations, those with poorly controlled and/or severe asthma, and those with 
IgE-mediated comorbidities. Based on these studies, it is expected that anti-IgE 
will be introduced as an (very expensive) add-on therapeutic [211]
7.2.3 Allergen immunotherapy 
Allergen immunotherapy is discussed here as a separate entity because the thera-
py is based on the observation that administering gradually increasing quantities 
of antigen sometimes leads to unresponsiveness to that particular antigen via 
only partially understood mechanisms, which may depend on the type of antigen 
(venoms or inhalation allergens) and route of sensitization. In vitro analysis of cy-
tokine production by PBMCs from patients after treatment showed evidence for 
either both a Th2 to Th1 shift and induction of Treg cells [212]. The efficacy of 
immunotherapy for the management of asthma is controversial. Studies assess-
ing the relationship between childhood immunotherapy and the development of 
asthma later in life suggest some preventive effect [213, 214]. Immunotherapy 
for patients with established asthma also showed some benefits, in particular in 
reduction of allergen-specific AHR [215]. However, at present allergen immu-
notherapy is not recommended medical practice, due to the limited efficacy, the 
risk for severe side effects (anaphylaxis) and the availability of safer and more 
effective pharmacological alternatives [215, 216].
7.3 Somatic gene therapy 
Somatic gene therapy is the introduction of new genetic material into the non-
germline cells of an individual for therapeutic purposes. It has some distinct 
pharmacological advantages over the more classical (protein) therapies. First, 
classical therapeuticals (e.g cytokines) are delivered systemically or semi-sys-
temically (e.g. aerosolisation) and will form a concentration gradient towards the 
affected tissue, which might be too low to ensure long-lasting therapeutic effect. 
Therefore, multiple doses need to be administrated at relatively high concentra-
tions, increasing the risk of intolerable side-effects. By contrast, depending on 
the delivery system used, gene therapy that is aimed at the affected tissue can 
achieve high concentrations of therapeutic agent locally, reducing the risk of 
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side-effects and reducing the number of treatments. Second, gene expression can 
be regulated. Several regulatory expression systems have been developed, either 
pharmacological based (e.g. the ‘tet-on’ and ‘tet-off’ systems; [217]) or regulated 
by pathophysiological processes; a recent example of this last category is a con-
struct consisting of the human IL-1ß enhancer with the IL-6 promoter region 
which drives gene expression under inflammatory conditions in a mouse model 
of arthritis [218]. A more  thorough review of the subject  is provided by Cherna-
jovsky et al. [219].
Efficient gene delivery is the key to successful gene therapy. Gene therapy can 
broadly be divided in in vivo gene therapy, with administration of the vector 
directly to patients, or ex vivo strategies. Ex vivo treatment consist of  remov-
ing cells from patients, which are subsequently genetically modified in vitro to 
encode for a therapeutic protein before their return to the patient. Ex vivo treat-
ment can further be divided based on the migration properties of the modified 
cells; mobile (e.g. DCs) or immobile cells (e.g. pancreatic islets cells). Several vec-
tor systems have been developed for gene delivery, which differ in features such 
as immunogenicity and the size of insert that can be cloned. The choice of vector 
is dependent on the followed strategy, and some common vector systems have 
been summarized in table 2.
7.3.1 Gene therapy for asthma
Gene therapy approaches targeting the pathophysiology of asthma are still in an 
experimental stage and have been focused on either modulation of the inflamma-
tory response or direct targeting of mechanisms responsible for the symptoms 
such as mucus production and bronchoconstriction. 
Similar strategies aimed at shifting the Th2 response towards Th1 as previously 
discussed at the immunotherapy section have been used for asthma gene therapy, 
including transduction of airway epithelium with vectors encoding for IL-12, IFN-
γ and IL-18 [202, 220-224]. The use of cytokine genes (which act in a paracrine 
fashion) and adenoviral constructs (having a natural tropism for airway epithe-
lia) in the majority of studies enhances the biological efficacy of these regimens. 
However, the conceptual problems behind this strategy, whether a Th2 to Th1 
shift is beneficial to asthma pathology, remains. A genetic approach to suppress 
the Th2 response has also been tested with an adeno-associated vector (AAV) ex-
pressing an IL-4Rα antagonist blocking IL-4 and IL-13-mediated signaling. Treat-
ment with this vector, either intravenously or applied locally in the airways, led 
to reduced inflammation, mucus production and AHR [225]. Finally, suppressing 
both Th1 and Th2 responses by adoptive transfer of IL-10 or TGF-ß engineered 
allergen-specific T cells is an alternative strategy [135, 226] , although clinical 
use is not foreseeable in the near future, due to the requirement for antigen 
characterization and the inherent risks associated with retroviral vectors as have 
been used in these studies [227].
Gene therapy aiming at the mechanisms responsible for asthma associated 
symptoms are also being investigated. Preliminary data suggests that adenoviral 
transduction of a ß2-adrenergic receptor in the bronchial epithelium of normal 
mice attenuates methacholine-induced bronchospasm [228]. Targeting gob5, en-
coding a Ca2+-dependent chloride channel, with antisense RNA attenuated mu-
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cus production and AHR in a mouse model of eosinophilic airway inflammation 
[229]
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8 Aim and outline of this thesis
Asthma is reaching epidemic proportions in the developed countries, having a 
negative impact on the quality of life and places an increasing burden on health-
care costs. The sharp increase in incidence during the last decades remains an 
enigma, yet the relative short time span of increasing prevalence points toward a 
large contribution of environmental factors. 
Although current treatment of asthma with inhaled corticosteroids and long-act-
ing ß2 agonist is adequate and safe, concerns remain of the long-term effects 
of corticosteriods, in particular in light of the decreasing age at which therapy 
starts for infants. Furthermore, current therapy does not seem to inhibit TGF-ß 
levels and collagen deposition, important for airway remodeling which in turn 
contributes to a great extent to airway hyperresponsiveness.
In essence, atopic asthma is the manifestation of an underlying aberrant Th2-de-
pendent immune response to innocuous airborne allergens. The requirement for 
a Th2-dependent immune response implies the involvement of antigen present-
ing cells for priming and recall responses to allergen. Dendritic cells (DCs) have 
emerged as the principal cell type for activation and differentiation of naïve CD4+ 
T cells towards the distinct subsets. Moreover, deletion of DCs during the primary 
and secondary immune response of eosinophilic airway inflammation in animal 
models of asthma revealed an absolute requirement for this cell type during both 
phases. Chapter 2 provides an up-to-date review of current research topics in DC 
biology, in the context of asthma.  However, less is known about modulation via 
DCs of the Th2 response in eosinophilic airway inflammation.
In this thesis, we investigated the effects of DC-driven modulation of the Th2 re-
sponse in a murine model of eosinophilic airway inflammation based on priming 
with bonemarrow derived DCs. Furthermore, the unsurpassed capacity of DCs to 
direct the differentiation of CD4+ T cells, in combination with its requirement for 
initiating and maintaining eosinophilic airway inflammation, provide potential 
new strategies for immunotherapy, aimed at modulating the asthma-associated 
CD4+ T cell response.
A well documented alternative route of CD4+ T cell differentiation is polarization 
towards the Th1 subset, which antagonizes function and development of Th2 
cells. DC-derived IL-12 is an important factor driving Th1 development and it has 
been postulated that decreased IL-12 production capacity of DCs is a key deter-
minant of allergic sensitization. Several stimuli have been described that promote 
IL-12 production by DCs, including endotoxins such as LPS. Further support for 
the role of IL-12 in allergic disorders was the discovery of an inverse correlation 
between endotoxin exposure and atopic sensitization, leading to the ‘hygiene hy-
pothesis’. Indeed, administration of LPS in animal models of asthma was capable 
of inhibiting eosinophilic airway inflammation development, but these studies 
did not examine the cellular targets of the administered LPS. In chapter 3 we in-
vestigated whether this LPS-mediated inhibition of Th2 priming was dependent 
on IL-12 production by DCs.
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A more direct approach to study the effects of IL-12 production by DCs on CD4+ T 
cell differentiation and subsequent eosinophilic airway inflammation was taken 
by immunizing with DCs retrovirally transduced with the genes encoding for 
IL-12. In addition, this approach served as a proof of concept for DC mediated 
immunotherapy for eosinophilic airway inflammation. Despite the fact that im-
mune deviation towards Th1 nowadays is not regarded to be the optimal treat-
ment strategy for allergic airway inflammation, the well documented functions 
of IL-12  makes it a good candidate to test the feasibility of DC immunotherapy 
in eosinophilic airway inflammation. The results of this work are described in 
chapter 4.
Another strategy to suppress or prevent eosinophilic airway inflammation is di-
rect inhibition of the associated Th2 response. Recently, new members of the B7 
family of costimulatory molecules with inhibitory functions have been identi-
fied. Two of these, PD-L1 (B7-H1) and PD-L2 (B7-DC) share the same receptor, 
expressed on activated T and B cells. This receptor, PD-1, attenuates TCR-me-
diated T cell activation upon ligation. The use of cell surface bound molecules 
for immunotherapy has the advantage that only T cells specific for the antigen 
are inhibited, minimizing unspecific inhibition of bystander T cells. We therefore 
analyzed the suppressive capacity of PD-L1 and PD-L2 transduced DCs in our 
model of eosinophilic airway inflammation (chapter 5).
A previously unacknowledged direction of signaling has recently been described 
for several costimulatory pathways, termed ‘reverse signaling’. It has been found 
that both CTLA-4 and CD28 are capable of transmitting signals into DCs, re-
sulting in an inhibitory or stimulatory DC phenotype, respectively. To address 
whether PD-1 can act in a similar fashion, we analyzed the effects of soluble PD-
1 on DC-T cell interaction as well as on each individual cell type. Moreover, we 
tested whether this reagent had suppressive properties in our mouse model of 
eosinophilic airway inflammation (chapter 6).
In the last chapter, chapter 7, the main findings of the previous chapters are sum-
marized and discussed, followed by a review of the pros and cons of the different 
strategies currently pursued for DC-mediated immunotherapy against allergic 
disorders such as asthma.
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Introduction
Allergic asthma is a chronic disease of the airways characterized by eosin-
ophilic inflammation, mucus hyperse-
cretion, and bronchial hyperreactivity, 
triggered by inhalation of environmen-
tal allergens, and eventually leading to 
structural abnormalities of the lung. 
T helper type 2 (Th2) cells are crucial 
for causing disease, by producing key 
cytokines like IL-4, IL-5 and IL-13 [1]. 
Dendritic cells (DCs) are essential for 
priming and Th2 differentiation of na-
ïve CD4+ T cells towards aeroallergens, 
and in recent years it has been well es-
tablished that these cells play a pivotal 
role in the initiation phase of allergic 
asthma [2]. Upon antigen encounter, re-
spiratory tract DCs migrate to the drain-
ing mediastinal lymph nodes where 
they control the activation and differen-
tiation of antigen specific T cells. Acti-
vated effector T cells will migrate back 
to the site of inflammation and will be 
(re)stimulated locally by activated DCs. 
(Figure 1) In this review, we will focus 
on recent advances in our knowledge 
of these distinct phases, and how these 
can be regulated by CD4+ regulatory T 
(Treg) cells.
Dendritic cell activation and mi-
gration
DCs form a network in the airway epi-
thelium that continuously samples the 
environment for antigen. They migrate 
to the draining lymph nodes of the lung, 
also under non-inflammatory condi-
tions [3-5]. This steady state migration 
of DCs to the mediastinal nodes neces-
sitates continuous replenishment from 
progenitor cells. It is now clear that 
blood Gr1lo CX3CRhi monocytes can 
serve as the immediate precursors of 
lung DCs in steady state conditions [6]. 
When DCs are activated however by al-
lergen exposure or viral infection, the 
migration rate is accelerated, enabling 
faster transfer of information about the 
pathogen to the secondary lymphoid 
organs [7-9]. Under most conditions, 
DC migration is linked to activation, 
and even in the absence of infection, the 
majority of epithelial derived DCs arrive 
in the mediastinal nodes in a partially 
mature CD86+ CD40+ state [5]. 
Whether distinct DC subsets are re-
sponsible for antigen transportation in 
response to different types of antigen 
exposure is an area of investigation. 
Belz and colleagues [10] reported that 
only a specific subset of CD8α- CD11b- 
CD11c+ DCs transported antigen to the 
draining nodes after viral infection of 
the lung, yet non-migratory CD8α+ 
CD11c+ DCs also acquired the capacity 
to prime naïve CD8 T cells. In response 
to harmless ovalbumin inhalation, we 
demonstrated that both myeloid and 
plasmacytoid DCs within the mediasti-
nal nodes had taken up antigen, while 
Abstract
Dendritic cells are essential for Th2 differentiation of naïve CD4+ T cells in 
response to aeroallergens, and in recent years it has been well established that 
these cells play a pivotal role in the initiation phase of allergic asthma.  Den-
dritic cells are also crucial for maintaining eosinophilic airway inflammation 
by controlling the recruitment and activation of primed Th2 cells in the lung. 
A picture is emerging wherein the balance of pathogenic Th2 cells and regula-
tory T cells is tuned by dendritic cells not only at the initiation but also at the 
effector stage of the allergic immune response.
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only the myeloid DC subset presented 
the antigen to naïve CD4 T cells [11]. 
If DC activation is a prerequisite for 
enhanced migration under inflam-
matory conditions, which signals are 
then responsible for DC activation? A 
molecular basis for DC activation has 
been provided with the discovery of 
pattern recognition receptors (PRRs). 
PRRs recognize conserved microbial 
structures, PAMPs, and signaling via 
PRRs lead to DC activation, defined by 
upregulation of MHCII and costimula-
tory molecules. The significance of this 
finding for induction of pulmonary im-
munity is underscored by the fact that 
lipopolysaccharide (LPS) is necessary 
for Th2 sensitization in mouse mod-
els of asthma [12, 13]. Whether other 
PAMPs such as peptidoglycan (TLR2/6 
agonist), ds RNA (TLR3 agonist) or un-
methylated CpG motifs (TLR9 agonist) 
can do the same remains to be shown.
The role of DCs in pulmonary 
tolerance
Under non-inflammatory conditions, 
the outcome of a pulmonary immune 
response to inhaled harmless antigen 
is tolerance [1, 2, 14]. Several mecha-
nisms have been proposed. The most 
probable explanation is that partially 
activated DCs migrate to the lympoid 
organs, inducing an abortive prolifera-
tive response of ‘unfit’ T cells that fail to 
reach the threshold for cytokine surviv-
al signals, leading to death by neglect 
Figure 1 Function of dendritic cells in allergic airway disease
DCs take up antigen when resident in the airway mucosa, and subsequently migrate to the draining 
mediastinal nodes where they arrive in a mature, antigen priming mode. Depending on the nature of the 
antigen and the inflammatory context, antigen specific T cells are induced to differentiate into T effector 
cells (Th1 or Th2) or regulatory T cells (Treg). Differentiated effector T and/or memory T cells subse-
quently migrate back to the site of allergen exposure where they control inflammation. Here again, they 
are restimulated by resident airway DCs.
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[15]. Another possibility is the genera-
tion of regulatory T cells that actively 
suppress immune responses. 
It was shown that, following exposure to 
harmless antigen, respiratory tract DCs 
of mice induced a regulatory T cell re-
sponse, dependent on the B7RP-1 (ICOS-
L) and CD86 pathway and on IL-10 se-
cretion. Transfer of these Treg cells to 
naïve mice before inhaled antigen chal-
lenge inhibited inflammatory responses 
[16-18]. In addition to induced Treg 
cells, naturally occurring Treg cells, 
characterized by CD4 and CD25 expres-
sion, also appear capable of suppress-
ing Th2 development and eosinophilic 
airway inflammation [19, 20]. Recently, 
these data from experimental models 
have been supported with clinical data. 
Comparison of IL-4, IL-10 and IFN-γ 
secretion of allergen-specific CD4+ T cell 
populations  in blood between atopic 
patients or healthy individuals revealed 
that healthy individuals have increased 
numbers of antigen-specific IL-10 se-
creting cells and decreased numbers 
of IL-4 secreting cells. An in vitro sup-
pression assay showed that these IL-10 
secreting CD4+ T cells have suppressive 
activity [21]. From these studies a pic-
ture is emerging in which the balance 
between allergen-specific regulatory T 
cells and Th2 cell is decisive in the de-
velopment of allergy.
It is presently unclear whether DC-me-
diated tolerance induction is a function 
of maturation state, or whether special-
ized DC subsets are responsible for this 
phenomenon. Steinman has suggested 
that peripheral tolerance induction is 
a function of immature DCs [22]. When 
bone marrow myeloid DCs were kept in 
an immature state through pre-treat-
ment with the peroxisome proliferator 
activating receptor (PPAR)-γ agonist 
and subsequently injected into the tra-
chea, they suppressed development of 
airway inflammation in an IL-10 depen-
dent way, whereas when maturation 
was allowed, they induced Th2 priming 
[23, 24]. However, data by Umetsu et 
al. showed that lung DC-mediated toler-
ance depended upon CD86 and ICOS-
L, suggesting that some degree of DC 
maturity was necessary for tolerance 
induction, consistent with the fact that 
mucosal tolerance is accompanied by 
vigorous naïve T cell division [17, 18, 
25]. More and more data seem to sug-
gest that fully mature DCs, induced in 
the presence of certain PAMPs such as 
Mycobacterium vaccae, can also induce 
Treg cells [26, 27]. 
Tolerance induction could also be the 
function of specialized DC subsets. A 
subset inducing peripheral tolerance 
under non-inflammatory conditions in 
the spleen and lymph nodes of mice 
might be the plasmacytoid DCs (pDCs) 
[28]. Recent work in our laboratory has 
extended these findings to the lung. 
We detected a CD11cint, GR-1+, B220+, 
CD45RB+, CD11b- subset of DCs in the 
lungs of mice, resembling the murine 
pDC phenotype. Strinkingly, depletion 
of this subset with a pDC-specific an-
tibody prior to exposure to PAMP-free 
OVA resulted in a breakdown of toler-
ance to this harmless antigen and led 
to all Th2-dependent cardinal features 
of asthma. Conversely, transfer of anti-
gen-laden pDC into naïve mice was able 
to induce tolerance in an alum-driven 
mouse model of asthma that normally 
elicits a strong pulmonary immune re-
sponse [11]. It is currently unclear how 
pDCs induce this inhalational tolerance, 
but ex vivo lung pDCs had the potential 
to induce Tregs while at the same time 
inhibiting the generation of effector 
Th2 cells by myeloid DCs. These find-
ings shed new light on a recent study by 
Hagendorens et al. [29] that observed a 
reduction in circulating pDCs in cord 
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blood of children that subsequently de-
veloped atopic wheezing compared to 
healthy controls. Defects in tolerogenic 
pDC function at an early age, such as 
those induced by respiratory viral in-
fection, might therefore predispose to 
atopic sensitization.
The role of pulmonary DCs in 
priming CD4+ Th2 immunity
The development of Th2-driven atopic 
asthma is dependent on a complex in-
teraction between genotypic and en-
vironmental factors in the developing 
immune system of a child. Some re-
cent studies have linked DC biology to 
known issues of asthma development. 
Infection with respiratory viruses may 
induce development and cause worsen-
ing of asthma [30, 31]. Recently, Dahl 
and colleagues provided a structural 
framework for this observation [32], 
by demonstrating that in an allergen-
induced mouse model of inflamma-
tion, pulmonary DCs acquired a stable 
Th1-promoting phenotype after infec-
tion with influenza virus. Surprisingly, 
subsequent Th2 immune responses to 
harmless antigen were also increased. 
Adoptive transfer of pulmonary DCs, 
obtained after viral infection and clear-
ance, to naïve recipients which were 
subsequently exposed to allergen 
showed that this effect was mediated 
by pulmonary DCs. Thus, contrary to 
current beliefs, there may be subsets of 
lung DCs that have an extended lifespan 
and are able to modulate unrelated im-
mune responses in the opposite polar-
izing direction. 
Alternatively, polarized effector T cells 
may modulate successive immune re-
sponses via modulation of DC function. 
An elegant study by Alpan et al. dem-
onstrated that antigen-specific CD4+ T 
effector cells could influence the CD4+ 
T cell differentiation directed against 
an unrelated antigen by modulating DC 
function, but only if antigens were pre-
sented by the same DCs [33]. This DC 
modulating capacity of activated CD4+ T 
cells was IL-4 and IL-10 dependent, pos-
sibly explaining why in a Th2-adoptive 
transfer model of asthma, Th2 priming 
to an unrelated novel inhaled antigen 
was dependent on IL-4 produced by the 
transferred Th2 cells [34]. 
Immune responses by DCs in the lung 
are Th2 biased, but nevertheless can be 
Th1 skewed when the need is there [35, 
36]. In recent years a myriad of envi-
ronmental instruction signals have been 
described that influence the Th polariz-
ing capacity of DCs. IL-12 is considered 
to be the key cytokine responsible for 
Th1 induction, although other cyto-
kines such as IL-23 and IL-27 appear to 
be important as well [37, 38]. We have 
shown that retroviral overexpression 
of IL-12 in myeloid DCs is sufficient to 
turn these cells into strong Th1 induc-
ers, even in the Th2 prone milieu of the 
lung [39].  However, IL-12 is not nec-
essary for Th1 development by DCs, as 
LPS-stimulated IL-12 p40-/- DCs still in-
duce Th1 development in the lung [40].
In contrast to the signals governing 
Th1 development, the mechanisms for 
DC-driven Th2 development have re-
mained somewhat enigmatic. According 
to one theory Th2 development occurs 
as a default in the absence of polarizing 
IL-12. Alternatively, some regard Th2 
development as an instructive event 
requiring specific cytokines or cell sur-
face molecules on DCs. Although the 
prototypic Th2 cytokine IL-4 is impor-
tant for Th2 development in vivo, it is 
not produced by DCs directly, but can 
be induced in other cells by DC contact. 
Early sources of IL-4 (and IL-13) might 
be naïve T cells, eosinophils or CD1d re-
stricted NKT cells, reacting to antigens 
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presented by CD1d on airway DCs [41]. 
Recent work form Amsen identified the 
cell surface Notch ligand families delta 
and jagged to instruct for Th1 and Th2 
differentiation, respectively [42]. The 
expression pattern of these ligands 
on DCs correlated with the ability of 
known Th1 or Th2 inducing stimuli like 
cholera toxin, PGE2 or LPS to induce T 
cell differentiation [43]. Ectopic expres-
sion of jagged1 and delta1 skewed na-
ïve CD4+ T cells towards Th2 and Th1, 
respectively. 
A role for DCs beyond sensitiza-
tion
Dendritic cells are mainly known for 
their capacity to induce primary T cell 
activation. Evidence is accumulating 
that these cells also control inflammato-
ry reactions to foreign and self antigens 
once T cell priming has occurred, and in 
this way contribute to the maintenance 
of T cell mediated diseases such as coli-
tis, diabetes, and asthma.
Following aerosol challenge of Th2 sen-
sitized mice with allergen to induce air-
way inflammation, there is a dramatic 
recruitment of myeloid DCs into the 
airway lumen, bronchial mucosa and 
lung interstitium, suggesting that DCs 
are functionally involved in control-
ling the activation of previously primed 
T cells [7, 8, 44]. The same pattern is 
seen after allergen challenge of human 
asthmatics, leading to an accumulation 
of myeloid but not plasmacytoid DCs in 
the airway mucosa [45, 46].
Several lines of evidence suggest that 
allergen-induced airway inflammation 
induces local DC maturation, accompa-
nied by upregulation of CD80, CD86, 
ICAM-1, CD40, PDL-1, PDL-2, but not 
ICOS ligand (BN Lambrecht, unpub-
lished; ref [7]). There are several possi-
bilities by which DC maturation might 
be induced. First, allergen activated epi-
thelial cells could release DC-matura-
tion factors such as GM-CSF, defensins 
or TSLP. Huh et al elegantly demon-
strated that airway, but not lung inter-
stitial, DCs upregulated the co-stimula-
tory molecule CD86 upon contact with 
allergen specific T cells. These findings 
suggest that T cells interact locally with 
primed Th2 cells in the airway mucosa 
to generate effector function and subse-
quent inflammation [44]. The question 
whether (all) costimulatory molecules 
expressed by mature DCs are impor-
tant for generating airway inflamma-
tion is a matter of debate. Despite the 
induction of CD80 and CD86 on lung 
DCs, we found that secondary immune 
responses induced by adoptive transfer 
of DCs to the lung were not dependent 
upon CD80, CD86 or ICOS-L [47]. One 
way by which DCs might control Th2 
effector function and eosinophilic air-
way inflammation independently of co-
stimulation is through recruitment to 
the airways of memory Th2 cells. Fol-
lowing allergen challenge, both mouse 
and human DCs produce the Th2-selec-
tive chemokines CCL17 and CCL22 [48, 
49]. In elegant studies, Voehringer et 
al. and Kelly-Welch et al. were able to 
show that bone marrow derived IL-4R 
positive cells, putative DCs, were impor-
tant for controlling the recruitment of 
inflammatory cells and Th2 cells into 
the inflamed lungs of mice, suggesting 
that IL-4 and/or IL-13 might be crucial 
for amplifying DC-driven Th2 inflam-
mation [41, 50]
The most direct evidence for a function-
al role for DCs in maintaining Th2 effec-
tor responses and eosinophilic airway 
inflammation came from mice in which 
myeloid DCs were conditionally deplet-
ed using a ganciclovir suicide technique, 
abolishing all the cardinal features of 
asthma [51]. These findings have been 
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extended recently using CD11c-pro-
motor driven diphteria toxin receptor 
transgenic mice, in which selective de-
pletion of CD11c+ APCs abolished even 
ongoing established inflammation and 
bronchial hyperreactivity by reducing 
Th2 effector production from primed 
Th2 cells (LS van Rijt and BN Lambre-
cht, unpublished). These data also indi-
rectly demonstrate that other proposed 
antigen presenting cell types such as 
eosinophils, macrophages or epithelial 
cells cannot take over antigen presenta-
tion to primed T cells in the lung.  Al-
though eosinophils can support T cell 
effector function of primed T cells in 
vitro, this function is very limited com-
pared with professional DCs. Although 
antigen pulsed eosinophils accumulate 
within the lungs and mediastinal nodes 
of allergic mice, they fail to strongly ac-
tivate T cells [52]. One of the striking 
findings emerging from the proteomics 
and transcriptomics analyses that have 
been performed recently is that many 
proteins expressed in allergic inflam-
mation are associated with alternative 
activation of macrophages, such as the 
Ym1 and Ym2 protein, Fizz-1, and ar-
ginase (BN Lambrecht, unpublished; 
refs[53, 54]). Whether alternatively ac-
tivated macrophages would contribute 
to ongoing Th2 stimulation in the aller-
gic lung remains to be tested.
Control of airway inflammation 
by regulatory T cells acting on 
dendritic cells
From the data described above it is 
becoming increasingly clear that DCs 
control effector T cell responses at sites 
of inflammation. An obvious question 
therefore is whether Treg cells also ex-
ert their action by regulating the func-
tion of DCs within sites of inflammation, 
by producing IL-10, TGF-β or through 
cell-cell contact. Induction of CD86 on 
DCs by inflammation might lead to the 
local expansion of Treg cells, and after 
a few days of inflammation, Treg num-
bers might outnumber pathogenic effec-
tor T cells [55]. Within sites of chronic 
inflammation such as colonic inflam-
mation induced by transfer of CD45RB+ 
cells into SCID mice, Tregs interact lo-
cally with DCs and pathogenic effector 
T cells and suppress effector T cell acti-
vation by downregulating OX40L [56]. 
This might also occur in asthma, where 
OX40L is critical for effector Th2 cells 
[57]. The chemokines produced by DCs 
in response to allergen recognition not 
only attract pathogenic Th2 cells, but 
also CCR4 and CCR8 expressing Tregs 
[49, 58]. 
How Tregs downregulate inflammation 
is a matter of debate. In one scenario, 
Tregs might keep DCs in an immature 
state, unable to induce Th immunity 
[59]. In a very interesting study, mice 
that were deficient in Runx3, a critical 
downstream mediator of TGF-β signal-
ing, had lung DCs that were in a spon-
taneously activated and mature state, 
leading to Th2 mediated lung inflam-
mation to environmental antigens [60]. 
It was also shown that murine natural 
Tregs have the capacity to induce 2,3- 
indoleamine deoxygenase (IDO) activity 
and tryptophan catabolism in myeloid 
DCs, thus leading to T cell suppression 
[61]. High level IDO expression, such as 
induced by treatment with CpG motifs 
has been shown to suppress eosinophil-
ic airway inflammation [62]. 
If Treg cell suppression of allergic im-
mune responses is mediated at the level 
of the DC, it will be important to find 
out if DCs from atopic individuals have 
a reduced capacity to interact with or 
stimulate Treg function or alternatively 
are resistant to Treg regulation. Inflam-
matory cytokines produced by DCs (e.g. 
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IL-6) might render effector T cells ir-
responsive to Treg suppression [63]. 
Alternatively, decreased Treg activity 
in atopic individual might contribute to 
chronic inflammation [64].
Conclusion
Dendritic cells have functions not only 
in the induction of allergic Th2 re-
sponses, but also during the effector 
response as it occurs in clinical asthma. 
In the coming years it will be interest-
ing to find out how these processes are 
regulated by regulatory T cells. From 
a therapeutic perspective, the capacity 
of DCs to stimulate the expansion and 
function of antigen specific Treg cells 
might be exploited to treat allergic dis-
ease. Exploiting this knowledge could 
lead to the design of better prevention 
or therapeutic strategies for asthma.
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Introduction
T helper type 1 (Th1) and type 2 (Th2) effector cells play a pivotal role in 
the adaptive immune response towards 
distinct classes of antigens [1]. Dendrit-
ic cells (DC)3 are generally considered 
to be the principal antigen presenting 
cells involved in the generation of po-
larized effector cells [2]. However, the 
exact mechanisms by which DC induce 
polarized T helper responses are only 
incompletely understood, and many of 
these mechanisms are complementary. 
As such, the route of antigen encounter 
and the subtype of DC presenting the 
antigen can profoundly influence Th 
differentiation [3-6]. The type of patho-
gen encountered or the adjuvant used 
for DC activation has an even greater 
impact on Th cell differentiation. DC 
activating molecular patterns such as 
LPS [7], poly I:C [8] and CpG motifs [9, 
10] induce Th1 polarization by signal-
ing through pattern recognition recep-
tors, while other products, like soluble 
egg Ags of the helminth Schistosoma 
mansoni, glycoproteins from the filarial 
nematode Acanthocheilonema viteae, 
or cholera toxin result in a skewing to-
wards Th2 [8, 11]. Recently, yet another 
model of DC-induced Th cell polariza-
tion in vitro was proposed [12]. Accord-
ing to this ‘kinetics of activation’ model, 
Th cell differentiation following DC en-
counter with microbial compounds is 
time-dependent, early in the response 
favoring Th1 activation while later on 
favoring Th2 polarization. 
All these different models of T cell po-
larization share the paradigmatic view 
that the type of Th response that arises 
correlates closely with the capacity of 
DC to produce polarizing cytokines such 
as bioactive IL-12, a dominant Th1 pro-
moting cytokine [2, 4, 13, 14]. Indeed, 
Abstract
The prevalence of atopic asthma, a Th2-dependent disease, is reaching epi-
demic proportions partly due to improved hygiene in industrialized countries. 
There is an inverse correlation between the level of environmental endotoxin 
exposure and the prevalence of atopic sensitization. As dendritic cells (DC) have 
been implicated in causing sensitization to inhaled antigen, we studied the ef-
fect of endotoxin on Th2 development induced by bone marrow (BM) DC in 
vitro and by intratracheal (i.t.) injection in vivo, with particular emphasis on the 
role played by the polarizing cytokine IL-12.
BM derived DC stimulated with E. coli LPS produced IL-12p70 for a limited 
period of time, after which production became refractory to further stimula-
tion with CD40L, a phenomenon previously called ‘exhaustion’. The level of 
IL-12 production of DC did not correlate with Th1 development, as exhausted 
OVA-pulsed DC were still capable of shifting the cytokine pattern of respond-
ing OVA-specific Th cells towards Th1 in vitro and in vivo. When mice were 
first immunized by i.t. injection of OVA-DC and subsequently challenged with 
OVA aerosol, prior in vitro stimulation of DC with LPS reduced the development 
of airway eosinophilia and Th2 cytokine production, typical of asthma. Most 
surprisingly, the capacity of LPS to reduce Th2 dependent eosinophilic airway 
inflammation was IL-12 independent altogether, as IL-12p40 knockout DC had 
a similar reduced capacity to prime for Th2 responses. These results suggest 
that LPS reduces sensitization to inhaled antigen by reducing DC-driven Th2 
development, but that IL-12 is not necessary for this effect.
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subsets of DC have differential capacity 
to produce IL-12 and many of the Th1-
prone molecular patterns in microbes 
induce IL-12 production in DC [7-9, 13]. 
Along the same lines, the kinetics of ac-
tivation model was explained by initial 
strong production of IL-12 by LPS-stim-
ulated DC, after which prolonged stimu-
lation would lead to exhaustion of IL-12 
production, thus favoring Th2 develop-
ment [12]. According to some models, 
Th2 development indeed occurs as a 
default pathway when DC fail to pro-
duce polarizing IL-12 [4], although the 
relevance of this depends on the nature 
of the antigen and the experimental 
model used [15-17].
The question how and under which mi-
crobial control mechanisms DC induce 
stable Th polarization is particularly rel-
evant to atopic asthma. Atopic asthma 
is characterized by chronic eosinophilic 
airway inflammation, and occurs in in-
dividuals with strongly polarized Th2 
recall responses to environmental aller-
gen. The incidence of atopy and asthma 
has greatly increased over recent years, 
concomitant with an improved hygienic 
status in the industrialized world, sug-
gesting some form of environmental 
control over Th2 development [18, 19]. 
Interestingly, it has been reported that 
exposure to high levels of LPS endotox-
ins during early childhood are corre-
lated with a lower incidence of asthma 
later in life [20]. The mechanisms by 
which this occurs are currently un-
known but systemic exposure to LPS 
during sensitization to inhaled antigen 
decreased the severity of airway inflam-
mation in animal models of asthma [21, 
22], possibly by shifting the balance of 
immune responsiveness towards Th1. 
We have previously shown in a murine 
model of asthma, that airway DC are es-
sential for inducing Th2 sensitization 
to inhaled allergen, leading to eosino-
philic airway inflammation [6, 23]. As 
DC are also responsive to LPS, we set 
out to study the effects of bacterial LPS 
on Th2 development induced by DC in 
vitro and in the airways in vivo, with a 
particular emphasis on the role played 
by the dynamic secretion of the polariz-
ing cytokine IL-12. Our data show that 
LPS reduces DC-driven Th2-develop-
ment in vitro and in vivo, through an IL-
12-independent mechanism, resulting 
in reduced eosinophilic airway inflam-
mation. 
Materials and methods
Mice
Female Balb/c mice (6-10 wks old) were purchased 
from Harlan (Horst, The Netherlands). OVA323-
339-specific, MHCII restricted, TCR transgenic 
(DO11.10) [24] and IL-12p40-/-  mice crossed back 
on a Balb/c background  were obtained from The 
Jackson Laboratory (Bar Harbor, ME). Mice were 
housed in microisolators under specified pathogen-
free conditions and experiments were performed 
under approval of the Erasmus MC committee for 
animal ethics. 
Antigen 
Chromatographically purified OVA was obtained 
from Worthington Biochemical Corp. (Lakewood, 
NJ). Endotoxin activity was 29 EU/mg, which cor-
responds to 2.9 ng LPS per mg OVA, as determined 
by BioWhittaker Europe (Verviers, Belgium). This 
residual endotoxin activity did not result in IL-
12p70 production when added to bone marrow 
(BM) DC cultures (data not shown). LPS (Escherich-
ia coli, strain O26:B6) was purchased from Sigma 
(St. Louis, MO) .
Generation and stimulation of bone mar-
row derived DC
BM derived DC were generated as described [25]. 
After RBC lysis, BM cells were resuspended at 
2*105 per ml in DC culture medium (DC-CM; RPMI 
1640 containing glutamax-I (Invitrogen, Carls-
bad, CA) supplemented with 5% (v/v) FCS (Biocell, 
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Rancho Dominguez, CA), 50 µM β-ME (Sigma), 
50 µg/ml gentamycin (Invitrogen) and 20 ng/ml 
rmGM-CSF (a kind gift from Prof. K. Thielemans, 
VUB, Brussels, Belgium). 2*106 cells were seeded 
in tissue-culture grade 100 mm petri dishes (day 
0). At day 3, 10 ml fresh DC-CM was added. On day 
6 and day 8, 10 ml of each plate was centrifuged 
and resuspended in 10 ml fresh DC-CM. At day 9, 
cells were pulsed for 24 h with either OVA (100 
µg/ml; OVA-DC), LPS (100-500 ng/ml; LPS-DC) or 
a combination of these two (OVALPS-DC). In some 
experiments, unstimulated DC (control-DC) were 
used as a negative control. At day 10, mature DC 
were harvested by gentle pipetting. In some ex-
periments BM cells were cultured in 6 wells-plates, 
with cell numbers and culture volumes adjusted to 
surface area. At day 9, LPS (25 ng/ml) was added 
for 8 or 24 h, cells were washed with DC-CM, and 
recultured for an additional 24 h either with or 
without soluble trimeric CD40L (sCD40L, a gen-
erous gift of Dr. C. Maliszewski, Immunex, Seattle, 
WA) at 2.5 µg/ml. After 24 h, cell recovery was 
determined and supernatants were kept at ‒20 °C 
till further analysis.
Real-time quantitative RT-PCR 
Cells were harvested at various time points and 
total RNA isolated using the RNeasy kit (Qiagen, 
Hilden, Germany) according to manufacturer’s in-
structions. cDNA was generated from total RNA us-
ing random hexamers and the Omniscript Reverse 
Transcriptase Kit (Qiagen). Relative expression 
levels were determined with an ABI PRISM 7700 
Sequence Detector (Applied Biosystems, Foster 
City, CA). Primers and probes for murine IL-12p40, 
IL-12p35, CCR7 and GAPDH were obtained from 
Perkin Elmer (Foster City, CA). PCR conditions 
were 50 °C for 2 min., 95 °C for 10 min., followed 
by 40 cycles of 95 °C for 15 sec. and 60 °C for 1 
min. PCR amplification of the housekeeping gene 
GAPDH was performed to control for sample load-
ing and to allow normalization between samples. 
Genomic DNA and water controls were included to 
ensure specificity. Data are expressed as the ratio 
between cytokine/chemokine transcript levels and 
GAPDH transcript levels.
CFSE labeling & analysis of T cell divi-
sion
For fluorescent cell labeling, cells were washed 
twice with serum-free medium, labeled with 1 µM 
(DC) or 5 µM (T cells) CFSE (Molecular Probes, 
Oss, The Netherlands) in serum-free medium for 
10 min. at 37 °C, and the reaction was stopped by 
adding excess ice-cold DC-CM [26]. For quantifica-
tion of cell division based on serial halving of CFSE 
intensity, algorithms provided by FlowJo software 
(Treestar, San Carlos, CA) were used. The number 
of events N under each CFSE fluorescence peak i 
was determined using a nonlinear least-squares 
fitting of a series of Gaussian functions. Once the 
data set had been fitted, the software derived two 
statistics to describe the proliferation. The prolif-
eration index (PRI) has been defined as the average 
number of divisions of the cell fraction that divided 
(equation 1).
The responder frequency (%D) has been defined 
as the percentage of input cells that responded to 
stimulation by dividing (equation 2). 
In addition to cell division parameters, the original 
T cell pool that was necessary to generate the to-
tal number of daughter cells can also be calculated 
and compared between treatment groups (equa-
tion 3). Therefore, this so-called ‘CFSE content’ is 
an indicator of cell death and/or recruitment of 
antigen-specific T cells within the lymph node.
Th cell priming in vitro
Spleen and lymph node cells were isolated from 
DO11.10 mice and labeled with CFSE. These cells 
(106/well) were cocultured in a 24-wells plate with 
OVA-DC (5*104/well), OVALPS-DC or control-DC. 
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After 96 h, cells were harvested and secretion lev-
els of IL-4 and IFN-γ detected by flow cytometry.
DC migration and IL-12 staining in vivo
On day 0, mice (n=5) were anaesthetized with 
avertin and 2*106 CFSE labeled OVA-DC or 
OVALPS-DC were injected intratracheally (i.t.) in a 
volume of 80 µl PBS using the technique of Ho and 
Furst [27]. After 36 h the mediastinal lymph nodes 
(MLN) were isolated and pooled. As a control for 
specific migration, the axillar lymph nodes (ALN) 
were resected. Lymph nodes were incubated for 
60 min. at 37 °C in digestion mixture (Collagenase 
type II, 1 mg/ml, Worthington Biochemicals; DNA-
seI, 2 U/ml, Sigma), supplemented with monensin 
(‘Golgi-Stop’, BD Biosciences, Alphen a/d Rijn, The 
Netherlands). Frequency and IL-12p40 production 
of CFSE+ DC were analyzed using flow cytometry. 
Primary immune response following in-
tratracheal injection of DC
On day ‒2, 107 CFSE labeled DO11.10 TCR trans-
genic cells were adoptively transferred i.v. into 
naïve Balb/c mice. On day 0, mice (n=9-10 per 
group) were i.t. immunized with 106 OVA-DC or 
OVALPS-DC. On day 4, mice were sacrificed and 
MLN, ALN and lungs were collected separately. 
Single cell suspensions of lymph nodes were pre-
pared by mechanical disruption and lungs were 
homogenized using digestion mixture. Single cell 
suspensions were analyzed by flow cytometry or 
were restimulated (2*106 cells per ml) with 10 µg/
ml OVA for 96 h, after which supernatants were 
harvested and assayed for IL-4, IL-5, IL-10, IL-13 
and IFN-γ content.
Secondary immune response following 
intratracheal injection of DC
On day 0, groups of mice (n=9-10 per group) were 
immunized i.t. with 1*106 OVA-DC or OVALPS-DC. 
In some experiments control animals received con-
trol-DC. From day 10 onwards, mice were exposed 
to OVA aerosols (1% (w/v) in PBS) for 3-4 consecu-
tive days, 30 min. daily. Twenty-four hours after 
the last exposure mice were sacrificed and broncho 
alveolar lavage (BAL) was performed as described 
[6]. MLN were isolated and single-cell suspensions 
were cultured in vitro as described above. As a site-
specific control, ALN of each group were pooled 
and treated identical to MLN. 
Airway histology
After BAL, lungs were slowly inflated with 10% 
buffered formalin, the right-middle lobe excised 
and fixed in formalin overnight. Subsequently, 
lungs were embedded in paraffin, 3 µm sections 
were stained with hematoxylin and periodic acid-
Schiff reagent (Sigma) and photographed with a 
Leica DM-LB microscope (Leica Microsystems, 
Rijswijk)
Cytokine measurements
Levels of IL-12p70, IL-4, IL-5, IL-10 and IFN-γ in 
culture supernatants or BAL were measured using 
OptEIA kits (BD Biosciences) according to manu-
facturer’s instructions. IL-13 levels were measured 
using a commercially available kit from R&D Sys-
tems (Minneapolis, MN)
Flow cytometry
To reduce non-specific antibody binding, anti-
FcγRII antibody (2.4G2, ATCC, Manassas, VA) was 
included in all cell surface stainings. To detect in-
tracellular IL-12p40, single-cell lymph node sus-
pensions were incubated for 3 h in the presence 
of monensin, followed by cell surface staining. 
Subsequently, cells were fixed with 4% parafor-
maldehyde for 20 min. at 4 °C. (Cells were either 
used directly or stored overnight in FACSwash 
(PBS, 0.5% BSA, 0.05% NaN3)). Cells were then re-
suspended in permeabilisation buffer (Perm/Wash 
Buffer, BD Biosciences) and stained for 30 min. at 4 
°C. The following antibodies were used: anti-CD3ε-
PE (145-2C11), anti-pan-NK-PE (DX5), anti-CD19-
PE (1D3) in combination with anti-IL-12p40-APC 
(C15.6) or an isotype matched control.
To assess Th cell priming in vitro, IL-4 and IFN-γ 
secretion levels were measured with cytokine se-
cretion assays (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to manufacturer’s instruc-
tions. Briefly, cell cultures were restimulated with 
platebound anti-CD3 (145-2C11, BD Biosciences, 1 
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µg/ml) and anti-CD28 (37.51, 4 µg/ml) for 4 h and 
subsequently labeled with the capture antibody for 
either IL-4 or IFN-γ. The cells were then diluted in 
medium and allowed to secrete cytokines for 45 
min. at 37 °C, under continuous rotation. CD4+ T 
cells secreting cytokines were identified by stain-
ing with PE-conjugated IL-4 or IFN-γ detection an-
tibody and CD4-APC (RM4-5). Prior to acquisition, 
propidium iodide (PI; 0.5 µg/ml) was added for 
discrimination of dead cells. 
To study the primary immune response in CFSE 
adoptive transfer experiments, cells were labeled 
with anti-CD4-APC in combination with the anti-
clonotypic DO11.10 TCR Ab KJ1-26 [24], conju-
gated to PE. Dead cells were excluded by labeling 
with PI prior to acquisition.
Anti-CCR3-PE was used to detect eosinophils in 
the lung [28], together with anti-CD19-FITC (1D3), 
anti-CD8-PECy5 (53-6.7) and anti-CD4-APC (RM4-
5) to determine the cellular composition in BAL. 
All fluorochrome-conjugated antibodies were pur-
chased from BD Biosciences, except anti-CCR3-PE, 
which was from R&D Systems (Minneapolis, MN) 
and anti-clonotypic-TCR-PE (KJ1-26), which was 
from Caltag Laboratories (Burlingame, CA). 5*104 
‒ 1.5*106 events were acquired on a FACS Calibur 
flow cytometer (BD Biosciences) and analyzed with 
FlowJo software.
Statistical analysis
Reported values are expressed as mean ± standard 
error of the mean (SEM), unless indicated other-
wise. Statistical analyses were performed with 
SPSS (SPPS Inc, Chicago, IL) using a Mann-Whit-
ney U-test. p-Values less than 0.05 were consid-
ered significant.
Results
Bone marrow derived  DC express IL-
12p70 encoding genes
IL-12p70 has been shown to be an 
important cytokine in the differentia-
tion and polarization of CD4+ Th cells 
towards type 1 [29, 30]. To investigate 
the IL-12p70 expression kinetics of mu-
rine BM derived DC in vitro, DC cultures 
were exposed to LPS (100 ng/ml) and 
relative mRNA expression levels of the 
subunit genes IL-12p35 and IL-12p40 
were determined. Both subunit genes 
were upregulated after LPS stimulation, 
reaching a maximum around 12 h after 
onset of stimulation (Fig. 1A and 1B). 
After 24 h of stimulation, expression 
levels of both subunits genes dropped 
significantly and remained low thereaf-
ter. Although LPS mediated apoptosis 
of DC could be a possible explanation 
Figure 1. murine DC produce IL-12 transiently after LPS stimulation. BM derived DC cultures were 
stimulated with LPS (100 ng/ml) at day 9. Cells were harvested at indicated time points, total RNA iso-
lated and converted to cDNA. mRNA expression levels of IL-12p35, (A) IL-12p40 (B) and CCR7 (C) were 
determined by quantitative real-time RT-PCR. mRNA levels are displayed relative to GAPDH mRNA 
expression levels in each sample.
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for the sharp decrease in gene expres-
sion observed, the CCR7 mRNA levels 
increased consistently after addition of 
LPS (Fig. 1C), arguing against LPS medi-
ated cell death during culture. 
The kinetics of IL-12 subunit gene ex-
pression suggested that no IL-12p70 
was produced beyond 24 h of LPS stim-
ulation. To test this hypothesis, cultured 
DC were stimulated for 8 or 24 h with 
LPS, extensively washed and recultured 
either in medium (to assess residual 
IL-12p70 production) or with sCD40L 
(to test IL-12p70 production capacity 
after secondary stimulation). As shown 
in Fig. 2, the residual release of IL-
12p70 into fresh medium was greatly 
reduced after LPS stimulation for 8 h 
and 24 h (hatched bars). Of note was 
the decreased production after 8 h of 
LPS stimulation, despite the expression 
of the IL-12p35 and IL-12p40 genes 
(Fig. 1A and 1B), still maximal at this 
point. However, secretion of IL-12p70 
was restored by culturing the cells in a 
second stimulus provided by sCD40L, 
a surrogate marker for T cell contact. 
This restoration did not occur after pro-
longed LPS stimulation for 24 h (Fig. 2, 
open bars). Levels of the DC maturation 
markers CD40, CD80 and CD86 also 
increased after 24 h of LPS stimulation 
(data not shown). Altogether, these data 
show that with progression in time, LPS 
activated DC acquire a higher costimu-
latory phenotype, but exhaust their IL-
12 production capacity, in agreement 
with previous findings with human 
monocyte derived DC [12, 31].
Th cell activation with LPS stimulated DC 
result in a reduced Th2 profile in vitro
We next determined the functional con-
sequences of LPS-induced DC matura-
tion and exhaustion of IL-12 secretion, 
on Th cell polarization in vitro. OVA-
pulsed-DC (OVA-DC) were pretreated 
or not for 24 h with LPS (OVALPS-DC) 
and were cocultured with naïve CFSE-
labeled lymphocytes from OVA-TCR 
transgenic mice. After 4 days, the cell 
division profile (Fig. 3A) as well as IL-
4 and IFN-γ secretion levels as a func-
tion of cell division number (Fig. 3B) of 
resulting Th effector cells were deter-
mined. LPS stimulation had no signifi-
cant effect on the stimulatory capacity 
of DC, as the division profile of OVALPS-
DC stimulated Th cells was almost simi-
lar to that of Th cells cultured with 
OVA-DC (Fig. 3A). This was confirmed 
by quantification of the cell prolifera-
tion, which revealed no major changes 
in the average number of divisions of 
the cell population that divided, here-
after referred to as proliferation index 
(OVA-DC: 2.52 ± 0.013, OVALPS-DC: 
2.09 ± 0.023), and the responder fre-
quency, defined as the cell population 
that participated in clonal expansion 
Figure 2. IL-12p70 producing capacity upon re-
stimulation depends on duration of LPS stimula-
tion. BM derived DC were stimulated for 8 h or 24 h 
with LPS (25 ng/ml). Supernatants were harvested 
(black bars) and cells were washed with DC-CM. 
DC were cultured for an additional 24 h either in 
DC-CM alone (hatched bars) or in the presence of 
sCD40L (2.5 µg/ml; open bars). Supernatants were 
harvested and the cell number of each condition 
was determined. IL-12p70 cytokine levels were 
measured by ELISA. The IL-12p70 levels are ex-
pressed on a per cell basis to account for differ-
ences in cell numbers. The data are representative 
of duplicate experiments.
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(OVA-DC: 68.9 ± 0.58, OVALPS-DC: 
75.3 ± 2.12). In the OVA-DC group, 
secretion of IL-4 increased with every 
cell division, reaching a plateau after 4 
divisions. The use of OVALPS-DC as APC 
resulted in significantly decreased lev-
els of IL-4 secretion in each generation 
of dividing CD4+ T cells compared to the 
OVA-DC group (Fig. 3B). No major dif-
ference in IFN-γ secretion was observed, 
with a large percentage of CD4+ T cells 
secreting IFN-γ irrespective of whether 
the DC were previously stimulated with 
LPS or not (Fig. 3B). Consistent with 
these single-cell secretion data, IL-4 
and IFN-γ levels in the supernatant, as 
measured by ELISA, exhibited the same 
secretion profile (data not shown). The 
levels of the Th2 associated cytokines 
IL-5 and IL-13 were also decreased in 
the supernatant of OVALPS-DC stimu-
lated T cell cultures (data not shown). 
Thus, LPS-stimulation of DC resulted 
in a selective decrease in Th2 cytokine 
secretion in responding T cells, without 
affecting Th1 cytokine secretion and 
despite the exhaustion of IL-12 produc-
tion in vitro. It is unlikely that this re-
duced Th2 development was due to less 
stimulatory capacity or apoptosis of 
OVALPS-DC, since IFN-γ production and 
T cell division were similar compared 
with the OVA-DC group.
Figure 3. Stimulatory capacity of LPS stimulated DC on naïve Th cells and the type of effector Th cell 
generated. BM derived DC were pulsed with OVA protein (100 µg/ml) in the absence of presence of 
LPS (100 ng/ml). After 24 h incubation, cells were thoroughly washed and used to stimulate CFSE la-
beled Th cells. Four days later, cells were harvested and IL-4/IFN-γ secretion was measured, together 
with the division profile of CFSE labeled cells. A, Division profile of living (PI-), CD4+ cells, stimulated 
with either OVA and LPS pulsed DC (dashed line) or OVA alone (solid line). B, IL-4 and IFN-γ secretion 
per generation of PI-, CD4+ T cells stimulated with OVA-DC (triangles) or OVALPS-DC (squares). Data 
is depicted as percentage secretion above background. Background secretion levels were defined as 
the cytokine secretion measured without stimulation and were determined for each group and cytokine 
individually. Non-pulsed or DC pulsed with LPS do not result in cell division or cytokine secretion of Th 
cells (data not shown). 
IL-12 independent suppression of airway Th2 responses by LPS 69
Effect of LPS stimulation of DC on prolif-
eration and differentiation of Ag-specific 
CD4+ T cell response in vivo
Next, we examined the effect of LPS on 
the stimulatory and polarizing capac-
ity of DC in vivo. CFSE labeled, OVA-
TCR transgenic T cells were adoptively 
transferred to syngeneic recipient mice, 
which were subsequently immunized 
via the airways with OVA pulsed DC, ei-
ther stimulated with LPS or not. After 
4 days, the frequency of OVA-specific 
T cells in the MLN, ALN and lungs was 
determined. In the MLN, up to 7 gen-
erations of divided cells could be dis-
tinguished (Fig. 4A). There was a slight 
decrease in frequency of OVA-specific T 
cells in the OVALPS-DC group compared 
to the OVA-DC group (0.48% ± 0.06% vs. 
0.36% ± 0.04%), respectively. Quantifi-
cation of the cell proliferation revealed 
a small decrease in the proliferation 
index, as well as a decrease in the re-
sponder frequency (Table I). The quan-
tification of cell division also enabled 
us to calculate the size of the original 
OVA-specific T cell population the prog-
eny had arisen from (‘CFSE content’), 
revealing differences in cell number at 
any given site as a result of recruitment, 
migration or cell death, independent of 
cell division. There was no significant 
decrease in the original OVA-specific T 
cell pool size in the OVALPS-DC group 
compared to the OVA-DC group, indi-
cating that LPS stimulated DC were 
equally capable to recruit naïve T cells 
(Table I). Due to the insufficient number 
of OVA-specific progeny T cells, we were 
unable to calculate the average division 
number of T cells in the non-draining 
ALN. However, as evident from Fig. 4A, 
a minor population of divided cells (>3 
divisions) was present. No significant 
differences in frequencies of the PI-, 
KJ1-26+ T cell subset could be observed 
Figure 4. LPS stimulated DC have equal stimu-
latory capacity but a distinct T helper cell differ-
entiation capacity. Naïve Balb/c mice received a 
cohort DO11.10 T cells (KJ1-26+) and were sub-
sequently immunized with either OVA pulsed DC 
(n=9) or OVA+LPS pulsed DC (n=10). Four days 
later, MLN, ALN and lungs were resected and ana-
lyzed for CFSE+ T cells directly or cultured in vitro 
in the presence of OVA for 4 days. A, Frequency 
and cell division profile of OVA transgenic T cells 
in the MLN, ALN (PI-, CD4+) and lungs (PI-) was 
assessed by flow cytometry. Dot plots shown are 
from representative mice of each group. B, Cyto-
kine levels after in vitro restimulation with OVA. 
No cytokines could be detected in cultures of ALN 
(data not shown). Results are expressed as mean 
± SEM from 5 mice per group. *: p< 0.05
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(OVA-DC: 0.47% ± 0.02%; OVALPS-DC: 
0.48% ± 0.02%). OVA-specific T cells 
that underwent multiple divisions were 
also present in the lung but the number 
was insufficient to quantify the aver-
age cell division (Fig. 4A). There were 
also no differences in the frequencies 
of the PI-, KJ1-26+ T cell subset in the 
lung (0.117% ± 0.015% versus 0.107% 
± 0.004% for OVA-DC and OVALPS-DC, 
respectively).
To determine the consequences of LPS 
stimulation on Th cell polarization in 
vivo, we also measured the cytokine 
levels of  ex vivo cultures of lymph node 
cells taken at day 4 of the primary re-
sponse after i.t. injection of DC (Fig. 4B). 
In the OVALPS-DC immunized animals 
a decrease in the production of all Th2 
cytokines (IL-4, IL-5, IL-10, IL-13) with 
a concomitant increase in IFN-γ secre-
tion was observed when compared with 
OVA-DC, indicating a clear shift in bal-
ance towards Th1 cytokine secretion.
Migration and IL-12 production of LPS 
stimulated DC in vivo
Our in vitro experiments indicated that 
LPS stimulation of DC resulted in ex-
haustion of IL-12p70 production after 
24 h, which would predict less Th1 de-
velopment and more Th2 development 
in responding T cells. However, our in 
vitro and in vivo polarization experi-
ments showed the opposite. To clarify 
this issue, we analyzed the expression 
of the IL-12p40 subunit by DC, previ-
ously used as a marker for IL-12p70 
production by DC in vivo [32], after 
the migration of i.t. injected DC to the 
draining lymph nodes of the lung. Af-
ter incubation with OVA and/or LPS, DC 
were labeled with CFSE and injected i.t. 
Thirty-six hours after instillation, there 
was a substantial increase in the per-
centage (Fig. 5A) and number (Fig. 5B) 
of OVALPS-DC migrating to the MLN 
compared with OVA-DC. These find-
ings of enhanced migration are con-
sistent with the upregulation of CCR7 
gene expression and downregulation 
of CCR5 and CCR6 expression follow-
ing LPS stimulation of BM derived DC 
(Fig. 1C and data not shown). The same 
migration trend was observed when we 
looked at an earlier time point (24 h; 
data not shown), which makes it unlike-
ly that there is a difference in migration 
kinetics between the 2 groups. 
In contrast to the in vitro findings, 
OVALPS-DC produced more IL-12p40 
following migration to the draining 
MLN compared with OVA pulsed DC 
alone (Fig. 5C).
LPS stimulation of DC results in de-
creased development of eosinophilic air-
way inflammation
Despite the discrepancies between T cell 
polarization capacity and IL-12 secre-
tion capacity of LPS-stimulated DC, the 
above data demonstrate that LPS-stimu-
lated DC reduce Th2 development dur-
ing the primary immune response. We 
next examined the effect of LPS activa-
tion of DC in a relevant Th2 dependent 
mouse model of eosinophilic airway in-
flammation [6]. In this model, sensitiza-
Table I: Quantification of OVA-specific CD4+ T cell proliferation in the MLN
Immunization Proliferation indexa Responder frequencyb
CFSE content/
105 PI- cells c
OVA-DC 1.97 ± 0.04d 15.70 ± 0.67 237 ± 35
OVALPS-DC 1.82 ± 0.04 11.98 ± 1.30 211 ± 17
a defined as the average number of divisions of the CD4+, KJ1-26+, PI- cell population that divided
b defined as the percentage of input CD4+, KJ1-26+, PI- cells that responded to stimulation by dividing
c defined as the original T cell pool size necessary to generate the total number of daughter cells present, expressed per 105 
living cells
d values represent the mean ± SEM of the data (n=4-5 animals per group)
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tion to OVA is induced by i.t. injection of 
OVA-DC, followed by OVA aerosol chal-
lenge 10 days later, resulting in peri-
bronchial and perivascular eosinophilic 
airway inflammation. When mice were 
immunized with control DC and subse-
quently challenged with OVA aerosol, 
there was no airway inflammation (data 
not shown and [6]). When analyzing the 
degree of lung inflammation, immuni-
zation with OVALPS-DC revealed only a 
slight decrease in total cell number in 
BAL fluid compared with OVA-DC (Fig. 
6A). However, the cellular composition 
of the BAL fluid was markedly different. 
A significant decrease in the frequency 
of eosinophils was observed, accom-
panied by an increase in frequency of 
alveolar macrophages in the mice im-
munized with OVALPS-DC (Fig. 6A). 
The frequency of T cells in BAL fluid 
was identical in both groups. Lung his-
tology data were in concordance with 
BAL data, with lower but marked cel-
lular infiltrate and mucus secretion in 
the OVALPS-DC group compared to the 
OVA-DC group (Fig. 6D). To explain why 
the development of airway eosinophilia 
was suppressed despite similar T cell 
recruitment, we also measured cytokine 
levels in lungs and MLN. In the BAL flu-
id there was a decrease in the levels of 
IL-5 and IL-13 after immunization with 
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Figure 5. LPS increases migration and IL-12 pro-
duction of DC in vivo. OVA pulsed DC (OVA-DC) 
and OVA+LPS pulsed DC (OVALPS-DC; both 
2*106/ mice) were CFSE labeled and injected i.t. 
(n=5 per group). Thirty-six hours later, mediasti-
nal lymph nodes from each group were isolated, 
pooled and analyzed by flow cytometry for migra-
tion and IL-12 production of injected DC. As a con-
trol for specific migration, the axillar lymph nodes of 
the OVALPS DC were analyzed as well. Frequency 
(A) and total number (B) of CFSE+ DC. C, IL-12p40 
staining of CFSE+ DC. Solid histogram; isotype-
matched control. Regular line; OVA-DC group. Bold 
line; OVALPS-DC group. 1.5*106 cells per sample 
were acquired. Data representative of 3 indepen-
dent experiments.
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OVALPS-DC compared with OVA-DC 
(Fig. 6B). Th2 associated cytokine levels 
were also decreased in the MLN, in par-
ticular IL-4, IL-5, IL-10 and IL-13, while 
the levels of the Th1 cytokine IFN-γ did 
not significantly change following LPS 
stimulation of OVA-DC (Fig. 6C). These 
results suggest that LPS stimulated DC, 
while still eliciting an immune response, 
have reduced capacity to prime for Th2 
effector cells. 
LPS mediated suppression of Th2 devel-
opment in vivo does not require IL-12 
In an attempt to dissect the contribu-
tion of DC-derived IL-12 and recipi-
ent-derived IL-12 on Th2 effector cell 
generation in vivo, we first immunized 
wild type mice with DC derived from 
IL-12p40 homozygous knock-out 
mice. In the absence of LPS stimula-
tion, BAL fluid analysis revealed that 
Figure 6. LPS activated DC reduce inflammation in a mouse model of eosinophilic airway inflamma-
tion independent of DC derived IL-12. On day 0, groups of mice were immunized by i.t. administration 
of 1*106 OVA-DC or OVALPS-DC, derived from either wildtype or IL-12p40-/- mice. On days 10-13, mice 
were exposed to OVA aerosols for 30 min. daily. At 24 h after the last exposure mice were sacrificed, BAL 
performed and lymph nodes isolated as described in Materials and methods. A, Cellular composition of 
BAL fluid. Alveolar macrophages were characterized by their light scatter and autofluorescence proper-
ties. Eosinophils are defined by their CCR3+, CD4-, CD8- staining pattern. The T cell fraction consists of 
CD4+ and CD8+ cells within the appropriate light scatter gate. B, Cytokine levels in BAL fluid. C, Cytokine 
levels after in vitro restimulation of MLN cells with OVA antigen. Note that ALN cells of each group were 
pooled and culture in an identical manner. No cytokines could be detected in these cultures (data not 
shown). Results are expressed as means ± SEM from 8-10 mice per group. *: p< 0.05. Data are repre-
sentative for 1-3 independent experiments. D, Leukocyte infiltration and PAS staining in lungs of wildtype 
OVA-DC or OVALPS-DC immunized mice. Solid arrowheads indicate cellular infiltrate, open arrowheads 
indicate mucus accumulation (PAS+)
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IL-12p40-/- OVA-DC induced a stron-
ger Th2 response compared with wild 
type OVA-DC, as the levels of BAL flu-
id eosinophilia were higher (Fig. 6A) 
and Th2 cytokine levels in BAL fluid 
revealed a significant increase in the 
Th2 cytokines IL-5 and IL-13 in the IL-
12p40-/- group (Fig. 6B). Restimulation 
of lymph node cells in vitro also showed 
an increase for the Th2 cytokines in 
the IL-12p40-/- group (Fig. 6C). To our 
surprise, LPS stimulation of IL-12p40-
/- OVA-DC had a similar suppressive 
effect compared with LPS stimulation 
of wild type OVA-DC. In the IL-12p40-
/- OVALPS-DC group, there was a slight 
decrease in total cell number accompa-
nied by a statistical significant change 
in cellular composition, consisting of a 
decrease in the frequency of eosinophils 
and an increase in the frequency of al-
veolar macrophages compared with the 
IL-12p40-/- OVA-DC group (Fig. 6A). Ad-
ditionally, the levels of IL-5 and IL-13 
were significantly lower in BAL fluid of 
IL-12p40-/- OVALPS-DC mice compared 
with the IL-12p40-/- OVA-DC group (Fig. 
6B). Finally, Ag specific restimulation of 
MLN cells in vitro revealed lower levels 
of the Th2 specific cytokines measured, 
in particular IL-5 and IL-10, accompa-
nied by a significant increase in the lev-
els of IFN-γ after stimulation with LPS 
(Fig. 6C). To rule out any role for IL-12 
in Th2 differentiation in this model, we 
next immunized IL-12p40-/- mice with 
IL12p40-/--derived DC. Immunization 
with OVALPS DC resulted in lower total 
cell number, frequency of eosinophils 
and Th2 associated cytokines in the 
BAL compartment, compared to OVA-
DC immunized mice (Fig. 7A & 7B). In 
summary, these data suggest that sup-
pression of Th2 effector cell develop-
ment by LPS stimulation of DC occurs 
independently of IL-12 secretion by 
either adoptively transferred DC or re-
cipient-derived IL-12.
Discussion
Th cell polarization is influenced by the 
route of antigen exposure, the subtype 
of DC presenting the antigen, the dose 
of antigen, the genetic background of 
the host, and most importantly, by the 
nature of the antigen [2]. It is increas-
ingly clear that different molecular pat-
terns expressed on pathogens can fun-
damentally influence Th differentiation 
by signaling through molecular pattern 
recognition receptors on DC [33, 34]. 
The way by which these various factors 
are integrated by DC into a signal that 
can determine Th cell polarization is an 
area of intense research but involves 
the generation of a particular peptide-
MHC density (signal 1), the provision of 
a particular combination of costimula-
tory molecules (signal 2) and the secre-
tion of polarizing cytokines such as IL-
Figure 7. LPS activated DC reduce airway in-
flammation independently of IL-12. A similar ex-
periment as described in figure 6 was performed 
with IL12p40-/- mice derived DC transferred into 
IL12p40-/- recipients. A, Cellular composition of 
BAL fluid. B, cytokine levels in BAL fluid. Results 
are expressed as means ± SEM from 8 mice per 
group. *: p< 0.05
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12, IL-18 and IL-27 [2, 8, 35, 36]. Many 
of the microbial patterns such as bacte-
rial LPS, peptidoglycan, CpG motifs and 
viral double stranded RNA, induce the 
secretion of IL-12 by signaling through 
the Toll-like receptors and the MyD88 
signaling pathway, thus inducing po-
larization towards Th1 responses [16, 
34].
We have examined the role of DC-de-
rived IL-12 in LPS-mediated suppres-
sion of Th2 responses and took into 
account the recently proposed mecha-
nism by which DC exert their influence 
on Th cell polarization by dynamic and 
time-dependent secretion of IL-12p70 
[12, 31]. We have shown that in vitro 
BM derived DC stimulated with LPS ex-
press IL-12p35 and IL-12p40 mRNA 
only transiently, in line with other re-
ports [37], while the expression of 
other maturation markers such as the 
chemokine receptor CCR7 gradually 
increased over time. Of note, the IL-
12p40 and IL-12p35 peaked at around 
12 h post LPS activation, followed by 
a steep decline in relative expression. 
The capacity to produce IL-12p70 upon 
restimulation with a surrogate T cell 
contact provided by sCD40L also de-
creased with increasing duration of the 
LPS stimulus, a phenomenon previously 
termed ‘IL-12 exhaustion’. Surprisingly, 
despite exhaustion of IL-12 production, 
LPS stimulated DC used as APC resulted 
in a more pronounced Th1 phenotype 
of Th cells in vitro, where individual T 
cells produced dramatically decreased 
levels of IL-4 and maintained levels of 
IFN-γ. Therefore, on a population level, 
the Th cell differentiation was skewed 
towards Th1, a finding also supported 
by the ELISA data. This was not due to 
a decreased strength of stimulation due 
to apoptosis of DC, as the overall degree 
of naïve T cell activation was similar in 
both groups. Our findings are in con-
trast with a study of Langenkamp et al. 
[12], which concluded that LPS-induced 
IL-12 exhaustion in human monocyte-
derived DC contributed to enhanced 
Th2 and non-polarized central memory 
Th0 development. In this in vitro model, 
human naïve T cells were stimulated by 
the TSST-1 superantigen on syngeneic 
human monocyte-derived DC, and react-
ing T cells were expanded for 3-9 days 
in neutral conditions using IL-2 before 
analysis of intracellular cytokine con-
tent, which might explain differences 
in outcome. To clarify this discrepancy 
further, we also examined the relevance 
of our findings in vivo, where DC inter-
act with naïve antigen specific T cells 
in the T cell area, providing a physio-
logically relevant stimulus for terminal 
functional maturation of DC function, 
rather than the artificial CD40L stimu-
lation in vitro [38, 39]. To our surprise, 
we saw that DC that were pulsed with 
LPS for 24 h and subsequently injected 
into the lungs migrated to the draining 
lymph nodes and were still producing 
IL-12p40 36 h after injection. It is pos-
sible that in vivo, many other ligand/
receptor interactions in addition to 
CD40/CD40L contribute to the rescue 
of IL-12 synthesis. As such, other mem-
bers of the TNF/TNFR family have been 
shown to enhance the terminal dif-
ferentiation of DC as they reach the T 
cell area [40]. Not surprisingly, also in 
vivo did the LPS-stimulated DC induce 
the proliferation and differentiation of 
naïve OVA-specific T cells towards Th1 
cells producing mainly IFN-γ, whereas 
unstimulated DC induced T cells that 
made predominantly IL-4, IL-5, IL-10 
and IL-13. Therefore, the in vivo data 
about Th polarization support the in 
vitro data and argue against the theory 
that IL-12 exhaustion would contribute 
to enhanced Th2 development [12]. 
Based on the observed inconsistency 
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between IL-12 production capacity 
and Th cell polarization by DC, we next 
studied the relevance of LPS-induced 
IL-12 production by DC using an estab-
lished model of Th2 effector cell-driven 
eosinophilic airway inflammation that 
utilizes DC for immunization [6, 41]. As 
DC can be manipulated in vitro before 
injection in vivo, this model is very use-
ful to address  the direct effects of LPS 
on sensitization via the airways, with-
out avoiding the effects of LPS on other 
cells in the lungs. When DC were pre-
treated with LPS prior to injection into 
the trachea, in particular the allergen-
induced influx of eosinophils was mark-
edly decreased. Cytokines associated 
with eosinophilic airway inflammation, 
IL-5 and IL-13, were also decreased in 
the lung. Histological findings were in 
agreement with the BAL data, with de-
creased, but not totally absent, cellular 
infiltrates and mucus secretion. This 
reduced inflammation in the lung was 
accompanied by a shift in the cytokine 
profile in the draining MLN towards a 
Th1 type of response, with decreased 
levels of Th2-associated cytokines. 
It has been shown that IL-12 has the 
capacity to downregulate eosinophilic 
airway inflammation and airway hyper-
reactivity in mouse models of asthma, 
when given during the sensitization 
phase of the response [42-44]. It has 
been hypothesized that IL-12 exerts 
its effect via induction of a Th1 type 
of response that reciprocally dampens 
the Th2 responses involved in asthma, 
analogous to what has been shown 
in models of parasitic infection [45]. 
Moreover, immunization with DC that 
constitutively express high levels of IL-
12 dramatically reduces eosinophilic 
airway inflammation (HK, DH and BNL, 
unpublished data). As LPS induced 
an increase in IL-12 production in DC 
following adoptive transfer in vivo we 
initially hypothesized that the devel-
opment of eosinophilic airway inflam-
mation was suppressed through the 
release of IL-12 in vivo. However, to 
our surprise, the experiments with IL-
12p40 knockout mice indicated that 
the LPS-induced suppression of eosino-
philic inflammation was independent of 
DC-derived IL-12.  Moreover, when both 
the immunizing DC and the recipient 
mice could not produce IL-12, LPS was 
still capable to suppress airway inflam-
mation. A possible explanation for this 
IL-12 independent effect of LPS might 
be that alternative pathways or cyto-
kines were involved. Freudenberg et al. 
showed IL-12 independent IFN-γ pro-
duction by Gram-negative bacteria via 
STAT4 activation with type I IFN and IL-
18 [46]. Other papers that reviewed the 
role of IL-12 in Th cell differentiation 
also found that Th1 cells did develop in 
the absence of IL-12 [16, 47]. In both 
cases however, IL-12 did amplify the 
Th1-dependent immune response. The 
recently described cytokine IL-27 may 
also be important as it induces IFN-γ 
production by naïve T cells and is pro-
duced by APC. Importantly, its expres-
sion is upregulated upon activation by 
LPS and mice deficient for its receptor 
TCCR have impaired Th1 responses [36, 
48]. Another novel candidate cytokine 
expressed by DC is IL-23, which shares 
the p40 subunit with IL-12 [49]. Since 
the IL-12-deficient mice carry an inac-
tivated p40 subunit, the Th1 polarizing 
capacity of the DC in these experiments 
can not be attributed to this cytokine. 
One finding that also appeared from 
our studies using IL-12p40 knockout 
mice was the enhanced Th2 response 
that was induced in the absence of IL-12 
production by DC. It is less established 
how DC can polarize Th2 responses as 
there is very little if any evidence that 
they can produce the Th2 skewing cy-
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tokine IL-4 [2]. Perhaps the simplest 
model for Th2 polarization would be 
one in which Th cells default to the Th2 
pathway in the absence of IL-12 secre-
tion by DC. Cholera toxin, IL-10 and 
PGE2 indeed induce Th2 development 
by suppressing the production of IL-12 
in DC in vitro [4, 50]. However, in the ab-
sence of IL-12, CD4+ T cell responses to 
the intracellular pathogens Toxoplasma 
gondii and Mycobacterium avium and 
to the parasite Trichinella spiralis fail to 
default to the Th2 pathway in vivo [16, 
17]. Therefore the exact contribution of 
DC-derived IL-12 to Th cell polarization 
is unclear and depends on the nature of 
the antigen and the experimental model 
used [4, 8, 16, 17]. It has however been 
suggested that deficient production of 
IL-12 by APC of allergic donors might 
be a key determinant of allergic sensiti-
zation [51, 52]. In accordance with this 
it was recently shown that polymor-
phisms in the IL-12p40 promotor gene, 
leading to lower levels of produced IL-
12, are clearly associated with the de-
velopment of atopic sensitization [53], 
a finding here supported by our data in 
the mouse model.
The findings in our study that LPS stim-
ulation of DC during the priming alters 
the outcome of Th responses has impli-
cations for understanding the develop-
ment of atopic sensitization. Studies of 
the effect of LPS on asthma appear to 
be complex. Epidemiological data has 
established a correlation between high 
endotoxin levels on farms and reduced 
likelihood of children living on these 
farms to develop asthma [20], while 
other studies found that endotoxins 
augment the severity of asthma once 
it is established [54, 55]. The effect of 
LPS in animal models of asthma has 
also been conflicting, with most studies 
assigning a protective role to LPS [21, 
22, 56], while others do not [57], prob-
ably depending on the time and route of 
antigen and/or LPS administration. One 
study implicated that outcome of sen-
sitization is dependent on the dose of 
LPS present during priming, with high 
doses favoring a Th1 response and low 
doses a Th2 response [58]. However, 
the majority of studies that administer 
LPS before or during sensitization show 
a decrease in airway inflammation, al-
though it is not exactly clear if this is 
due to an increase in Th1 effector func-
tion. Other bacterial factors that sup-
press development of Th2-associated 
sensitization and eosinophilic airway 
inflammation such as bacterial CpG mo-
tifs have also been shown to exert their 
effects independently of IL-12 and even 
IFN-γ, suggesting that they do not work 
by inducing a counter regulatory Th1 
population [59]. A recent epidemiologi-
cal study in German children correlated 
current levels of LPS exposure in mat-
tress covers with risk of atopic sensiti-
zation and diseases and found that in-
creasing levels of LPS exposure led to 
reduced occurrence of atopic diseases, 
but also to lower levels of IL-12 produc-
tion in polyclonally stimulated PBMCs, 
again arguing against a dominant role 
for IL-12 production in mediating the 
effects of LPS on sensitization [60].. We 
are currently addressing if LPS-stimu-
lated DC reduce eosinophilic airway 
inflammation by inducing a particular 
population of regulatory T cells, which 
have been shown to be involved in toler-
ance induction in the lung [61]. Indeed, 
other bacterial motifs such as present 
in Mycobacterium vaccae suppress eo-
sinophilia by such a mechanism [62]. 
To summarize, we have shown that LPS 
stimulation of DC suppresses the Th2 
dependent development of eosinophilic 
airway inflammation independently 
of IL-12. In addition, the IL-12 expres-
sion levels of DC could not predict their 
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polarizing capacity in vitro and in vivo, 
arguing against the recently proposed 
pathway of kinetics of activation, in 
which LPS-induced exhaustion of IL-12 
secretion determines Th cell polariza-
tion. 
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Introduction
Asthma is an inflammatory disease of the airways leading to significant 
morbidity and mortality. With advances 
in the understanding of the molecular 
and cellular mechanisms involved in 
the asthmatic response, researchers 
have identified specific mediators that 
may be targeted to control the inflam-
matory state of asthma. The Th2 hy-
pothesis proposes that the inflamma-
tion in asthma arises from an imbalance 
between the two CD4+ T lymphocyte 
subsets, Th1 and Th2. Th2 cells release 
many cytokines that have been shown 
to regulate the inflammatory response, 
while it has been suggested that the 
Th1 cytokines counteract this response 
[1]. As Th2 cells are the main orches-
trators of allergic airway inflammation, 
elucidating how these cells arise from 
their precursors is an area of intense re-
search [2]. Airway dendritic cells play a 
crucial role in this process as they pick 
up allergen in the lung and transport it 
to the draining lymph nodes (LN) where 
they prime naïve CD4+ T cells to differ-
entiate into Th1, Th2 or regulatory T 
cells [3-9]. The precise mechanisms by 
which DCs determine Th polarization in 
the lung are currently unknown. It was 
suggested that the lung tissue microen-
vironment is Th2-prone, although the 
exact explanation for this observation 
is unclear [10-12]. Several factors be-
sides tissue environment influence Th 
cell differentiation through effects on 
DCs, in particular the type and dose of 
antigen, and the presence of polarizing 
microbial motifs acting through pattern 
recognition receptors [13-16]. Integra-
tion of these different stimuli in DCs 
leads to the expression of MHC-peptide 
and costimulatory molecules, and to the 
release of cytokines and chemokines, 
resulting in a polarization signal for na-
Abstract
It has been postulated that low level IL-12 production of antigen presenting 
cells is associated with the risk of developing atopic asthma. To study the re-
lationship between IL-12 production capacity of dendritic cells (DCs) and de-
velopment of T helper (Th) type 2 responses in the lung, we genetically engi-
neered DCs to constutively overexpress bioactive IL-12. Retrovirally mediated 
overexpression of IL-12 in DCs strongly polarized naïve ovalbumin (OVA)-spe-
cific CD4+ T cells towards Th1 effector cells in vitro. After intratracheal injec-
tion, OVA-pulsed IL-12 overexpressing DCs failed to induce Th2 responses in 
vivo and no longer primed mice for Th2 dependent eosinophilic airway inflam-
mation upon OVA aerosol challenge, readily observed in mice immunized with 
sham-transfected OVA pulsed DCs. Analysis of a panel of cytokines and chemo-
kines in the lung demonstrated that the lack of Th2 sensitization was accompa-
nied by increased production of the Th1 cytokine IFN-γ, chemokines induced 
by IFN-γ and of the immunoregulatory cytokine IL-10. When Th2 priming was 
induced using OVA/alum prior to intratracheal DC administration, DCs consti-
tutively expressing IL-12 were no longer capable of preventing eosinophilic 
airway inflammation, and even enhanced it. These data directly show that high 
level expression of IL-12 in DCs prevents the development of Th2 sensitization. 
Enhancing IL-12 production in DCs should be seen as a primary prevention 
strategy for atopic disorders. Enhancing IL-12 production in DCs is less likely 
to be of benefit in already Th2 sensitized individuals.
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ïve CD4+ T cells [2, 13]. A key cytokine 
produced by DCs involved in Th polar-
ization is IL-12, which polarizes naïve 
CD4 T cells towards the Th1 end of the 
spectrum [17, 18]. It has been suggested 
that lung DCs in a resting state produce 
little bioactive IL-12p70, which might 
explain the Th2 prone state of the lung 
[5, 12].  
Based on several observations, a re-
duced capacity of DCs to provide pro 
Th1 signals, such as IL-12, has been 
implicated in the development of Th2 
responses to inhaled allergens. Firstly, 
DCs from atopic individuals and their 
immediate blood monocyte precursors 
produce less IL-12p70 compared with 
non-atopic controls [19, 20].  Secondly, 
sensitization to inhaled allergens occurs 
predominantly before the age of 12, 
when the capacity to produce IL-12 is 
severely reduced compared with adults, 
potentially explaining the Th2 bias at a 
young age [21, 22]. In children at risk 
for allergic diseases, low IL-12 produc-
tion by circulating DCs in the neonatal 
period is associated with stronger Th2 
responses to inhaled and food allergens 
[23]. Thirdly, polymorphisms in the IL-
12B gene promoter leading to lower 
levels of IL-12 production are associat-
ed with an enhanced severity of atopic 
asthma in children [24]. Finally, certain 
diseases characterized by high level 
production of IL-12 such as multiple 
sclerosis are associated with a reduced 
risk of developing allergic diseases [25, 
26]. 
Together, these papers suggest that low 
IL-12 levels in DCs are associated with 
the risk of developing Th2 immunity 
to allergens, whereas high levels of IL-
12 production seem to offer protection 
from allergic diseases.  In this paper, we 
have directly addressed this issue by 
retrovirally overexpressing IL-12 p35 
and p40 in DCs that were subsequently 
used to sensitize mice to inhaled anti-
gens. For this purpose we used a previ-
ously established model of eosinophilic 
airway inflammation that utilizes ex-vivo 
generated bone marrow DCs injected in 
the airways to prime naïve CD4+ T cells 
[4, 27]. Overexpression of IL-12 in DCs 
(IL12-DC) strongly reduced Th2 sensiti-
zation to inhaled antigen and abolished 
subsequent eosinophilic airway inflam-
mation, by skewing the response to-
wards strong Th1 immunity. However, 
DCs overexpressing IL-12 were not ca-
pable of preventing eosinophilic airway 
inflammation in animals sensitized pri-
or to IL12-DC instillation, and even en-
hanced eosinophilic airway inflamma-
tion. These data directly show that high 
level expression of IL-12 in DCs can pre-
vent the development of Th2 sensitiza-
tion and therefore should be seen as a 
primary prevention strategy for atopic 
disorders. Enhancing IL-12 production 
in DCs is less likely to be beneficial in 
already sensitized individuals. 
Material & Methods
Mice
Female Balb/c mice (6-10 wks old) were pur-
chased from Harlan (Horst, The Netherlands). 
OVA323-339-specific, MHCII restricted, TCR trans-
genic (DO11.10) mice [28] were obtained from 
The Jackson Laboratory (Bar Harbor, ME). Mice 
were housed in microisolators under specified 
pathogen-free conditions and experiments were 
performed under approval of the Erasmus MC 
committee for animal ethics.
Retroviral vectors and generation of ret-
roviral particles
The retroviral construct secreting bioactive IL-
12p70 (pMFG-IL12) was generated by cloning of 
the murine IL-12 subunits p35 and p40 into the 
moloney murine leukemia virus derived backbone 
MFG [29]. The p35 gene was cloned by PCR from 
pcDNA1Amp-p35 (a kind gift from Dr. T. Gajew-
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ski) with the forward primer 5’-cccatgggtcaatcac-
gctacctcc-3’ and the reverse primer 5’-cccctcag-
gcggagctcagatagccc-3’. This PCR product was 
cloned in pCR2.1 and completely sequenced. The 
p35 fragment was digested with NcoI and EcoRV 
and cloned into NcoI-SmaI restricted pBlue-IRES 
(obtained by transfer of the EcoRI-BamHI IRES 
fragment). The HindIII-XhoI p40 fragment from 
pcDNA1Amp-p40 (also a gift from Dr. T. Gajew-
ski) and the XhoI-BamHI IRES-p35 fragment were 
cloned in a three-fragment ligation in pEE14 Hin-
dIII-BamHI. The entire IL-12 (p40-IRES-p35) gene 
was excised with BamHI and cloned in pMFG (a gift 
from Dr. O. Danos). A retroviral vector not express-
ing a gene was used to control for virus-specific 
effects (pMFG-S). Retroviral particles were pro-
duced by transient transfection as described [30], 
with the minor modification that the medium con-
sisted of DC culture medium (DC-CM; RPMI 1640 
containing glutamax-I (Invitrogen, Carlsbad, CA) 
supplemented with 5% (v/v) FCS (Biocell, Rancho 
Dominguez, CA), 50 µM β-ME (Sigma, St Louis, 
MO) and 50 µg/ml gentamycin (Invitrogen). 
Generation and retroviral transduction 
of bone marrow derived DCs
Bone marrow (BM) derived DCs were generated 
as described [30], with some minor modifications. 
After red blood cell lysis, BM cells were incubated 
for 30 min with a panel of monoclonal antibodies 
consisting of anti-CD4 (GK1.5), anti-CD8 (53-6.7), 
anti-CD45R (RA3-6B2) anti-Ly6-G (RB6.8C5) and 
anti-I-Ab,d,q/I-Ed,k (M5/114) to deplete lineage posi-
tive cells. All the Abs used were purchased from 
BD Biosciences (San Diego, CA), except anti-I-Ab,d,q/
I-Ed,k which was produced in-house. Ab-labeled 
cells were incubated with sheep anti-rat Ab-coated 
magnetic beads (Dynal, Oslo, Norway) at a cell-
to-bead ratio of 1:4. Lineage-negative cells were 
plated in 24-well culture plates (106 cells/ml; 1 
ml/well) in DC-CM supplemented with 20 ng/ml 
recombinant mouse GM-CSF (produced in-house) 
and 10 ng/ml recombinant human Flt3-L, (a gener-
ous gift of Dr. C. Maliszewski, Amgen, Seattle, WA). 
After overnight incubation, the cells were replated 
in 24-well culture plates (5 x 105 cells/well in 1 
ml). On days 2, 3, and 4 the medium was removed 
and replaced with 1 ml viral transfection superna-
tant containing 8 µg/ml polybrene (Sigma). DCs 
transduced with MFG-IL12 containing supernatant 
are hereafter designated IL12-DC, MFG-S trans-
duced DCs are hereafter named control-DC. The 
cells were transduced during centrifugation of the 
24-well plates for 2 h at 2500 rpm at 32 °C, after 
which the supernatant was replaced with DC-CM 
supplemented with 10 ng/ml recombinant human 
Flt3-L and 20 ng/ml recombinant mouse GM-CSF. 
At day 7 and 9, the medium was refreshed with 
DC-CM supplemented with 20 ng/ml recombinant 
mouse GM-CSF. At day 10, cells were pulsed with 
OVA protein (100 µg/ml). This batch of OVA con-
tained low levels of LPS (29 endotoxin units per 
mg; Worthington Biochemical Corp, Lakewood, 
NJ) and did not induce IL-12 production in puri-
fied BM-DCs (data not shown).  After 24 h, DCs 
were harvested by gentle pipetting and washed 
three times with PBS. Expression and secretion of 
IL-12p70 was confirmed with a commercial avail-
able ELISA (BD Biosciences).
Effect of IL-12 overexpression in DCs on 
T cell polarization in vitro and in vivo
Spleen and LN cells were obtained from DO11.10 
mice and untouched CD4+ T cells were isolated by 
negative depletion with a commercially available 
panel of biotin-conjugated antibodies, followed 
by labeling with anti-biotin MACS beads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). The resulting 
population was typically > 95% CD4+. Cells were 
labeled with CFSE as described previously [8, 27]. 
5 x 105 cells were cultured with OVA-pulsed, MFG-
IL12 or control virus transduced DCs, starting at a 
DC to T cell ratio of 1:10 up to 1:160 in 48-wells 
plates. After 96 h, cells and supernatant were har-
vested and OVA-specific T cell proliferation and 
cytokine levels were determined.
To examine the primary immune response in vivo, 
107 CFSE labeled transgenic CD4+ T cells specific 
for OVA323-339 were adoptively transferred i.v. 
into naive Balb/c mice on day -2. On day 0, mice 
(n=8-10 per group) were intratracheally (i.t.) im-
munized with 106 OVA-pulsed IL12-DC or OVA-
pulsed control-DC. On day 4, mice were sacrificed 
and mediastinal LN (MLN) and axillary LN (ALN) 
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were collected separately. Single cell suspensions 
of LNs were prepared by mechanical disruption 
and analyzed by flow cytometry or were restimu-
lated (2 x 106 cells per ml) with 10 µg/ml OVA 
for 96 h, after which supernatants were harvested 
and assayed for IL-4, IL-5, IL-10, IL-13 and IFN-γ 
content. 
Effect of IL-12 overexpression in DCs on 
the potential to induce asthma
Groups of mice (n=4-10 per group) were immu-
nized i.t. on day 0 with 1 x 106 IL12-DC or con-
trol-DC pulsed overnight with OVA. From day 10 
onwards, mice were exposed to OVA aerosols (1% 
(w/v) in PBS generated through jet nebulizers) for 
3-4 consecutive days, 30 min daily as previously 
mentioned [8]. Twenty-four hours after the last ex-
posure mice were sacrificed and bronchoalveolar 
lavage (BAL) was performed as described [31]. In 
one experiment analyzing gene expression levels 
of cytokines, chemokines and chemokine recep-
tors, lungs were excised, snap-frozen in liquid ni-
trogen and stored at ‒80 °C until processing for 
RNA analysis. 
In a second experiment, the effect of IL-12 over-
expressing DCs on the development of asthma in 
already sensitized mice was studied. Therefore, 
groups of mice (n=5-10 per group) were first im-
munized i.p. with 10 µg OVA emulsified in 1 mg 
aluminum hydroxide (Sigma), a protocol previ-
ously shown to induce strong Th2 priming for 
OVA [31]. Ten days later, control-DC and IL12-DC, 
either pulsed or not with OVA, were i.t. injected. 
At day 20, 21 and 22, mice were challenged with 
OVA aerosol as described above, and after 24 h the 
degree of airway inflammation was analyzed.
Airway histology 
In some experiments, after BAL lungs were slowly 
inflated with a 1:1 (v/v) mixture of PBS and OCT 
compound, excised, snap-frozen in liquid nitrogen 
and stored at ‒80 °C until further processing. 7 
µm sections were cut, subsequently stained with 
hematoxylin and periodic acid-Schiff reagent (PAS; 
Sigma) and photographed with a Leica DM-LB mi-
croscope (Leica Microsystems, Rijswijk, The Neth-
erlands).
Flow cytometry 
To reduce non-specific antibody binding, anti-
FcγRII antibody (2.4G2, ATCC, Manassas, VA) was 
included in all cell surface stainings. To study T cell 
priming in vitro or the primary immune response in 
adoptive transfer experiments, T cells were labeled 
with CFSE and with the anti-clonotypic DO11.10 
TCR Ab KJ1-26 [28]. For the in vivo experiments 
anti-CD4-APC (RM4-5) was also included. Dead 
cells were excluded by labeling with TOPRO-3 
(Molecular Probes, Leiden, The Netherlands) or 
propidium iodide (PI) prior to acquisition. Cell divi-
sions were quantified as described [8]. Briefly, the 
CFSE data set was fitted with algorithms provided 
by the analysis program FlowJo (Treestar, San Car-
los, CA), resulting in two parameters that describe 
the proliferation. The proliferation index (PRI) has 
been defined as the average number of divisions of 
the cell fraction that divided and the responder fre-
quency (%D) as the percentage of input cells that 
responded to stimulation by dividing.
Anti-CCR3-PE was used to detect eosinophils in 
the lung [32], together with anti-CD8-PECy5 (53-
6.7) and anti-CD4-APC to determine the cellular 
composition in BAL. All fluorochrome-conjugated 
antibodies were purchased from BD Biosciences, 
except anti-CCR3-PE, which was from R&D Sys-
tems (Minneapolis, MN) and anti-clonotypic-TCR-
PE (KJ1-26), which was from Caltag Laboratories 
(Burlingame, CA). Events were acquired on a FACS 
Calibur flow cytometer (BD Biosciences) and ana-
lyzed with FlowJo software.
Cytokine measurements
Levels of IL-12p70, IL-4, IL-5, IL-10 and IFN-γ in 
culture supernatants or BAL were measured using 
OptEIA kits (BD Biosciences) according to manu-
facturer’s instructions. IL-13 levels were measured 
using a commercially available kit from R&D Sys-
tems.
Real-time quantitative RT-PCR
Frozen lung tissue was homogenized, RNA isolated 
with RNeasy midi-prep columns (Qiagen, Hilden, 
Germany) and treated on-column with DNaseI, ac-
cording to the manufacturer’s protocol. 1 µg RNA 
was reverse transcribed using SuperscriptII (Invit-
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rogen) and random hexamers (Amersham Biosci-
ences, Roosendaal, The Netherlands) for 120 min 
at 42 °C. Primer sequences are listed in table 1. 
PCR conditions were 2 min at 50 °C, 10 min at 95 
°C, followed by 40 cycles of 15 s at 95 °C and 60 
°C for 1 min using an ABI PRISM 7900 HT (Applied 
Biosystems, Foster City, CA) and SYBR Green mas-
termix (Stratagene, La Jolla, CA). Water controls 
were included to ensure specificity and primer 
pairs were evaluated for integrity by analysis of 
the amplification plot, dissociation curves and ef-
ficiency of PCR amplification. PCR amplification of 
the housekeeping gene ubiquitin C was performed 
during each run for each sample to allow normal-
ization between samples.
Statistical analysis
Reported values are expressed as mean ± standard 
error of the mean (SEM), unless indicated other-
wise. Statistical analyses were performed with 
SPSS (SPPS Inc, Chicago, IL) using a Mann-Whit-
ney U-test. p-values less than 0.05 were considered 
significant.
Results
Genetically engineered DCs expressing 
high levels of IL-12 polarize naïve CD4+ 
T cells towards Th1 in vitro
Following transduction of DCs with a 
retroviral vector encoding for IL-12p70 
(IL12-DC), we detected significantly 
higher levels of IL-12 p70 in the super-
natant at day 11 (median 183 ng/ml, 
range 73-919 ng/ml, n=8 transduc-
tions) compared with DCs transduced 
with the control constructs (control-DC; 
median 0 ng/ml, range 0-2.2 ng/ml, 
n=8 transductions). Phenotypic analy-
sis at day 11 by FACS revealed that 
the cells exhibited cell surface expres-
sion of markers characteristic for DCs 
(CD11c, MHCII, CD40, CD80, CD86; 
data not shown), which has been previ-
ously shown by us and others [30, 33]. 
It should be noted that no differences 
Table 1: Primer sequences used for real-time quantitative RT-PCR
gene forward primer reverse primer Amplicon (bp)
UbiquitinCa AGGTCAAACAGGAAGACAGACGTA TCACACCCAAGAACAAGCACA 80
IL-4b CTCATGGAGCTGCAGAGACTCTT CATTCATGGTGCAGCTTATCGA 70
IL-5b CTCACCGAGCTCTGTTGACAAG CCAATGCATAGCTGGTGATTTTTAT 79
IL-6b ACACATGTTCTCTGGGAAATCGT AAGTGCATCATCGTTGTTCATACA 84
IL-10a GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT 191
IL-13b TGACCAACATCTCCAATTGCA TTGTTATAAAGTGGGCTACTTCGATTT 132
IFN-γa TCAAGTGGCATAGATGTGGAAGAA TGGCTCTGCAGGATTTTCATG 92
CCL2a CTTCTGGGCCTGCTGTTCA CCAGCCTACTCATTGGGATCA 127
CCL7b GGGAAGCTGTTATCTTCAAGACAAA CTCCTCGACCCACTTCTGATG 74
CCL11b CCAGGCTCCATCCCAACTT TGGTGATTCTTTTGTAGCTCTTCAGT 88
CCL17b GGATGCCATCGTGTTTCTGA GCCTTCTTCACATGTTTGTCTTTG 75
CXCL5c TCACACTATCGGAAATTGTGATACTTTA AATGCAATAGTCACCCTCAGTTCA 96
CXCL9b TGCACGATGCTCCTGCA AGGTCTTTGAGGGATTTGTAGTGG 63
CXCL10b GACGGTCCGCTGCAACTG GCTTCCCTATGGCCCTCATT 65
References
a Pattyn, F., Speleman, F., De Paepe, A. & Vandesompele, J. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids 
Res 31, 122-3 (2003), b Hurst, S.D. et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function 
of the novel cytokine IL-25. J Immunol 169, 443-53 (2002). c S. Manning, Millenium Pharmaceuticals
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could be observed in the levels of matu-
ration markers between control and 
IL-12 transduced DCs as determined 
by FACS analysis (data not shown and 
[30]).
As DC-derived IL-12 is a potent induc-
er of Th1 responses in vitro as well as 
in vivo [18], we first established the T 
cell polarizing capacity of IL12-DC in 
vitro. OVA-specific, CFSE labeled CD4+ 
T cells were cultured with OVA-pulsed 
IL12-DC or control-DC at various ratios 
of DC and T cells. After four days the 
proliferation of OVA-specific T cells and 
the levels of cytokines in the culture su-
pernatants were assayed. There was a 
major difference in cytokine secretion 
pattern, with increased levels of the Th1 
prototype cytokine IFN-γ as well as IL-
10 when IL12-DC were used as APC at a 
high DC-T cell ratio, while priming with 
control-DC resulted in higher levels of 
the Th2-associated cytokines IL-4, IL-5 
and IL-13 compared with IL12-DC (Fig. 
1A). Because cytokine production was 
not quantified on the single-cell level 
but on the whole population and it has 
been reported that cytokine produc-
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Figure 1 IL-12 producing DCs have equal stimula-
tory capacity but skew naïve CD4+ T cells towards 
Th1 in vitro. BM derived DCs were retrovirally trans-
duced with a vector encoding IL-12p70 (IL12-DC) 
or a control construct (control-DC) and pulsed with 
OVA (100 µg/ml). After 24 h, cells were harvested, 
washed and put into culture with purified, CFSE 
labeled, OVA-specific (DO11.10) CD4+ T cells (5 
x 105) at various ratios. Four days later, cells and 
supernatant were harvested, the division profile of 
CFSE labeled cells as well as cytokine levels in the 
supernatant were determined. A, Levels of cyto-
kines in the supernatant at various DC to T cell ra-
tios. Results are representative for two independent 
experiments. Note the different scale of the graph 
depicting IFN-γ levels. B, Division profile of living 
(TOPRO-3-), OVA-specific (KJ1-26+) CD4+ cells, 
stimulated with either control-DC (dashed line) or 
IL12-DC (solid line). The various ratios of DC to T 
cells are indicated above each histogram. Of note, 
there was no cell division when unpulsed DCs were 
used as APC (data not shown). 
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tion may be dependent on the number 
of T cell divisions [34], we also veri-
fied whether the observed differences 
in cytokine production were attribut-
able to differences in division profiles 
of divided T cells. The division profiles 
of T cells stimulated with either IL12-
DC or control-DC were identical, except 
for the highest DC to T cell ratio, when 
IL12-DC driven T cell proliferation was 
slightly lower compared to the control-
DC group (Fig. 1B). Thus, the observed 
differences in cytokine expression pat-
terns are likely to be caused by differ-
ences in polarization of primed T cells 
and not in differences in total CD4+ T 
cell number or division history. More-
over, the efficient proliferation of naïve 
CD4+ T cell demonstrated that retro-
virally transduced DCs are functional 
APC. 
Genetically engineered DCs expressing 
high levels of IL-12 migrate efficiently 
to lung draining lymph nodes but do not 
strongly polarize naïve CD4+ T cells in 
vivo
Next, we investigated the polarizing 
capacity of IL12-DC in the draining LN 
of the lung. OVA-specific T cells were 
adoptively transferred into syngeneic 
recipient mice which were subsequent-
ly immunized with OVA-pulsed IL12-
DC or control-DC. Four days later the 
MLN and ALN were removed, lympho-
cytes cultured ex-vivo and cytokines in 
the supernatant determined (Fig. 2A). 
In contrast to the in vitro studies, the 
Th2-type cytokines IL-4 and IL-5 were 
similar when IL12-DC were used as 
APC, only the IL-13 levels were statisti-
cally significantly decreased compared 
to control-DC. High levels of IFN-γ were 
produced in mice immunized with both 
control-DC and IL12-DC. Also, IL-10 lev-
els were decreased in the IL12-DC im-
munized group, contradictorily to the in 
vitro studies. 
To rule out the possibility that the prim-
ing of T cell was weaker or altered due 
to decreased migration or increased 
cell death of i.t. injected DCs, we inject-
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Figure 2 IL12-DC have equal stimulatory capac-
ity but a distinct T helper cell differentiation capac-
ity in vivo. Naïve Balb/c mice received a cohort of 
DO11.10 T cells and were subsequently immu-
nized with either OVA pulsed IL12-DC (n=8-10) or 
OVA pulsed control-DC (n=8-9). Four days later, 
mediastinal lymph nodes (MLN) and axillar lymph 
nodes (ALN) were resected and analyzed for the 
presence of OVA-specific, CFSE+, CD4+ T cells di-
rectly or stimulated with OVA in vitro for four days. 
A, Cytokine levels after in vitro restimulation with 
OVA. No cytokines could be detected in cultures 
of ALN (data not shown). Results are expressed 
as mean ± SEM from 7-8 mice per group. *: p< 
0.05. B, Cell division profile of OVA transgenic T 
cells (KJ1-26+, PI-, CD4+) in the MLN and ALN was 
assessed by flow cytometry. Dot plots shown are 
from representative mice of each group. Results 
are representative for one (cytokines) or two (divi-
sion profile) independent experiments.
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ed mice with a cohort of CFSE labeled, 
OVA-TCR CD4+ T cells which we subse-
quently immunized with OVA-pulsed 
IL12-DC or control-DC. Four days later, 
MLN and ALN were dissected and the 
division profile of OVA-specific T cells 
was analyzed. The division profile in 
the MLN was identical in control-DC 
and IL12-DC immunized animals (Fig. 
2B, upper panels). This was confirmed 
by quantification of the cell prolifera-
tion, which revealed a slight increase in 
both the average number of divisions of 
divided T cells (PRI) and the responder 
frequency, defined as the cell popula-
tion that participated in clonal expan-
sion (Table 2). In the ALN, representing 
the non-draining lymph nodes, some 
OVA-specific T cells that underwent 
multiple divisions (>5) were present 
(Fig. 2B, lower panels). As no cells that 
had divided 1-2 times were present at 
this non-draining site these cells rep-
resent recirculating effector cells, as 
previously shown [27]. Thus, these data 
show that IL-12 transduced DCs have 
a similar stimulatory capacity in vivo 
compared with control-DC and induce a 
T cell response characterized by a de-
creased IL-13 production. 
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Figure 3 IL12-DC fail to induce eosinophilic airway 
inflammation. On day 0, groups of mice were im-
munized by i.t. administration of 1 x 106 IL12-DC 
or control-DC. On days 10 to13, mice were ex-
posed to OVA aerosols for 30 min daily. At 24 h 
after the last exposure mice were sacrificed, BAL 
and lung histology performed, and lymph nodes 
isolated as described in Materials and methods. 
A, total cell number in BAL fluid. B, Cellular com-
position of BAL fluid. Alveolar macrophages were 
characterized by their light scatter and autofluores-
cence properties. Eosinophils are defined by their 
CCR3+, CD4-, CD8- staining pattern. The T cell 
fraction consists of CD4+ and CD8+ cells within the 
appropriate light scatter gate. C, Cytokine levels in 
BAL fluid. D, Leukocyte infiltration and PAS stain-
ing in lungs of control-DC or IL12-DC immunized 
mice. Solid arrowheads indicate cellular infiltrate, 
open arrowheads indicate mucus accumulation 
(PAS+). Results are expressed as means ± SEM. 
*: p< 0.05. Data shown is representative of 3 in-
dependent experiments with 4-10 mice per group. 
ND, none detected
Table 2: Quantification of OVA-specific CD4
+
 T 
cell proliferation in the MLN
Immunization Proliferation index 
(PRI) a
Responder frequencyb
IL12-DC 2.34 ± 0.05c 24.4 ± 3.5
control-DC 2.19 ± 0.04 19.9 ± 2.5
a defined as the average number of divisions of the CD4+, KJ1-26+, 
PI - cell population that divided
b defined as the percentage of input CD4+, KJ1-26+, PI - cells that 
responded to stimulation by dividing
c values represent the mean ± SEM of the data (n=8 animals per 
group)
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Genetically engineered DCs expressing 
high levels of IL-12 fail to induce eosino-
philic airway inflammation 
We have previously shown that OVA-
pulsed BM-DCs injected into the tra-
chea of naïve Balb/c mice induce sen-
sitization to inhaled OVA and to Th2 
dependent eosinophilic airway inflam-
mation upon OVA aerosol challenge [4]. 
This model was therefore well suited 
to study the effect of IL-12 overexpres-
sion on the potential of these cells to 
induce Th2 sensitization. As a measure 
of airway inflammation, we measured 
the total number of BAL fluid cells 24 h 
after a series of OVA aerosol challenges 
and observed that cellularity was lower 
when mice were immunized with OVA-
pulsed IL12-DC compared with control 
DCs (Fig. 3A). Unpulsed DCs did not in-
duce airway inflammation, as previous-
ly reported (data not shown and [4]). 
Further characterization revealed that 
the remaining cell population in IL-12 
DC immunized group was almost de-
void of eosinophils, in contrast to con-
trol-DC immunized mice. However, both 
groups contained identical frequencies 
of T lymphocytes, well above the level 
seen in mice immunized with unpulsed 
DCs (3-5%, ref [4]) (Fig. 3B). The levels 
of the Th2-associated cytokines IL-5 
and IL-13 in the BAL fluid were also 
significantly decreased in the IL-12 DC 
group compared with the control-DC 
group (Fig. 3C). As reported, histologi-
cal examination of the lungs demon-
strated large peribronchial infiltrates 
rich in eosinophils, as well as PAS-posi-
tive goblet cell hyperplasia in the OVA-
pulsed control-DC immunized group 
[4]. Animals immunized with IL12-DC 
however, showed only small peribron-
chial infiltrates devoid of eosinophils 
and almost no mucus production (Fig. 
3D), which is consistent with the BAL 
fluid data. 
Altogether, these data demonstrated 
that immunization with IL-12 produc-
ing DCs did not lead to eosinophilic 
airway inflammation, although the 
presence of peribronchial infiltrates 
in the lung and increased numbers of 
T cells in the BAL fluid indicated that 
mild inflammation was present. To fur-
ther characterize the type of inflamma-
tion induced, we measured an array of 
cytokines and chemokines which have 
been shown to be highly informative 
of the type of induced Th response in 
the lung [35]. Mice were immunized 
with OVA-pulsed IL12-DC or control-
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Figure 4 Gene expression pattern in the lungs of IL12-DC immunized mice suggests a Th1 response. 
Mice were immunized (4-5 per group) as described for figure 3. To account for OVA aerosol induced 
effects, a control group of non-immunized mice receiving only OVA aerosols was included. At day 14, 
lungs were excised, snap-frozen, RNA isolated and gene expression of selected cytokines and chemo-
kines was analyzed with real-time quantitative RT-PCR. A, expression levels of cytokine transcripts. B, 
expression levels of chemokine transcripts. Data shown are the ubiquitin-normalized values of transcript 
RNAs. Results are expressed as mean ± SEM. *: p< 0.05.
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DC and subsequently challenged via the 
airways. As a control, for the effect of 
OVA exposure per se, mice that did not 
receive DCs were challenged as well. 24 
h after the final aerosolization, lungs 
were harvested, snap-frozen and pro-
cessed for RNA. Gene expression levels 
were determined with real-time quan-
titative RT-PCR. Compared to S-DC and 
IL12-DC immunized animals, almost 
no cytokine and chemokine expression 
was observed in the lungs of mice that 
were solely challenged with OVA aero-
sol (‘no DC’ group, Fig. 4A). The cyto-
kine expression pattern observed in the 
lung when animals were immunized 
with IL12-DC consisted of a Th1-like re-
sponse, with significantly elevated lev-
els of IFN-γ mRNA and a trend towards 
a lower expression of the Th2-type cy-
tokines IL-5 and IL-13 (Fig. 4A). Of note 
is the concurrent increased expression 
of IL-10 in IL-12 DC immunized mice, 
also observed during in vitro CD4+ T cell 
priming by these DCs (Fig. 1A). The che-
mokine expression pattern in the lung 
of these mice correlated highly with 
the Th1-type cytokine expression pat-
tern, as the IFN-γ-inducible chemokines 
IP10/CXCL10 and MIG/CXCL9 were 
strongly increased compared to con-
trol-DC immunized mice. Also, the levels 
of MCP-1/CCL2 mRNA were increased. 
However, gene expression of the Th2-
associated chemokines eotaxin/CCL3, 
TARC/CCL17 and LIX/CCL5 was simi-
lar or slightly decreased when com-
pared to control-DC immunized mice 
(Fig. 4B). Taken together, it can be con-
cluded that the overall gene expression 
pattern of cytokines and chemokines of 
IL12-DC-immunized mice suggested a 
Th1-type of response in the lung, which 
is in agreement with the cellular com-
position and cytokine levels in the BAL 
fluid (Fig. 3B&C).
Genetically engineered DCs expressing 
IL-12 fail to revert Th2 sensitization and 
exacerbate Th2-dependent lung inflam-
mation in sensitized mice. 
In view of the potential of Th1 cells 
to suppress the development of Th2 
responses, it has been suggested that 
Th1 cells might be of potential thera-
peutic benefit for Th2 mediated dis-
eases. Therefore, we next investigated 
if IL12-DC could suppress or revert a 
developing Th2 response (secondary 
prevention). Mice were first sensitized 
to OVA in the Th2 adjuvant alum and 
subsequently treated with OVA-pulsed 
IL-12 DC or OVA-pulsed control-DC ten 
days later. Another 10 days later, mice 
were challenged with 3 OVA aerosols. 
As a control, mice received unpulsed 
IL12-DC, control DC, or no DCs. As 
shown in figure 5, administration of 
unpulsed IL12-DC or control DC after 
priming did not affect eosinophilic air-
way inflammation and Th2 cytokine in 
the BAL fluid. Exposure of mice to OVA-
pulsed DCs, irrespective of their IL-12 
production capacity, led to severely en-
hanced eosinophilic airway inflamma-
tion, with enhanced total cell recovery, 
increase in the frequency of eosinophils 
(Fig. 5A) and increase of IL-5 and IL-13 
in the BAL fluid (Fig. 5B). Thus, IL12-DC 
are not capable of suppressing a devel-
oping Th2-dependent airway response, 
but rather enhance it when presenting 
OVA to previously sensitized mice.
Discussion
In this paper, we have directly ad-
dressed whether high level expression 
and secretion of IL-12 in DCs is suffi-
cient to reduce sensitization to inhaled 
antigens. For this, we first overex-
pressed the IL-12 p35 and p40 subunit 
using a retroviral vector that minimally 
94
Ch
ap
te
r 
4
affected the expression of costimula-
tory molecules on DCs and studied the 
effect on Th differentiation in vitro and 
in vivo by injecting DCs into the Th2 
prone lung compartment [10]. In vitro, 
we observed a profound polarization of 
the cytokine production of naïve CD4+ 
T cells towards a Th1 phenotype when 
IL-12 producing DCs were used as APC. 
This was reflected by decreased levels 
of IL-4, IL-5, IL-13 and increased levels 
of IFN-γ compared to control-DC. A strik-
ing observation was the concurrent in-
crease of IL-10 with IFN-ã when IL12-DC 
were used to prime CD4+ T cells. This was 
shown before for human T cells derived 
from cell cultures primed in the pres-
ence of IL-12 [36, 37]. As we examined 
IL-10 gene expression at the population 
level but not at the single-cell level, we 
cannot conclude that IL-10 and IFN-γ 
are produced by the same cell. An ap-
propriate candidate would be a subset 
of regulatory T cells, which produce IL-
10 and IFN-γ and have been shown to 
be generated in the lungs of mice upon 
challenge with microbial pathogens 
that induce IL-12 [38]. At a high DC to 
T cell ratio (1:10), T cell proliferation 
was slightly lower when IL12-DC were 
used as APC. Grogan et al., reported a 
similar phenomenon, when they stimu-
lated naïve CD4+ T cells with anti-CD3 
and anti-CD28 antibodies under strong 
Th1 polarizing conditions, implicating 
that lower proliferation is intrinsic to 
strongly polarized Th1 cells [39]. At 
lower DC to T cell ratios, proliferation 
was identical between both groups, in-
dicating that Th1 polarization was a di-
rect effect of IL-12 overexpression and 
was not due to the fact that IL12-DC 
were more mature APCs and thus pro-
vided a stronger strength of stimulus to 
T cells, known to influence Th polariza-
tion [40-42]. Ex-vivo lymph node recall 
responses to OVA antigen from mice im-
munized with IL12-DC were less clearly 
polarized. As only a small percentage of 
i.t. injected DCs migrate to the MLN [8], 
a possible explanation might be that na-
ïve T cells became less polarized in vivo 
due to a lower DC to T cell ratio, as sup-
ported by the in vitro data.
The Th2 hypothesis of asthma pro-
poses that airway inflammation arises 
from an imbalance between Th1 and 
Th2 CD4+ T lymphocyte subsets. Th2 
cells release many cytokines that have 
been shown to regulate the inflamma-
tory response, while it has been postu-
lated that Th1 cytokines may counter-
act this response [1]. Not surprisingly, 
systemic or lung administration of the 
Th1-polarizing cytokines IFN-γ or IL-12 
during sensitization to inhaled allergen 
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Figure 5 IL12-DC are unable to suppress a developing eosinophilic airway inflammation. Mice were 
immunized by i.p. injection of OVA/alum. Ten days later, mice were injected i.t. with IL12-DC and control-
DC, either or not pulsed with OVA. To control for the effect of i.p. immunization alone, one group did not 
receive DCs (‘no DC’). From day 20 onwards, mice were challenged with OVA aerosol for three consecu-
tive days. Airway inflammation was analyzed at day 24, as described for figure 3. Results are expressed 
as mean ± SEM from 9-10 mice per group. *: p< 0.05 vs. ‘no DC’ group.
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was able to inhibit all the cardinal fea-
tures of asthma through induction of a 
counterregulatory Th1 subset [43-46]. 
It was therefore of interest to study 
whether IL-12 overexpression in DCs 
also abolished the potential of these 
cells to prime for eosinophilic airway 
inflammation, a defining characteristic 
of asthma. DCs overexpressing IL-12 
p70 no longer induced eosinophilic air-
way inflammation or goblet cell hyper-
plasia, and concomitantly a reduction 
was seen in IL-5 and IL-13, known to 
cause eosinophilic airway inflammation 
and goblet cell hyperplasia [47, 48].  In 
contrast, untransfected DCs producing 
low levels of bioactive IL-12 caused all 
the salient features of asthma, as pre-
viously reported [4, 8]. These obser-
vations have important implications 
for understanding the mechanisms 
underlying Th2 sensitization and de-
velopment of allergic diseases. Several 
authors have suggested that low level 
production of bioactive IL-12 in APCs 
underlies the propensity of atopic in-
dividuals to develop Th2 responses to 
commonly inhaled allergens [19, 20, 
24]. Conversely, the level of exposure 
to microbial stimuli in early life, known 
to induce high level production of IL-
12 in APCs, is inversely correlated with 
the development of atopic sensitization 
[49]. Several animal models have shown 
that bacterial stimuli such as heat killed 
Listeria monocytogenes, bacterial LPS 
and mycobacterium Bacille Calmette 
Guérin (BCG) reduce the onset of Th2 
sensitization and eosinophilic airway 
inflammation typical of asthma, while 
at the same time strongly enhancing 
the production of IL-12 in vivo [7, 8, 50-
53]. Our data suggest that the induction 
of IL-12 by these microbial patterns is 
more than just a marker of the Th1 bias 
induced by microbes but is causally re-
lated to the inhibition of sensitization. 
Although airway inflammation was 
strongly reduced in IL12-DC immu-
nized mice, compared with control DC 
immunized mice, there was still induc-
tion of BAL fluid lymphocytosis (18%, 
Fig. 3A) and mild lymphocytic infiltra-
tion around blood vessels (Fig. 3D), well 
above the levels of 1-5% normally seen 
in naïve or sham sensitized mice [4]. 
Although this could be the reflection 
of a Th1 response to OVA aerosol, it 
was striking to see no associated neu-
trophilic inflammation, classically as-
sociated with Th1 responses to inhaled 
OVA [54-56]. It was therefore of interest 
to study the cytokine and chemokine 
expression pattern in the lungs of IL12-
DC immunized mice [35, 57]. By quan-
titating the mRNA expression level of a 
panel of cytokines and chemokines, we 
obtained evidence that immunization 
with IL12-DC resulted in a Th1 domi-
nated lung pathology, with significantly 
increased levels of IFN-ã mRNA in the 
lung. The chemokine expression pattern 
was in accordance with a predominant 
Th1 response as increased expression 
of CXCL9/MIG and CXCL10/IP-10 was 
seen [39, 57, 58]. CXCL9 and CXCL10 
are ligands for CXCR3, a chemokine 
receptor highly expressed on Th1 cells 
and believed to be important for migra-
tion of these cells to the lung [58-60]. 
The mRNA levels of the macrophage 
derived CCL2/MCP-1 chemokine, were 
also slightly increased as a reflection of 
Th1 mediated pathology, the most likely 
source being the increased numbers of 
alveolar macrophages [35]. Strikingly, 
BAL fluid lymphocytosis and monocyto-
sis is characteristic of many Th1 medi-
ated lung diseases such as sarcoidosis, 
hypersensitivity pneumonitis and early 
transplant rejection. In these diseases, 
there is an increased production of IL-
12, eventually leading to expression of 
CXCL10/IP-10 chemokine within the 
96
Ch
ap
te
r 
4
lung [61, 62]. Our data suggest that IL-
12 overproduction in DCs in response 
to recognition of the known or un-
known antigens might be the cause of 
the deranged Th1 response leading to 
lymphocytary and monocytary alveoli-
tis.
Although these findings suggest a pre-
dominant Th1 response, we did not see 
a decrease in the expression of Th2 
associated chemokine CCL11/eotaxin 
mRNA nor in levels ofIL-5 and IL-13 
transcripts between the IL12-DC and 
control-DC group. As these chemokines 
and cytokines are known to attract eo-
sinophils to the lung [63], it was strik-
ing that there was a dramatic reduc-
tion in airway eosinophilia in IL12-DC 
immunized mice. This might reflect a 
discrepancy between mRNA levels and 
protein levels, as for IL-5 and IL-13 it is 
known that protein levels in the BAL are 
significantly decreased (Fig. 3C). Anoth-
er explanation could be the induction of 
IL-10 and IFN-γ production by IL12-DC. 
These cytokines have been shown to 
directly inhibit airway eosinophilia by 
reducing the recruitment of eosinophils 
or by inducing their apoptosis [64, 65]. 
Moreover, it was very recently shown 
that CXCL9/MIG can act as a direct an-
tagonist of eotaxin-mediated eosinophil 
recruitment to the lungs [66]. Therefore 
the high levels of CXCL9/MIG in IL12-
DC mice might explain the absence of 
airway eosinophilia despite high levels 
of eotaxin production in the lung.
In view of the induction of a polarized 
Th1 response by IL12-DC in the lung, 
we questioned whether IL-12 DC were 
also able to revert or suppress a devel-
oping Th2 response to OVA antigen. 
In contrast to the strong inhibition of 
Th2 responses seen in the primary im-
mune response to OVA, IL12-DC were 
unable to suppress eosinophilic airway 
inflammation in OVA/alum Th2 sensi-
tized mice. Rather, DCs given after Th2 
sensitization strongly enhanced airway 
inflammation and Th2 cytokine produc-
tion, irrespective of IL-12 production. 
It is known that polarization of primed 
Th2 cells is hard to revert, due to loss of 
IL-12R expression on these cells [67]. It 
has also been shown that antigen-spe-
cific Th1 lymphocytes can enhance the 
potential of Th2 lymphocytes to cause 
all the cardinal features of asthma, and 
therefore IL-12 DCs might exacerbate 
disease via Th1 induction [68, 69]. De-
spite this, exogenous administration 
of recombinant IL-12 can inhibit the 
salient features of asthma, even when 
given during the challenge phase in 
Th2 sensitized mice [43, 44, 70]. It is 
likely that these treatments lead to ef-
fects of IL-12 that are not mediated di-
rectly on T cell polarization. It has been 
shown that high systemic levels of IL-
12 suppress the bone marrow output of 
eosinophil precursors and can directly 
induce the apoptosis of eosinophils in 
the lungs [71]. Moreover, IL-12 directly 
suppresses the formation of eotaxin 
by lung epithelial cells, independently 
of IFN-γ [72]. As overexpression of IL-
12 was limited to injected DCs in our 
system, high local levels of IL-12 are 
only thought to occur in the draining 
mediastinal lymph nodes during inter-
action with T cells, not leading to high 
systemic or lung concentrations, which 
might explain the differences between 
recombinant IL-12 administration and 
IL-12 overexpression in DCs.
In summary, we show in this report that 
high level expression of IL-12 in DCs 
renders these cells incapable of induc-
ing Th2 sensitization to inhaled anti-
gen. Finding strategies that enhance IL-
12 production in endogenous lung DCs 
might lead to novel forms of prevention 
of allergic sensitization. 
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sponse induction
Manuscript in preparation
Harmjan Kuipers, Femke Muskens, Daniëlle Hijdra, Monique Willart, Thomas 
Soullié, Friso van Assema, Henk. C. Hoogsteden and Bart N. Lambrecht
104
Ch
ap
te
r 
5
Introduction
According to the two signal hypoth-esis of T cell activation, triggering 
of the TCR by peptide-MHC molecules 
(signal 1) needs to be accompanied by 
a second signal that cooperates with 
TCR signaling to induce optimal T cell 
activation and avoidance of anergy. Co-
stimulatory molecules were originally 
defined as signals that are necessary 
for activation of T cells but have no 
function in the absence of TCR signal-
ing [1]. However, numerous subsequent 
studies have shown that elimination of 
even crucial costimulatory molecules 
such as CD80 and CD86 or of the recep-
tor CD28 on T cells does not eliminate 
T cell responses in vivo, illustrating re-
dundancy of co-stimulatory molecules 
[2-4]. The two-signal hypothesis was 
further refined with the discovery of 
co-signaling molecules that deliver in-
hibitory signals, such as programmed 
death ligand-1 (PD-L1) and PD-L2 [5, 
6]. These findings, together with new 
insights in the role of antigen affinity in 
T cell activation as well as the contribu-
tion of the duration of T cell-APC inter-
actions to this process, has culminated 
in the definition of a progressive model 
of T cell activation. This model proposes 
that total signal strength delivered to T 
cells regulates the progression of T cells 
through hierarchical thresholds of pro-
liferation, differentiation an cell death 
[7]. As a consequence, costimulation 
can be viewed as a component of the 
Abstract
T cell activation is a complex, multi-step complex involving many molecules. 
One subset of molecules of particular importance is the family of costimulatory 
molecules expressed by antigen presenting cells. New members of this fam-
ily have been discovered in recent years including molecules with inhibitory 
properties such as programmed death ligand-1 (PD-L1) and PD-L2. PD-L1 (also 
known as B7-H1) and PD-L2 (B7-DC) are members of the B7 family of costimu-
latory molecules which are expressed on a variety of cells, including profes-
sional APCs such as dendritic cells (DC), but also non-lymphoid organs such as 
heart, lung and placenta. The receptor for these ligands is PD-1, expressed by 
T and B cells, which contains inhibitory ITIM/ ITSM domains. PD-1 deficient 
mice demonstrate generalized T cell hyperreactivity and mice develop signs of 
severe auto-immunity. Interestingly, PD-L1 expression by human tumors has 
been implicated in immune evasion. These data have raised the interesting hy-
pothesis that overexpression of PDL-1 and/or PDL-2 might be used to engineer 
APCs to induce tolerance to self or foreign antigens. We engineered bone mar-
row-derived DCs to overexpress murine PD-L1 or murine PD-L2 and used these 
engineered DCs to stimulate naïve OVA-specific (DO11.10) CD4+ T cells with 
increasing concentrations of antigen. Our results demonstrate that despite 
profound effects of PD1 ligation on IL-2 production, there were no defects in 
primary immune response induction in vitro or in vivo when DCs overexpressed 
PDL-1 or PDL-2, not even when the CD80 and CD86 pathway were eliminated 
by genetic targeting. These data suggest that strategies aimed at overexpress-
ing negative costimulatory ligands on APCs to induce tolerance to self or trans-
plantation antigens or to allergens are unlikely to be successful. PD-L1 and 
PD-L2 expression by non-APCs on peripheral tissues might be a more effective 
means of silencing T cell effector responses.
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total signal strength, capable of either 
stimulating or inhibiting TCR mediated 
signaling. Under physiological condi-
tions, T cell stimulation occurs at the 
dendritic cell-T cell synapse. Dendritic 
cells (DCs) are unsurpassed in their ca-
pability to activate naïve CD4+ T cells 
and express many costimulatory sig-
nals besides CD80 (B7-1), CD86 (B7-2), 
including PDL-1 and PDL-2 [8, 9]. They 
also produce cytokines such as IL-2, IL-
6 and IL-15 that have important roles 
in T cell stimulation and differentiation 
into effector cells [10-13].
Among the new inhibitory co-signaling 
molecules, PD-L1 (also known as B7-
H1) and PD-L2 (B7-DC) are members 
of the B7 family of costimulatory mol-
ecules which are expressed on a variety 
of cells, including professional APCs 
such as dendritic cells (DC), but also 
non-lymphoid organs such as heart, 
lung and placenta [5, 6, 14-17]. Inter-
estingly, PD-L1 expression by human 
tumors has been implicated in immune 
evasion [18, 19]. The receptor for these 
ligands is PD-1 [20], which contains an 
ITIM motif and an ITSM motif in its cy-
toplasmic tail [21, 22]. PD-1 deficient 
mice demonstrate generalized T cell 
hyperreactivity and mice develop signs 
of severe auto-immunity [23, 24]. Upon 
PD-1 ligation in the presence of CD3/
CD28 signaling, these domains recruit 
the phosphatases SHP-1 and SHP-2, 
leading to attenuation of TCR-medi-
ated signaling [25, 26]. Consequently, 
stimulation of human and mouse CD4+ 
T cells in the presence of  PD-1 signal-
ing inhibits proliferation and cytokine 
production [14, 15, 27, 28]. These data 
have raised the interesting hypothesis 
that overexpression of PDL-1 and/or 
PDL-2 might be used to engineer APCs 
to induce tolerance to self or foreign 
antigens, by analogy to what has been 
performed with overexpression of FasL 
on DCs [29].
As DCs are the most relevant APCs 
that express costimulatory signals that 
contribute to the total signal strength, 
we decided to overexpress PDL-1 and 
PDL-2 during interaction with naïve 
CD4+ T cells. We engineered bone mar-
row-derived DCs to overexpress murine 
PD-L1 or murine PD-L2 and used these 
engineered DCs to stimulate naïve OVA-
specific (DO11.10) CD4+ T cells with 
increasing concentrations of antigen, 
thereby providing a more physiologi-
cal stimulus. Our results demonstrate 
that despite profound effects of PD1 
ligation on IL-2 production, there were 
no defects in primary immune response 
induction in vitro or in vivo when DCs 
overexpressed PDL-1 or PDL-2, not even 
when the CD80 and CD86 pathway were 
eliminated by genetic targeting. These 
data suggest that strategies aimed at 
overexpressing negative costimulatory 
ligands on APCs to induce tolerance to 
self or transplantation antigens or to 
allergens are unlikely to be successful. 
PD-L1 and PD-L2 expression by non-
APCs on peripheral tissues might be a 
more effective means of silencing T cell 
effector responses. 
Material & Methods
Mice
Female Balb/c mice (6-10 wks old) were pur-
chased from Harlan (Horst, The Netherlands). 
OVA323-339-specific, MHCII restricted, TCR trans-
genic (DO11.10) mice [30] were obtained from 
The Jackson Laboratory (Bar Harbor, ME) and bred 
in-house. Mice deficient in B7-1 and B7-2 on the 
Balb/c background [31] were a kind gift from Dr 
M. Oosterwegel (Utrecht University, Utrecht, The 
Netherlands). Mice were housed in microisolators 
under specified pathogen-free conditions and ex-
periments were performed under approval of the 
Erasmus MC committee for animal ethics.
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Vector construction
The retroviral vector expressing murine PD-L1 was 
constructed by PCR amplification of the murine 
PD-L1 cDNA using pMET7-mPD-L1 as a template 
( a gift from Dr. A. Coyle, Millenium Pharmaceuti-
cals, Boston, MA) with the forward primer 5’-AG-
ATCTTCTCCTCGCCTGCAGATAGT-3’, containing 
a BglII restriction site, and the reverse primer 5’-
CTCGAGAAGCTGCCAATCGACGATCA-3’, contain-
ing a XhoI restriction site. The PCR product was 
cloned into pGEMTeasy (Promega, Madison, USA) 
and sequenced. The BglII/XhoI PD-L1 cDNA frag-
ment was ligated into the BglII/XhoI digested ret-
roviral vector pRES-GFP RV ([32]; provided by K.M. 
Murphy), resulting in pmPD-L1-IRES-GFP RV.
The retroviral vector expressing  murine PD-L2 
was constructed by PCR amplification of the mu-
rine PD-L2 cDNA using pBluescriptSK+-mPD-L2 
as a template ( a gift from Dr. A. Coyle, Millenium 
Pharmaceuticals, Boston, MA) with the forward 
primer 5’- GAAGATCTCACCATGCTGCTCCTGCT-3’, 
containing a BglII restriction site, and the reverse 
primer 5’- CCTCGAGCCCTGCTCTAGATTAGATCCT-
3’, containing an AvaI restriction site. The BglII/
AvaI digested PCR product was cloned into BglII/
XhoI digested pIRES-GFP-RV, resulting in pmPD-
L2-IRES-GFP RV. For verification, the cloned mPD-
L2 cDNA fragment was fully sequenced.
DC transduction
Retroviral particles were produced by transient 
transfection as described [33]. Bone marrow-de-
rived DCs were transduced as described [33]. At 
day 11, DCs were harvested by gentle pipetting, 
resuspended in PBS and GFP-positive DCs were 
sorted with a FACSDiva or FACSAria flow cytom-
eter (BDBiosciences, Erembodegem, Belgium). DCs 
transduced with IRES-GFP-RV, mPD-L1-IRES-GFP 
RV or mPD-L2-IRES-GFP RV are hereafter desig-
nated control-DC,  PDL1-DC and PDL2-DC, respec-
tively.
DC-T cell coculture
Spleen and lymph node (LN) cells were obtained 
from DO11.10 mice and untouched CD4+ T cells 
isolated by negative selection using  the CD4 T 
cell isolation kit and autoMACS  (Miltenyi Biotec, 
Bergisch Gladbach, Germany) The resulting popu-
lation was typically > 90% CD4+. Cells were labeled 
with CFSE as described previously [34]. 
5 x 105 CFSE-labeled CD4+ T cells were cultured 
with either 2.5 x 104 control-DC, PDL1-DC or PDL2-
DC in 48-wells plates and indicated concentrations 
of OVA323-339 peptide (Ansynth, Roosendaal, The 
Netherlands) After four days, cells and supernatant 
were harvested and OVA-specific T cells prolifera-
tion and IL-2 levels determined.
Cytokine measurements
Levels of cytokines in culture supernatants or 
BAL were measured using OptEIA kits (BD Biosci-
ences) according to manufacturer’s instructions 
except for IL-13 levels, which were measured us-
ing a commercially available kit from R&D Systems 
(Minneapolis, MN).
In vivo studies
To induce eosinophilic airway inflammation, groups 
of mice (n=3-4 per group) were immunized and 
challenged as described  [34], with the modifica-
tion that 0.5*106 EGFP+ sorted control-DC, PDL-1 
DC or  PDL2-DC, pulsed overnight with OVA, were 
used for immunization. Twenty-four hours after 
the last aerosol exposure, mice were sacrificed and 
bronchoalveolar lavage (BAL) performed.
Flow cytometry 
Functional expression of  murine PD-L1 and PD-L2 
after transfection  was confirmed by staining with 
biotinylated anti-PD-L1 (MIH5) and biotinylated 
anti-PD-L2 (TY25) (both purchased from ebiosci-
ence, San Diego, USA) against these molecules, fol-
lowed by streptavadin-APC (BD Biosciences). For 
the DC-T cell coculture experiments and BAL stain-
ings, anti-FcγRIII/II antibody (2.4G2, ATCC, Manas-
sas, VA) was included in all cell surface stainings to 
reduce non-specific antibody binding,. Dead cells 
were excluded by labeling with TOPRO-3 (Mo-
lecular Probes, Leiden, The Netherlands) prior to 
acquisition. To study DC mediated T cell division 
in vitro, cells were labeled with CFSE and with the 
anti-clonotypic DO11.10 TCR mAb KJ1-26 (Caltag 
Laboratories, Burlingame, USA) [30]. Anti-CCR3-PE 
(R&D Systems) was used to detect eosinophils in 
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the lung [35], together with anti-CD8-PECy5 (53-
6.7; BD Biosciences) and anti-CD4-APC (RM4-5; BD 
Biosciences) to determine the cellular composition 
in BAL fluid. Events were acquired on a FACS Cali-
bur flow cytometer (BD Biosciences) and analyzed 
with FlowJo software (Treestar, Ashland, OR).
Results
Isolation of PD-L1 or PD-L2 overexpress-
ing DCs
PD-L1 and PD-L2 function in a cell-cell 
contact dependent manner which ne-
cessitates purification of  transduced 
DC from a bulk population consisting 
of both transduced and nontransduced 
DCs. To accomplish this, we transduced 
bonemarrow cultures supplemented 
with GM-CSF with a bicistronic retrovi-
ral vector expressing GFP in combina-
tion with either PD-L1 or PD-L2. This 
permits sorting of DCs based on GFP ex-
pression (Fig 1). Purity of GFP-positive 
DCs after sorting was on average 88% 
(85-92%, 95% confidence interval).
Effect of overexpression of PD-L1 or PD-
L2 on DC-driven IL-2 production and T 
cell proliferation
The majority of data concerning the 
suppressive function of PD-L1 and PD-
L2 have been obtained using highly 
artificial in vitro systems, including 
overexpression of PD-L1 and PD-L2 
in cell lines co-transfected with MHCII 
molecules  [14, 28]. To obtain insight in 
the role of PD-L1 and PD-L2 in a more 
physiological system, we transduced 
DCs with retroviral vectors expressing 
either murine PD-L1 or PD-L2. Although 
mature bone marrow-derived DCs al-
ready express PD-L1 and PD-L2 at high 
levels (data not shown and [16]), we 
wondered whether constitutive overex-
pression of PD-L1 and PD-L2 would re-
sult in an additional inhibitory effect on 
T cell proliferation and IL-2 production, 
as previously observed with artificial 
APCs. To address this issue, we cultured 
bonemarrow-derived DC transduced 
with either mPD-L1 (PDL1-DC), mPD-L2 
(PDL2-DC) or control vector (control-
DC) with CFSE labeled DO11.10 CD4+ T 
cells, which have an OVA-specific T cell 
receptor,  at various OVA peptide con-
centrations.  After four days, analysis 
of the CFSE dilution pattern between 
control-DC stimulated and PDL1-DC or 
PDL2-DC stimulated  T cells revealed 
no differences in  T cell proliferation at 
any of the OVA peptide concentrations 
tested (Fig. 2A). IL-2 levels however, 
were decreased in the cultures contain-
ing PDL1-DC or PDL2-DC, in particular 
at OVA peptide concentrations of 10 
and 1 µg/ml (Fig. 2B). Thus, although 
DCs constitutively expressing PD-L1 or 
PD-L2 were not capable of decreasing 
CD4+ T cell proliferation, production of 
the autocrine growth factor IL-2 was 
impaired, demonstrating that even in a 
strong stimulatory setting as provided 
by mature DCs constitutive overexpres-
sion of inhibitory ligands could convey 
an inhibitory signal to T cells. 
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Figure 1 Sorting of transduced DCs. Bonemarrow 
cells, depleted of lineage positive cells, were trans-
duced at day 2, 3 and 4 with either IRES-GFP-RV, 
mPD-L1-IRES-GFP RV or mPD-L2-IRES-GFP RV 
in the presence of GM-CSF. At day 11, cells were 
harvested, washed with PBS and sorted based on 
GFP expression. Shown are plots of a representa-
tive sort of IRES-GFP-RV transduced DCs. Num-
bers shown in dotplots are percentages of GFP-
positive cells of total cells.
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Inhibitory effect of PD-L1 or PD-L2 over-
expression in the absence of B7-1 and 
B7-2 costimulation on DCs
With the discovery of inhibitory co-sig-
naling molecules such as PD-L1 and 
PD-L2,  the original two-signal theory 
of lymphocyte activation has been fur-
ther refined. Typically,  the current view 
on T cell activation is that signals deliv-
ered via co-signaling molecules, either 
stimulatory or inhibitory, are integrated 
with TCR-mediated signaling to deter-
mine a net effect on T cell activation [5]. 
Considering the small inhibitory effect 
seen on T cell activation when DCs con-
stitutively expressing PD-L1 or PD-L2 
were used as APCs, we next wondered 
whether this inhibitory effect would be 
more pronounced if strong costimulato-
ry molecules for naïve T cells were ab-
sent. To address this question, we trans-
duced DCs obtained from CD80/CD86 
deficient bonemarrow cells (B7KO DCs) 
with PD-L1, PD-L2 or control vector 
and used these DCs to stimulate naïve 
CD4+ T cells at varying antigen concen-
trations. After four days, we analyzed 
the CD4+ T cell division profile and IL-
2 production. Not surprisingly, T cell 
proliferation was decreased at any in-
dicated concentration of antigen when 
B7KO DCs were used to stimulate T 
cells (Fig. 3A). However, in the absence 
of B7 costimulation, we did not observe 
any inhibition in cell proliferation when 
PD-L1 or PD-L2 transduced DCs  were 
used compared to control-DC. Indeed, at 
an antigen concentration of 10 µg/ml, 
we even observed a slightly increased 
proliferation of  PDL1-DC and PDL2-DC 
stimulated T cells compared to control-
DC, suggestive of a costimulatory role 
of PD-L1 or PD-L2 (Fig. 2A, right pan-
els).
IL-2 concentrations in T cell cultures 
stimulated with B7-1 and B7-2 deficient 
APCs were lower compared to wildtype 
DC cultures, irrespective of the con-
struct transduced into DCs, except for 
an OVA peptide concentration of 0.001 
µg/ml, where PD-L1 and PD-L2 trans-
duced DCs result in higher IL-2 levels 
(Fig. 3B). Within the B7KO DC group, 
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Figure 2 Overexpression of PD-1 ligands by 
DCs has a partial inhibitory effect on CD4+ T cell 
responses. CFSE-labeled CD4+ T cells were co-
cultured with DC transduced with either IRES-
GFP-RV (control-DC), mPD-L1-IRES-GFP RV 
(PDL1-DC) or mPD-L2-IRES-GFP RV (PDL2-DC) 
in the presence of indicated concentrations OVA323-
339 peptide. At day four T cell division was analyzed 
and levels of IL-2 in the supernatant determined. 
A, CFSE profile of gated TOPRO-3+, KJ1-26+ cells. 
B, IL-2 levels in supernatants of DC-T cell cultures. 
Data representative for one out of three experi-
ments are shown.
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constitutive expression of PD-L1 and 
PD-L2 resulted in a strong decrease in 
IL-2 production at  a high antigen dose, 
which is in contrast with the observed 
increased proliferation. Surprisingly, 
at a low OVA peptide concentration of 
0.001 µg/ml, the IL-2 production is in-
creased when PD-L1 or PD-L2 DCs were 
used as stimulators (Fig. 3B; open bars), 
but again no correlation was observed 
with T cell division. To summarize, DCs 
deficient in B7-1 and B7-2 are poor T 
cell stimulators compared to wildtype 
DC, as defined by T cell division and IL-
2 production. However, transduction of 
the inhibitory costimulatory molecules 
PD-L1 and PD-L2 still did not result in 
decreased T cell divisions. It should also 
be noted that at high OVA peptide con-
centrations, there was no correlation 
between T cell division and IL-2 produc-
tion in B7KO DC.
Effect of PD-L1 and PD-L2 overexpres-
sion on DCs to generate effector T cell 
responses in vivo
Despite reduced levels of IL-2 in our 
in vitro culture systems when APCs 
constitutively expressed the inhibitory 
‘signal-2’ molecules PD-L1 or PD-L2, we 
could not observe any decrease in pro-
liferation. Gett and co-workers recently 
showed that priming of naïve T cells 
in vitro under suboptimal conditions 
resulted in similar T cell division com-
pared to stimulation under optimal con-
ditions. However, survival of T cells that 
received a low overall stimulus-strength 
was much lower,  in vitro as well as in 
vivo, than survival of fully stimulated T 
cells, a phenomenon termed ‘T cell fit-
ness’ [36]. To test whether CD4+ T cells 
stimulated with PDL1-DC or PDL2-DC 
in vivo have a reduced T cell fitness, 
we analyzed the immune response in a 
well-established mouse model of effec-
tor T cell dependent eosinophilic air-
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Figure 3 Stimulation of CD4+ T cells by B7 deficient 
DCs constitutively overexpressing PD-1 ligands 
does not inhibit T cell proliferation. CFSE-labeled 
CD4+ T cells were co-cultured with bonemarrow-
derived DCs from wildtype (wildtype DCs) or B7 
deficient mice (B7KO DCs), transduced with either 
IRES-GFP-RV (control-DC), mPD-L1-IRES-GFP 
RV (PDL1-DC) or mPD-L2-IRES-GFP RV (PDL2-
DC) in the presence of indicated concentrations 
OVA323-339 peptide. At day four T cell division was 
analyzed and levels of IL-2 in the supernatant 
determined. A, CFSE profile of gated TOPRO-
3+, KJ1-26+ cells. B, IL-2 levels in supernatants 
of DC-T cell cultures. Numbers above B7KO DCs 
cultures indicate levels of IL-2 in pg/ml.  No CD4+ 
T cell division occurred in the absence of antigen 
(data not shown). BD; below detection.
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way inflammation [37], after immuniza-
tion with either OVA-pulsed control-DC, 
PDL1-DC or PDL2-DC. In this model, 
sensitization to OVA is induced by in-
tratracheal injection of OVA-pulsed DC, 
followed by OVA aerosol challenge 10 
days later. This results in peribronchial 
and perivascular eosinophilic airway in-
flammation, which is analyzed 24 hours 
after the last aerosol exposure through 
analysis of the cellular composition of 
BAL fluid, BAL cytokine levels and cyto-
kine production profile in the draining 
lymph nodes of the lung to determine 
the type and magnitude of immune 
response. No statistical significant de-
crease in the number of eosinophils 
could be detected in the groups immu-
nized with PDL1-DC or PDL2-DC com-
pared to control-DC (Fig. 4A). Likewise, 
the levels of the Th2 associated cyto-
kines IL-5 and IL-13 in BAL fluid did 
not differ significantly between groups 
(Fig. 4B). In conclusion, based on these 
in vivo data, it can not be concluded 
that constitutive, high-level expression 
of PD-L1 and PD-L2 inhibits the devel-
opment of eosinophilic airway inflam-
mation, although a trend towards lower 
inflammation can be observed when 
PDL2-DC were used for sensitization.
Discussion
Most of the studies that have addressed 
the role of PD-1 ligation on T cell ac-
tivation have used either antibody-
mediated delivery of TCR-and CD28 
costimulatory signals, or cell lines 
artificially expressing peptide-MHC 
complexes and CD80/86  to stimulate 
T cells. This approach carries the risk 
of over-interpreting the results due to 
the often high signal strength delivered 
and the limited number of co-signaling 
pathways used. Moreover, use of artifi-
cial APCs or direct ligation of purified T 
cells by antibodies largely ignores the 
role that cytokines released by antigen 
presenting cells (IL-2, IL-15, IL-6) play 
in T cell activation [10-13]. 
In this study, we investigated the con-
tribution of constitutively expressed 
inhibitory ‘signal 2’ molecules PD-L1 
and PD-L2 to the total signal strength 
provided by mature, bonemarrow-de-
rived DCs. DCs differentiated in vitro 
from bonemarrow cells in the pres-
ence of GM-CSF express high levels of 
PD-L1 and PD-L2 (data not shown and 
[16]), questioning the relevance of this 
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Figure 4 PD-L1 and PD-L2 overexpression by DCs 
can not suppres eosinophilic airway inflammation 
development. On day 0, groups of mice were im-
munized by intratracheal administration of 0.5*106 
control-DC, PDL1-DC or PDL2-DC. On days 10-
13, mice were exposed to OVA aerosols for 30 min. 
daily. At 24 h after the last exposure mice were sac-
rificed, BAL performed and lymph nodes isolated. 
A, Cellular composition of BAL fluid. Alveolar mac-
rophages were characterized by their light scatter 
and autofluorescence properties. Eosinophils are 
defined by their CCR3+, CD4-, CD8- staining pat-
tern. The T cell fraction consists of CD4+ and CD8+ 
cells within the appropriate light scatter gate. B, 
Cytokine levels in BAL fluid. Results are expressed 
as mean ± SEM from 3-4 mice per group. Data are 
representative for 2 independent experiments.
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method. However, constitutive overex-
pression of molecules already endog-
enously expressed by DCs such as IL-12 
or OX40L have shown beneficial effects 
in CD4+ T cell polarization and antitu-
mor respectively [33, 38]. Despite the 
high expression of PD-L1 and PD-L2 by 
mature bonemarrow-derived DCs, con-
stitutive overexpression of these inhibi-
tory molecules resulted in decreased IL-
2 production by T cells, in agreement 
with other reports [14, 28]. A mechanis-
tic explanation was provided by analy-
sis of the signal transduction pathways 
affected by PD-1 signaling. Ligation of 
PD-1 in combination with TCR signaling 
inhibits phosphorylation of ZAP70 and 
its association with TCRζ [25]. In addi-
tion, phosphorylation of PKCθ, a novel 
PKC family member required for IL-2 
production [39], is strongly inhibited 
in the presence of PD-1 signaling [25]. 
However, at none of the antigen con-
centrations used in this study did we 
observe an inhibition of T cell prolifera-
tion when PDL1-DC or PDL2-DC were 
used as APC. Latchman and colleagues, 
using a similar OVA-restricted TCR T 
cell assay, reported similar findings, 
with no inhibition of T cell prolifera-
tion at higher antigen concentrations 
[14]. Another study, using a bead-based 
T cell activation system with agonistic 
anti-CD3 antibodies, showed profound 
inhibition of T cell proliferation in the 
presence of PD-L1 protein. However, 
when costimulation was provided by 
anti-CD28 antibodies, the inhibitory 
effect of PD-L1 was absent or reduced. 
Interestingly, exogenous IL-2 could 
overcome inhibition of proliferation at 
all time points examined [28]. Although 
the different experimental setups used 
make direct comparison between IL-2 
levels as reported in this work and the 
studies mentioned above difficult, we 
observe much higher levels of IL-2 in 
our culture systems. As CD28-mediated 
costimulation acts to a large extent by 
promoting IL-2 production [40], it ap-
pears that mature bonemarrow DCs as 
used in our experimental setup provide 
sufficient costimulation for T cell prolif-
eration, even at low antigen concentra-
tions. These findings were supported by 
an in vitro study blocking PD-L1/2-PD-
1 pathway in an allogeneic monocyte-
derived human DC-T cell assay. The ef-
fects of PD-L1/2 inhibition were more 
pronounced when immature DC were 
used as APC compared to mature DC, in-
dicating that the expression of costimu-
latory molecules such as CD40, CD80 
and CD86, which highly correlates with 
the maturation level of DCs, can bal-
ance the negative signals provided by 
PD-L1 and PD-L2 [41].  One explanation 
for the fact that overexpressio of PDL-1 
and PDL-2 in DCs did not result in T cell 
suppression might be the production of 
IL-2 and IL-15 by dendritic cells. It was 
indeed shown that PD-1 mediated inhi-
bition of human cells was overcome by 
IL2, IL-7 and IL-15, acting to increase 
the phosphorylation of STAT-5 and thus 
upregulating the high affinity IL-2 re-
ceptor rendering cells more sensitive to 
low amounts of IL-2 [42]. It is known 
that mouse and human DCs produce 
both IL-2 and IL-15 and this could be 
the explanation why we still see prolif-
eration despite low IL-2 levels
T cells stimulated with B7-1 and B7-2 
deficient DCs (B7KO DCs) exhibited de-
creased proliferation and IL-2 produc-
tion, as expected [43]. However, even 
in the absence of costimulation pro-
vided by B7-1 and B7-2, we could not 
detect any differences in proliferation 
when B7 KO DC were transduced with 
PD-L1 or PD-L2. On the contrary, at 
an antigen concentration of 10 µg/ml 
OVA protein we consistently observed 
increased proliferation compared to DC 
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transduced with control vector. We can 
not explain these data in light of the 
total signal strength hypothesis. It has 
been proposed that a second, unidenti-
fied, receptor expressed by T cells exists 
for PD-L1 and PD-L2 that has costimu-
latory properties [5], which might be 
dominant over PD-1 expression or sig-
nal transduction  in the absence of B7-
2/B7-2. In line with this speculation is 
the observation that PD-1 expression of 
T cell is lower at higher antigen concen-
trations [14]. Alternatively, there might 
be some redundancy in costimulatory 
molecules, as various other costimula-
tors of the B7 family have been recently 
described, such as B7-RP1 [44], which 
could counter-balance inhibitory PD-1 
signaling even in the absence of B7-1 
and B-2.
Despite the fact that no differences in 
T cell proliferation could be detected, 
IL-2 production was consistently lower 
when T cells were primed with PD-L1 
or PD-L2 transduced DCs. Models of T 
cell proliferation in vitro incorporating 
the effects of IL-2 reveal that small dif-
ferences in IL-2 concentrations below 
a threshold concentration have large 
differences in the final total cell num-
ber [45]. Furthermore, analysis of T cell 
proliferation in vivo indicated that T cell 
exposure to IL-2 is more restricted than 
in vitro [46]. Taken together, based on 
these studies it can be predicted that 
inhibition of IL-2 production in vivo by 
PD-L1 or PD-L2 transduced DC could 
have large outcome on ‘T cell fitness’ 
[36] and on the subsequent effector 
response generated. Therefore, we 
analyzed the immune response in vivo 
after priming with PD-L1 and PD-L2 
transduced DC. We did not observe any 
statistically  significant inhibition of the 
Th2-dependent eosinophilic airway in-
flammation, suggesting that the CD4+ T 
cell response was independent of PD-L1 
and PD-L2 overexpression. It could be 
argued that antigen transfer from adop-
tively transferred DCs to endogenous 
DCs dissociate antigen presentation 
from PD-L1/2 overexpression. How-
ever, from experiments involving adop-
tive transfer of antigen loaded class II 
deficient DCs it can be concluded that 
antigen transfer is limited in this par-
ticular model of eosinophilic airway in-
flammation (HK, data not shown)
Based on the data derived from this 
study it can be concluded that the co-
stimulatory function of PD-L1 and PD-
L2 expressed by DCs is relatively mi-
nor compared to other pathways such 
as CD28 and CTLA-4 signaling. Unlike 
CTLA-4, PD-1 lacks the cysteine resi-
due that allow CTLA-4 to homodimer-
ize. This CTLA-4 conformation allows 
binding of B7 molecules in a zipper-like 
oligomerization, forming the basis of the 
unusually stable signaling complexes at 
the T cell surface [47]. Therefore, it is 
now postulated that the principal role 
of PD-1 signaling is to downregulate 
immune responses in peripheral tissues 
through expression of PD-L1 and PD-L2 
by ‘non-professional’ APC [5]. This hy-
pothesis supported by the tissue distri-
bution of these proteins and the abun-
dant PD-L1 expression by many types 
of tumors [48]. Our data disprove the 
hypothesis that DCs overexpressing the 
inhibitory cosignaling molecules PDL-1 
or PDL-2 can be used to suppress T cell 
responses.
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Abstract
PD-L1 and PD-L2 are members of the B7-family of costimulating molecules, 
highly expressed by dendritic cells. Although signaling via their receptor PD-
1 is thought to inhibit T cell activation, recent studies have suggested a co-
stimulatory role for these molecules as well. In this study we used soluble PD-1 
to block both PD-L1 and PD-L2 in a more physiologically relevant dendritic 
cell driven T cell activation system, using OVA-specific TCR transgenic T cells. 
The addition of soluble PD-1 to DC-T cell cultures decreased IL-2 production 
and T cell proliferation, particularly when the amount of antigen was limiting, 
while at the same time increasing the production of IL-10. These inhibitory ef-
fects of soluble PD-1 were mainly affecting DCs which acquired a suppressive 
phenotype, expressing less CD80 and CD86 but producing more IL-10 upon 
exposure. The high expression of PD-L1 and PD-L2 on pulmonary DCs during 
T cell driven eosinophilic airway inflammation prompted us to investigate the 
inhibitory effects of soluble PD-1 in vivo. Administration of soluble PD-1 during 
sensitization and challenge to OVA in a DC-driven mouse model of asthma re-
sulted in less eosinophilia, IL-5 and IL-13 cytokine production in the BAL fluid 
of inflamed lungs. Our findings using soluble PD-1 suggest either a costimula-
tory role for PD-L1/PD-L2 via signaling through a yet unidentified receptor, 
or similar to soluble CTLA-4, soluble PD-1 exerts its inhibitory effects through 
acting on DCs. Soluble PD-1 might have therapeutic potential in T cell mediated 
diseases such as asthma.
Introduction
Dendritic cells (DCs) are extremely proficient inducers of T cell activa-
tion due to their high expression level of 
peptide-MHC and an array of accessory 
molecules involved in cell migration, 
adhesion and co-signaling molecules. 
In particular the B7-1/2-CD28/CTLA-4 
axis of co-signaling molecules has been 
shown to play an important role in this 
respect. A new layer of complexity has 
been added with the discovery of new 
B7 family members, both with stimu-
latory as well as inhibitory properties. 
Two of these newly described mole-
cules are PD-L1 (also known as B7-H1) 
[1, 2] and PD-L2 (also known as B7-DC) 
[3, 4]. PD-L1 is expressed on a broad 
variety of murine tissues and cells, in-
cluding DCs, and can be upregulated 
by inflammatory stimuli. PD-L2 expres-
sion is restricted to macrophages and 
DCs [5]. Both co-stimulatory molecules 
share the same receptor PD-1 which 
is expressed on activated T cells. The 
majority of experimental data suggests 
that ligation of PD-1 inhibits T cell ac-
tivation or induces cell death [6]. PD-1 
contains an immunoreceptor tyrosine-
based inhibitory motif and mice defi-
cient in PD-1 develop autoimmune dis-
orders suggesting a defect in peripheral 
tolerance [7, 8]. Whereas most investi-
gators agree that PD-1 delivers an in-
hibitory signal to T cell, various studies 
have shown that PD-L1 and PD-L2 can 
act as co-simulators [2, 4, 9, 10]  as well 
as co-inhibitors [1, 11, 12] of T cell ac-
tivation in vitro. A possible explanation 
for the observed discrepancies could be 
the fact that most studies used differ-
ent highly artificial T cell stimuli, con-
sisting of CD3-or TCR-specific agonistic 
antibodies or artificial antigen present-
ing cell lines expressing MHC-peptide 
complexes and transfected with PD-L1 
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or PD-L2. 
Due to the absence of physiologically 
relevant APCs (DCs, macrophages, B 
cells) a possible caveat in these stud-
ies could be the lack of the recently 
described phenomenon of ‘reverse sig-
naling’. This feedback mechanism con-
sists of B7 family members acquiring 
receptor functions and transmitting 
signals into the APC, upon triggering of 
their receptor (CD28 related immuno-
glublin superfamily members). Studies 
by Grohmann and colleagues showed 
that stimulation of CD80/CD86 on DCs 
with soluble CTLA-4 (CTLA4-Fc fusion 
protein) resulted in upregulation of the 
enzyme indoleamine 2,3-dioxygenase 
(IDO) activity, which  subsequently in-
hibited T cell activation by tryptophan 
depletion, while stimulation of the same 
pathway with soluble CD28 results in 
DC activation [13, 14]. Along similar 
lines, stimulation of DCs with a PD-L2 
cross-linking IgM antibody resulted in 
activation of DCs [15]. Another possibil-
ity explaining the contrasting results 
between studies might be the existence 
of a second receptor for PD-L1 and/or 
PD-L2 that has co-stimulatory proper-
ties. In support, engineered PD-L1 and 
PD-L2 mutants that lost the capacity to 
bind to PD-1 still possessed co-stimula-
tory properties [16], and cytokine pro-
duction of PD-1-deficient T cells stimu-
lated with PD-L2 is similar to wild-type 
T cells [10]. 
In this study, we have used bone mar-
row (BM)-derived DCs to stimulate 
OVA-specific CD4+ T cells in the pres-
ence of soluble PD-1, consisting of the 
extracellular domain of PD-1 fused to 
the constant domain of human IgG1. 
In addition to providing a more physi-
ologically relevant T cell stimulus, the 
use of DCs as APCs also enabled us to 
study possible occurrence of PD-L1/L2-
mediated reverse signaling in DCs. We 
also addressed the potential of soluble 
PD-1 to block T cell activation in vivo, 
in a T cell mediated model of asthma. 
Together our data demonstrate that 
soluble PD-1 inhibits DC-driven T cell 
activation in vitro and in vivo, and that 
this effect may be mediated in part via 
reverse signaling into DCs. 
Materials & Methods
Mice
Female Balb/c mice (6-10 wks old) were pur-
chased from Harlan (Horst, The Netherlands). 
OVA323-339-specific, MHCII restricted, TCR trans-
genic (DO11.10) mice [17] were obtained from 
The Jackson Laboratory (Bar Harbor, ME) and 
bred in-house. Mice were housed in microisolators 
under specified pathogen-free conditions and ex-
periments were performed under approval of the 
Erasmus MC committee for animal ethics.
Generation of dendritic cells
For the DC-T cell co-culture and DC stimulation 
experiments, DCs were generated from bone mar-
row (BM) progenitors as described [18], with some 
minor modifications. At day 1, cells were reseeded 
at 2.5 x 105 cells per ml in DC culture medium 
(DC-CM; RPMI 1640 containing glutamax-I (Invi-
trogen, Carlsbad, CA) supplemented with 5% (v/v) 
FCS (Biocell, Rancho Dominguez, CA), 50 µM β-ME 
(Sigma, St Louis, MO) and 50 µg/ml gentamycin 
(Invitrogen) supplemented with 20 ng/ml recom-
binant mouse GM-CSF and 10 ng/ml recombinant 
human Flt3-L. Medium was refreshed on day 4, day 
7 and day 9 (Flt3-L was omitted at day 7 and 9). On 
day 10 or day 11, mature DCs were harvested by 
gentle pipetting.
BM-derived DCs used as APCs in the mouse model 
of eosinophilic airway inflammation were gener-
ated as described [19].
Soluble PD-1 in vitro studies
Soluble PD-1 consists of the extracellular domain 
of murine PD-1 fused to the Fc fragment of human 
IgG1 (Chimerigen Laboratories, Allston, MA). As a 
control, human IgG1 (hIgG1, Sigma-Aldrich) was 
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used. 
For the DC-T cell co-culture and T cell stimulation 
experiments, spleen and lymph node (LN) cells 
were obtained from DO11.10 or Balb/c mice and 
untouched CD4+ T cells isolated by negative deple-
tion with a commercially available panel of biotin-
conjugated antibodies, followed by labeling with 
anti-biotin MACS beads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) The resulting population was 
typically > 95% CD4+. 
To measure proliferation through [3H]thymidine 
incorporation, 1x105 CD4+ T cells were cultured 
together with 5x103 DCs and various concentra-
tions of OVA323-339 peptide (Ansynth, Roosendaal, 
The Netherlands) in 96-wells U-bottom plates for 
four days. soluble PD-1 or hIgG1 was present at 
a concentration of 30 µg/ml. [3H]thymidine (0.5 
µCi/well) was added for the last 8 h.
For the CFSE labeling studies, cells were labeled 
with CFSE as described previously [19]. 5 x 105 
CFSE-labeled CD4+ T cells were cultured with 2.5 
x 104 BM-derived DCs in 48-wells plates and vari-
ous concentrations of OVA323-339 peptide (Ansynth, 
Roosendaal, The Netherlands) in the presence of 
30 µg/ml soluble PD-1 or 30 µg/ml hIgG1 as a 
control. After 96 h, cells and supernatant were har-
vested and OVA-specific T cells proliferation and 
cytokine levels determined. 
To stimulate CD4+ T cells in the absence of DCs, 
96-wells U-bottom plates were coated wit anti-
CD3 mAb (145-2C11; BD Biosciences) at various 
concentrations. Next, 2 x 105 purified CD4+ T cells 
from Balb/c mice were stimulated in the presence 
of  2.5 µg/ml anti-CD28 mAb (37.51; BD Biosci-
ences) and soluble PD-1 or hIgG1 (30 µg/ml). Pro-
liferation was measured by [3H]thymidine incor-
poration (0.5 µCi/well) for the last 8 h of a 72 h 
culture.
For DC stimulation experiments, DCs were harvest-
ed at day 10, washed, replated at 2 x 105 DCs in 
96-wells U-bottom plates and stimulated for 24h 
with soluble PD-1 or hIgG1 (30 µg/ml). In some 
experiments, DCs were cultured in the presence of 
recombinant murine IFN-γ (200 U/ml; Peprotech, 
Rocky Hill, NY) to upregulate IDO expression. Af-
ter 24h, cells and supernatants were harvested to 
determine cell surface marker expression and cyto-
kine levels, respectively. For quantitative RT-PCR, 
cell pellets were snapfrozen in liquid nitrogen and 
stored at ‒80 °C until RNA isolation.
Real-time quantitative RT-PCR
Frozen cell pellets were homogenized, RNA isolated 
with RNeasy mini-prep columns (Qiagen, Hilden, 
Germany) and treated on-column with DnaseI, ac-
cording to the manufacturer’s protocol. 1 µg RNA 
was reverse transcribed using SuperscriptII (Invit-
rogen) and random hexamers (Amersham Biosci-
ences, Roosendaal, The Netherlands) for 120 min 
at 42 °C. Quantitative PCR was performed with 
Taqman Universal PCR Mastermix (Applied Biosys-
tems, Foster City, CA) and  preformulated primers 
and probe mixes (‘Assay on Demand’, Applied Bio-
systems). PCR conditions were 2 min at 50 °C, 10 
min at 95 °C, followed by 40 cycles of 15 s at 95 
°C and 60 °C for 1 min using an ABI PRISM 7900 
HT (Applied Biosystems). PCR amplification of the 
housekeeping gene ubiquitin C was performed 
during each run for each sample to allow normal-
ization between samples.
Eosinophilic airway inflammation model
Eosinophilic inflammation in the lower airways 
was induced essentially as described [19]. In brief, 
mice were sensitized to OVA by intratracheal injec-
tion of 1 x 106 OVA-pulsed DCs on day 0, followed 
by OVA aerosol challenge (1% OVA in PBS using a 
jet nebulizer) on day 10-12. 100 µg soluble PD-1 
or hIgG1 as a control was injected i.p. daily during 
the sensitization period (day -1, 0, 1, 2) and during 
the challenge period (day 9, 10, 11, 12). One group 
of mice did not receive any i.p. injection (‘no treat-
ment’ group). Twenty-four hours after the last ex-
posure mice were sacrificed and broncho alveolar 
lavage (BAL) was performed. To determine PD-L1 
and PD-L2 expression on DCs in the lung tissue 
compartment, the right middle lobe was excised 
and enzymatically digested as described [20].
Flow cytometry 
To reduce non-specific antibody binding, anti-
FcγRIII/II antibody (2.4G2, ATCC, Manassas, VA) 
was included in all cell surface stainings. In the 
T cell proliferation experiments, dead cells were 
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excluded by labeling with TO-PRO-3 (Invitrogen) 
prior to acquisition. To study DC mediated T cell 
division in vitro, cells were labeled with CFSE and 
with the anti-clonotypic DO11.10 TCR mAb. KJ1-
26 [17]. For the DC stimulation experiments, DCs 
were stained with anti-I-A/I-E-FITC (2G9) in combi-
nation with anti-CD11c-APC (HL3) and anti-CD80-
PE (16-10A1), anti-CD86-PE (GL1) or anti-CD40-
PE (3/23).
Anti-CCR3-PE was used to detect eosinophils in 
the lung [21], together with anti-CD8-PECy5 (53-
6.7) and anti-CD4-APC (RM4-5) to determine the 
cellular composition in BAL. To determine PD-L1 
and PD-L2 expression on DCs in BAL and lung di-
gests, cell populations were stained with anti-I-A/
I-E-FITC in combination with anti-CD11c-APC and 
either biotinylated anti-PD-L1 (MIH5) followed by 
streptavadin-PE or anti-PD-L2-PE (TY25).
All fluorochrome-conjugated antibodies were pur-
chased from BD Biosciences, except anti-CCR3-PE, 
which was from R&D Systems (Minneapolis, MN), 
anti-clonotypic-TCR-PE (KJ1-26), which was from 
Caltag Laboratories (Burlingame, CA) and biotinyl-
ated anti-PD-L1 and anti-PD-L2-PE, which were 
from eBioscience (San Diego, CA). Events were 
acquired on a FACS Calibur flow cytometer (BD 
Biosciences) and analyzed with FlowJo software 
(Treestar, Ashland, OR).
Cytokine measurements
Levels of cytokines in culture supernatants or 
BAL were measured using OptEIA kits (BD Biosci-
ences) according to manufacturer’s instructions 
except for IL-13 levels, which were measured us-
ing a commercially available kit from R&D Systems 
(Minneapolis, MN).
Statistical analysis
Reported values are expressed as mean ± standard 
error of the mean (SEM). Statistical analyses were 
performed with SPSS (SPPS Inc, Chicago, IL) using 
a Mann-Whitney U-test. p-values less than 0.05 
were considered significant.
Results
Inhibition of T cell proliferation in the 
presence of soluble PD-1 is consistent 
with the observed cytokine production 
pattern
In an attempt to further clarify wheth-
er PD-L1 and PD-L2 expressed by DCs 
have a costimulatory or inhibitory role 
in CD4+ T cell stimulation, we cultured 
OVA323-339-specific T cells with OVA323-
339-presenting DCs  in the presence or 
absence of  soluble PD-1 and measured 
the proliferation of T cells. To take into 
account any aspecific effects of the im-
munoglobulin heavy chain, T cells were 
exposed to human IgG1 as a control pro-
tein. As it has been shown that contribu-
tion of the PD-L1 and PD-L2 pathways 
to T cell stimulation is dependent on the 
TCR stimulus [1, 3], we titrated the an-
tigen concentration. When hIgG1 was 
present during the T cell stimulation, 
proliferation was maximal at 0.1 µg/
ml OVA323-339 and decreasing at higher 
concentrations, presumably to activa-
tion induced cell death. However, when 
soluble PD-1 was added to the culture, 
CD4+ T cell proliferation was decreased 
OVA323-339 conc. (µg/ml)
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Figure 1 Soluble PD-1 blocks T cell prolifera-
tion in vitro at low antigen concentrations. 1 x 105 
OVA323-339-specific CD4
+ T cells were plated with 5 
x 103 BM-derived DCs in the presence of indicated 
concentrations of OVA323-339 peptide and soluble 
PD-1 (dashed line; triangles) or hIgG1 (solid line; 
squares) at 30 µg/ml. Proliferation was measured 
after 4 days by 3[H]thymidine incorporation (0.5 
µCi/well) for the last 8 h of culture.  Results are ex-
pressed as mean ± SEM of three wells
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Figure 2 T cell stimulation in the presence of soluble PD-1 decreases IL-2 production but augments 
IL-10 levels. 5 x 105, CFSE labeled, OVA323-339-specific (KJ1-26
+), CD4+ T cells were plated with 2.5 x 
104 BM-derived DCs in the presence of indicated concentrations of OVA323-339 peptide and soluble PD-1 
or hIgG1 (30 µg/ml). Four days later, cells and supernatant were harvested. A, Division profile of TO-
PRO-3-, KJ1-26+ cells. B, cytokine levels in the supernatant. All cytokine concentrations are expressed 
in pg/ml. Shown results are representative for 5 independent experiments.
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at lower antigen concentrations but in-
creased at higher concentrations (1 and 
10 µg/ml; Figure 1). This suggests that 
soluble PD-1 inhibits CD4+ T cell activa-
tion by increasing the threshold of T 
cell activation.
Because measurement of T cell prolif-
eration through 3[H]thymidine incor-
poration only captures the prolifera-
tion during the last 8 h of the assay, we 
repeated the assay with CFSE-labeled 
CD4+ T cells which permits visualization 
of the entire division history. The divi-
sion profile of  T cells obtained through 
CFSE labeling correlated with the pro-
liferation data of radioactive thymidine 
incorporation, with decreased prolif-
eration at lower antigen concentrations 
when soluble PD-1 was present during 
the T cell stimulation (Fig. 2A). Thus, 
these proliferation data support a co-
stimulatory role for the PD-L1 and/or 
PD-L2 pathway rather than an inhibi-
tory function. 
Next, we analyzed whether soluble PD-
1 also influences the cytokine profile of 
stimulated CD4+ T cells. After day four 
of the T cell stimulation, supernatants 
were harvested and assayed for cyto-
kines known to be involved in T cell 
proliferation or differentiation. Levels 
of the autocrine growth factor IL-2 were 
significantly decreased when soluble 
PD-1 was present during the T cell stim-
ulation, suggesting a mechanism for the 
observed inhibition of T cell prolifera-
tion (Fig. 2B). Analysis of the levels of 
the Th1 prototypic cytokine IFN-γ and 
the key Th2 cytokine IL-4 revealed a re-
duction of both cytokines in the soluble 
PD-1-containing DC-T cell cultures (Fig. 
2B), indicating that soluble PD-1 does 
not influence CD4+ T cell polarization. 
Another cytokine with known T cell sup-
pressive properties is IL-10. In our in vi-
tro CD4+ T cell culture system, levels of 
IL-10 were increased in the presence of 
soluble PD-1 compared to hIgG1, irre-
spective of antigen dose (Fig. 2B). Thus, 
to summarize, soluble PD-1 blocks T 
cell proliferation when the TCR signal 
is limited, possibly due to inhibition of 
IL-2 production or an increase in IL-10 
production. 
Soluble PD-1 cannot inhibit T cell prolif-
eration in the absence of DCs
It has been reported that the known li-
gands for PD-1, PD-L1 and PD-L2, are 
expressed on murine CD4+ T cells [5], 
and that reverse signaling via these li-
gands can occur in human CD4+ T cells 
[22]. Therefore, we examined the effect 
of soluble PD-1 on pure CD4+ T cells, 
without any other cell population pres-
ent. Purified CD4+ T cells were activat-
ed with anti-CD3 mAb and anti-CD28 
mAb in the presence of soluble PD-1 or 
hIgG1 and after 72 h the proliferation 
was measured. 
As shown in figure 3, proliferation in re-
sponse to increasing CD3 stimulation in 
the presence of soluble PD-1 was nearly 
identical to hIgG1 exposed T cells, al-
though a slightly lower but consistent 
inhibition of proliferation was observed 
when T cells were exposed to soluble 
PD-1. Taken together, these results sug-
gest that although signaling via PD-1 
ligands on T cells might have a minor 
contribution to suppression of CD4+ T 
cell activity, this pathway probably does 
not solely account for the strong inhibi-
tion of T cell proliferation and cytokine 
expression pattern as observed in the 
Ag-specific assays.
DCs exposed to soluble PD-1 acquire a 
suppressive phenotype 
Because direct PD-1 stimulation of CD4+ 
T cells did not result in a significant 
inhibition of proliferation, we next fo-
cused our attention on the direct effects 
of soluble PD-1 on DCs. BM-derived DCs 
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were harvested at day 10 and cultured 
for 24 h in the presence of soluble 
PD-1 or hIgG1, followed by analysis 
of maturation-associated cell surface 
markers and cytokine production. The 
percentage of DCs, as defined by CD11c 
and MHCII expression, was similar in 
the soluble PD-1 culture compared to 
hIgG1 exposed DCs (data not shown). 
However, when soluble PD-1 was add-
ed, the levels of the cell surface expres-
sion of the maturation markers CD80 
and CD86 on DCs was lower compared 
to the hIgG1 exposed DC culture, while 
CD40 expression was similar (Fig. 4A). 
It has been shown that ‘reverse signal-
ing’ via either B7-1 or B7-2 leads to al-
teration of DC phenotype and function, 
which manifests either as upregulation 
of IDO activity [13] or IL-6 production 
[14], depending on the stimulus used. 
Furthermore cross-linking of PD-L2 on 
DCs results in IL-12 production [15]. 
Therefore, we analyzed cytokine pro-
duction and ido expression in soluble 
PD-1 stimulated DCs. The production of 
IL-6 and IL-12 of soluble PD-1 stimulat-
ed DCs were similar to hIgG1 exposed 
DCs, but levels of the immunosuppres-
sive cytokine IL-10 were increased in 
the supernatants of soluble PD-1 stimu-
lated DC cultures (Fig. 4B). As shown in 
Figure 4C, soluble PD-1 stimulation, in 
contrast to IFN-γ, did not lead to upreg-
ulation of IDO gene expression as as-
sessed by quantitative RT-PCR. We con-
clude that DCs stimulated with soluble 
PD-1 acquire a suppressive phenotype 
as defined by increased IL-10 produc-
tion and decreased expression of matu-
ration markers, which may explain the 
observed inhibition of CD4+ T cell pro-
liferation.
PD-L1 and PD-L2 are upregulated dur-
ing eosinophilic airway inflammation 
Having shown the inhibitory effects of 
soluble PD-1 on DC driven T cell activa-
tion, we next questioned whether this 
molecule would also inhibit T cell ac-
tivation in vivo making use of a T cell 
driven model of allergic asthma that 
uses the same OVA antigen as in our 
in vitro studies. As it has been reported 
that Th2 cytokines upregulate PD-L1 
and PD-L2 on DCs [5, 23], we decided to 
determine the expression of PD-L1 and 
PD-L2 on DCs isolated from BAL fluid 
and lung tissue from mice with Th2-de-
pendent eosinophilic airway inflamma-
tion. Mice were sensitized to OVA via 
intratracheal injection of OVA-pulsed 
DC, followed by OVA aerosol challenge 
10 days later (OVA-group). This results 
in peribronchial and perivascular eo-
sinophilic airway inflammation, which 
is analyzed 24 h after the last aerosol 
exposure [24].As a control, mice were 
immunized with unpulsed DC followed 
by PBS aerosols (control-group). PD-L1 
and PD-L2 expression on DCs (CD11c+, 
MHCIIhi) was assessed by flowcytomet-
ric analysis of BAL fluid and digested 
whole lungs. PD-L1 was constitutively 
expressed on DCs isolated from BAL 
fluid or lung tissue under non-inflam-
matory conditions (Fig. 5A, left panels), 
��CD3] (µg/ml)
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Figure 3 soluble PD-1 does not exert its effect di-
rectly on T cells. 2 x 105 purified Balb/c CD4+ T cells 
were stimulated with indicated concentrations of 
plate-bound anti-CD3, soluble anti-CD28 (2.5 µg/
ml) in the presence of soluble PD-1 or hIgG1 (30 
µg/ml) for 72 h. Proliferation was measured after 4 
days by 3[H]thymidine incorporation (0.5 µCi/well) 
for the last 8 h of culture. Results are expressed as 
mean ± SEM of three wells. Results are represen-
tative for two independent experiments.
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and only slightly upregulated when eo-
sinophilic airway inflammation was in-
duced (Fig. 5A, right panels). In contrast, 
PD-L2 expression was absent in lungs 
and BAL fluid of naïve mice (Fig. 5B, left 
panels), but strongly upregulated dur-
ing pulmonary inflammation (Fig. 5B, 
right panels). 
Soluble PD-1 suppresses eosinophilic 
airway inflammation
Based on the observation that PD-L1 
and PD-L2 are highly expressed on pul-
monary DCs during eosinophilic airway 
inflammation, we were interested in the 
effects of soluble PD-1 on a pulmonary 
inflammation response. When mice re-
ceived soluble PD-1 fusion construct 
during the sensitization and challenge 
phase, inflammation was slightly sup-
pressed, as judged by total cell number 
in the BAL fluid (Fig. 6A). Concomitant-
ly, analysis of the cellular composition 
of the BAL fluid revealed a decrease in 
the frequency of eosinophils retrieved 
(Fig. 6B) and levels of the prototypic 
eosinophilic airway inflammation as-
sociated cytokines IL-5 and IL-13 were 
significantly decreased (Fig. 6C). These 
data implicate that even in a more com-
plex in vivo environment, where PD-L1 
is likely also expressed by a variety of 
other tissues during lung inflammation, 
soluble PD-1 is still capable of blocking 
CD4+ T cell proliferation.
Discussion
The data obtained in this study with 
OVA-specific CD4+ T cell cultures stim-
ulated with OVA-pulsed DCs indicate 
that, in this experimental set up, PD-L1 
and PD-L2 have a co-stimulatory func-
tion. This confirms the findings of other 
studies stimulating T cells in vitro in the 
presence of  PD-L1 and PD-L2 block-
ing agents [2, 4, 9], but contradict with 
other studies [1, 11]. Interpretation of 
the data is complicated by the variety 
of experimental conditions used, and 
all these studies have in common that 
they use agonistic anti-CD3 antibody to 
mimic antigen signaling in combination 
with PD-L1-immunoglobulin or PD-L2-
immunoglobulin. As a consequence, 
only T cell mediated signaling events, 
either via PD-1 or a putative co-stimula-
tory receptor, can be investigated. 
Two recent reports however, did use a 
more physiological approach to dissect 
the role of the PD-1 ligands in DC-T cell 
interaction, using human CD4+ T cells 
cultured with allogenic DC in the pres-
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Figure 4 DCs exposed to soluble PD-1 acquire a 
suppressive phenotype. BM-derived DCs were har-
vested at day 10 and reseeded at 1 x 106 DCs/ml in 
96-wells U-bottom plates in the presence of soluble 
PD-1 or hIgG1 (30 µg/ml). Twenty-four hours later, 
cells and supernatants were harvested. A, Cell-
surface expression of CD40, CD80 and CD86 on 
mature (CD11c+, MHCII+) DCs. Shaded histograms 
indicate isotype control stainings and mean fluo-
rescence intensity is shown for CD80 and CD86 
stainings. B, cytokine levels in culture supernatant. 
ND; none detected. C, IDO gene expression.
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ence of antibodies to PD-L1, PD-L2 or 
both [12, 25]. Contrarily to our obser-
vations, they found an increase of T cell 
proliferation when antibodies against 
PD-L1 or PD-L2 were present, favoring 
an inhibitory role for PD-L1 and PD-L2 
during T cell stimulation. IFN-γ pro-
duction was increased in both studies, 
but IL-10 levels were decreased in one 
study [25], while Brown et al., similar to 
our findings, observed an increase in IL-
10 levels in the mixed DC-T cell culture 
[12]. A possible explanation for this 
discrepancy between studies might be 
the use of different blocking reagents, 
the extracellular domain of PD-1 in this 
study versus antibodies against PD-L1 
and PD-L2 in the other two studies. Fur-
thermore, although not published be-
fore for this pathway, there might be a 
difference in co-signaling effects of PD-
L1 or PD-L2 between species, as previ-
ously noted for the B7 family member 
B7-H3 [26, 27].
Several reports have shown the exis-
tence of reverse signaling of B7 family 
ligands into DCs, as shown in studies 
using soluble CTLA-4 or CD28, and has 
been illustrated for the HVEM-BLTA 
pathway as well [13, 14, 28]. More spe-
cifically, a recent study demonstrated 
that reverse signaling via  PD-L2 ex-
pressed by DCs lead to activation of 
DCs, as measured by  enhanced  T cell 
activation ability, migration capacity, 
IL-12 production and survival. Interest-
ingly, maturation markers CD80 and 
CD86 remained similar between the 
treatment and control group [15]. The 
antibody directed against PD-L1 iso-
lated by Selenko-Gebauer and co-work-
ers did not activate DCs, as judged by 
CD80 expression, CD86 expression and 
cytokine production [25]. In our experi-
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Figure 5 PD-L1 and PD-L2 expression pattern on 
pulmonary DCs. On day 0, groups of mice were 
immunized by intratracheal administration of 1 x 
106 OVA-pulsed BM-DC (OVA group) or unpulsed 
BM-DC (control group). On days 10-12, mice were 
challenged with OVA aerosols (OVA group) or PBS 
(control group) for 30 min. daily. At 24 h after the 
last aerosol exposure mice were sacrificed, BAL 
performed, right-middle lobe excised and single-
cell suspensions were prepared from enzymati-
cally digested lungs. To acquire sufficient events for 
analysis, 15 BAL samples of control mice, 10 BAL 
samples of the OVA group, and 5 lung cell sus-
pensions of each group were pooled. Cells were 
stained for CD11c and MHCII to characterize DCs, 
in combination with PD-L1 or PD-L2. A, PD-L1 ex-
pression of DCs in BAL and lungs of unsensitized 
mice (control) or mice with eosinophilic airway 
inflammation (OVA). B, PD-L2 expression of pul-
monary DCs. All shown populations are gated on 
CD11c+, MHCIIhi. Numbers in histograms denote 
mean fluorescence intensity. Shaded histograms 
indicate isotype control stainings.
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ments, DCs stimulated with soluble PD-
1 acquired a suppressive phenotype, 
secreting IL-10 and decreased expres-
sion of CD80 and CD86, while we did 
not detect increased IL-12 production. 
Whether these contrasting effects of 
PD-1 ligand-mediated reverse signaling 
are dependent on the type of stimulus 
used (PD-1- fusion protein versus a pa-
tient-isolated anti-PD-L2 IgM) remains 
to be seen. Moreover, we have not for-
mally established whether signaling 
occurs via PD-L1, PD-L2 or perhaps 
another ligand for PD-1. DC stimulation 
experiments using BM-derived DC from 
PD-L1 and PD-L2 deficient animals are 
necessary to verify this. 
As PD-L1 is also expressed on activated 
CD4+ T cells, we also analyzed the effect 
of soluble PD-1 on CD4+ T cell prolifera-
tion directly. Proliferation was similar 
to hIgG1 control, indicating no reverse 
signaling occurred via PD-L1 expressed 
by CD4+ T cells. Such signaling is pos-
sible, as antibodies have been isolated 
from serum of rheumatoid arthritis 
patient that stimulated CD4+ T cell pro-
liferation and IL-10 production [22]. 
Intriguingly, in this study soluble PD-1 
was also able to deliver these costimula-
tory signals. This increased proliferation 
was accompanied by increased apopto-
sis, which could be partially blocked by 
anti-IL-10 antibody. Although we have 
not directly assessed apoptosis of solu-
ble PD-1 stimulated T cells and we also 
found increased IL-10 levels in DC-T cell 
cultures, we do not observe increased 
proliferation in response to PD-1 ligand 
signaling. Moreover, both anti-IL-10 
mAb and anti-IL-10R could not restore 
the soluble PD-1-mediated inhibition 
of T cell proliferation in DC-T cell cul-
tures (data not shown), suggesting that 
IL-10-mediated CD4+ T cell apoptosis is 
not responsible for the inhibition in cell 
cycling. This is in agreement with find-
ings of Latchman et al. who observed 
cell cycle arrest but not apoptosis upon 
stimulation of CD4+ T cell with PD-L2-Ig 
[3].
We also addressed the potential of solu-
ble PD-1 to block DC-driven T cell acti-
vation in vivo, taking advantage of a DC 
driven model of asthma, where T cells 
play a key effector role by inducing air-
way eosinophilia through the release of 
IL-5 and IL-13. Interpretation of the ef-
fects of soluble PD-1 in vivo is bound to 
be more difficult than interpretation of 
the more defined in vitro culture system, 
especially because PD-L1 and PD-L2 are 
not only expressed on pulmonary DCs 
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Figure 6 soluble PD-1 suppresses eosinophilic air-
way inflammation. On day 0, groups of mice (n=3-
4) were immunized by intratracheal administration 
of 1 x 106 OVA-pulsed BM-DC. On days 10-12, 
mice were challenged with OVA aerosols for 30 
min. daily. During sensitization and challenge mice 
were treated with 100 µg soluble PD-1 or hIgG1 i.p. 
daily for four consecutive days. One group was not 
administered protein (‘no treatment’ group). At 24 
h after the last OVA aerosol exposure mice were 
sacrificed, BAL performed and lungs isolated. A, 
total cell number in the BAL. B, cellular composition 
of BAL fluid. Alveolar macrophages were charac-
terized by their light scatter and autofluorescence 
properties. Eosinophils are defined by their CCR3+, 
CD4-, CD8- staining pattern. The T cell fraction con-
sists of CD4+ and CD8+ cells within the appropriate 
light scatter gate. C, IL-5 and IL-13 levels in BAL 
fluid. Results are expressed as means ± SEM. 
Data are representative for 2 independent experi-
ments. *: p< 0.05
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and macrophages (this study and [23, 
29], but PD-L1 is also expressed on a 
variety of tissues of non-hematopoietic 
origin, particularly under inflammatory 
conditions [6]. Nonetheless, the results 
of treatment with soluble PD-1 in this 
model of Th2-dependent asthma are 
in line with our in vitro data as we ob-
serve a decrease in eosinophils in the 
BAL fluid and, even more importantly, 
a concomitant decrease in the Th2-as-
sociated cytokines IL-4 and IL-13. This 
suggests that also in vivo soluble PD-1 
is capable of blocking T cell activation. 
As we have previously shown that air-
way DCs are crucial for inducing Th2 
effector function after allergen chal-
lenge to the airway [30], it is very likely 
that soluble PD-1 had its effect through 
altering DC function. We are currently 
investigating the phenotype of pulmo-
nary DCs in inflamed airways during 
treatment with soluble PD-1.
The majority of studies interfering 
with PD-L1 or PD-L2 signaling in vivo 
supported a inhibitory role for these 
molecules [23, 31-33]. One such study 
involved eosinophilic airway inflam-
mation. Matsumoto and colleagues 
showed that treatment with anti-PD-L2 
mAb at the time of allergen challenge in 
a mouse model of eosinophilic airway 
inflammation lead to increased airway 
inflammation, consistent with an in-
hibitory role for PD-L2 [29]. A possible 
explanation for the contrasting results 
between our work and this study might 
be the way in which PD-L2 blocking 
is achieved; the monoclonal antibody 
used by Matsumoto might only have 
blocked the signaling via the inhibitory 
PD-1 receptor on T cells, while soluble 
PD-1 used by us could have exerted its 
effect additionally through reverse sig-
naling via PD-L1 or PD-L2 expressed on 
DCs and macrophages, thus reducing 
immunostimulatory potential. This lat-
ter pathway leading to less efficient T 
cell stimulation might be dominant over 
the direct effect of inhibiting the cross-
linking of PD-1, very similar to what has 
been shown for CTLA-4-Ig.
Despite these studies supporting an 
inhibitory role for PD-L1/PD-L2, some 
studies have clearly shown the oppo-
site. A costimulatory role for PD-L1 in 
vivo has been noted in a murine model 
of colitis [29, 34]. Likewise, transplan-
tation of PD-L1 expressing Langerhans 
islets resulted in increased incidence of 
diabetes [29, 34]. Another very recent 
study by Oflazoglu and colleagues using 
an agonistic mPDL-2-hFc fusion protein 
demonstrated that PDL2 induced Th2 
effector cytokines and enhanced eosin-
ophilic airway inflammation, consistent 
with a costimulatory role for this mol-
ecule and consistent with our findings 
[23]. The feasibility of  an immunother-
apy against eosinophilic airway inflam-
mation based on modulation of PD-1 li-
gand signaling has already been shown 
by Radhakrishnan and colleagues, who 
demonstrated that administration of an 
IgM antibody crosslinking PD-L2 could 
block eosinophilic airway inflammation, 
even when it was fully established [35]. 
It remains to be determined however 
whether soluble PD-1 functions similar 
to this crosslinking IgM antibody, which 
suppresses the Th2-associated airway 
inflammation via a STAT4-dependent 
polarization towards a suppressive Th1 
response. A plausible mechanism for 
this Th1 polarization is IL-12 produc-
tion by DCs upon PD-L2 crosslinking 
[15], which is capable of preventing the 
development of eosinophilic airway in-
flammation [36]. However, it is also of 
interest to note the increase in IL-10 
production by restimulated splenocytes 
isolated of anti-PD-L2 IgM antibody 
treated mice,  which resembles the ob-
served production of IL-10 in our in vi-
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tro system. As it has been reported that 
IL-10 producing DCs have the capacity 
to induce IL-10 producing regulatory T 
cells [37], we are currently investigat-
ing whether soluble PD-1 stimulation 
leads to the development of regulatory 
T cells in vitro and in vivo.
In conclusion, the data described in 
this paper implicate that soluble PD-1 
blocks CD4+ T cell stimulation in vitro 
and in vivo, presumably via reverse sig-
naling into DCs as has been described 
for B7-1, B7-2 and BLTA [13, 14, 28]. 
Further studies are required however, 
to delineate the signal transduction 
pathways involved in reverse signaling 
and the effector molecules responsible 
for T cell inhibition. Nevertheless, the 
observed suppression of eosinophilic 
airway inflammation after treatment 
with soluble PD-1 offers a new perspec-
tive for immunotherapy against T cell 
mediated allergic disorders.
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Abstract
Atopic asthma is a chronic inflammatory disease of the airways, characterized 
by airway hyperreactivity and mucus hypersecretion that result in intermit-
tent airway obstruction. This chronic inflammation is the result of an aberrant 
Th2-mediated response to innocuous environmental proteins. The prevalence 
of this disease has increased dramatically in the industrialized world in the 
last decades. Current treatment is mainly based on pharmacological interven-
tions which control the disease but are not curative. Although the etiology is 
not completely understood, it becomes increasingly clear that dendritic cells 
play an important role in both the sensitization phase and maintenance of the 
disease. In this review we explore the different possibilities to exploit dendritic 
cell vaccines in order to prevent the development of (or inhibit established) 
atopic asthma.
Introduction : the natural history of asthma
Atopic asthma is a chronic inflammatory disease of the airways, characterized by 
airway hyperreactivity and mucus hyperssecretion that result in intermittent air-
way obstruction [1]. Histologically, eosinophilic airway inflammation, goblet cell 
hyperplasia and epithelial fragility are consistent findings [2]. The natural history 
of allergic asthma begins by an early and persistent Th2 skewed immune re-
sponse to commonly ingested (cow milk) and inhaled allergens (house dust mite, 
pollen allergens, animal dander), as reflected by the occurrence of Th2 dependent 
allergen-specific IgE antibodies in the serum. The immunological basis of asthma 
is supported by some genetic susceptibility studies that have seen an associa-
tion between polymorphisms at the Th2 cytokine gene cluster at locus 5q23-31 
(containing the IL-4, IL-9 and IL-13 gene locus) and risk of developing atopy and 
asthma [3, 4]. At young age, some sensitized children develop atopic dermatitis 
and/or intermittent periods of wheezing, coughing and shortness of breath upon 
contact with allergens or upon non-specific stimuli such as cold air or exercise. 
In adolescents, asthma subsequently disappears clinically (although subclinically 
bronchial hyperreactivity and/or inflammation can often persist [5]), whereas in 
others the disease progresses into a chronic phase into adulthood.  
It is currently believed that the symptoms associated with chronic asthma are a 
result of structural changes in the lung in response to chronic inflammation and 
remodeling of the airway wall, leading to fixed airway obstruction. The chronic 
nature is exemplified by the observation that airway biopsies of asthmatic chil-
dren show already signs of remodeling and inflammation [6]. Second, an indirect 
finding indicating the relative importance of airway remodeling is the identifica-
tion of the asthma susceptibility gene Adam33 [7]. ADAM33 is a member of the 
dysintegrin and metalloproteinase family and expressed in smooth muscle cells, 
fibroblasts and myofibroblasts but not in T lymphocytes or other cells of the 
immune system, suggesting it is involved in remodeling rather than the immuno-
logical aspects of disease. 
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Risk factors for developing asthma
The best known and validated risk factor for developing asthma is Th2 sensitiza-
tion to commonly inhaled allergens. The contribution of allergen sensitization 
to the risk of subsequently developing asthma seems inversely correlated with 
the age at which allergy initially manifests [8], reinforcing the idea that the re-
spiratory system is particularly vulnerable to inflammatory damage during early 
life [9]. Asthma is inherited as a polygenic trait, but clearly, environmental fac-
tors greatly influence the manifestation of asthma, including family size, early 
day-care attendance and maternal smoking during pregnancy [10, 11]. Another 
important early life risk factor for developing asthma is the occurrence of child-
hood respiratory infections [8, 12]. The incidence of atopic diseases has risen 
dramatically in westernalized countries since the 1950’s, concomitantly with a 
reduced incidence of infectious diseases such as measles, tuberculosis, hepatitis 
A virus, streptococcal infection as well as helminth infections [13]. This reduction 
in infectious diseases has been the result of increased hygiene, large scale vac-
cination campaigns and early use of antibiotics. The immunological explanation 
of the hygiene hypothesis is surrounded by controversy. Most likely, the reduced 
infectious pressure from the environment leads to aberrant or persistent Th2 re-
sponses because of a lack of counterregulatory anti-infectious Th1 responses or 
anti-inflammatory regulatory T cells (Tregs). As a nice illustration to the hygiene 
hypothesis, it was shown that children raised at a farm, with frequent contact 
with cows and drinking unpasteurized milk in the first year of life were protected 
from developing atopic sensitization and atopic diseases possibly due to high 
level exposure to LPS [14]. Subsequently, the same group showed that even in 
non-farmers, the level of LPS exposure in mattress covers in the bedroom are 
negatively associated with the risk of developing atopic symptoms [15].
Understanding the origin of the sensitization process : a critical 
role for dendritic cells.
From the above it is clear that the initiation of a Th2 response to inhaled aller-
gens is a critical checkpoint in the development of the ‘atopic march’ towards 
persistent asthma.  If we are to intervene at this point, it is imperative that we 
understand the process of sensitization much better and also study how this 
process is influenced by genetic and environmental factors. In the last decades, 
antigen presenting dendritic cells (DCs) have emerged as the principal cell that 
orchestrates adaptive immunity [16]. By their expression of a vast array of anti-
gen receptors and Toll like receptors shared with the cells of the innate immune 
system, these cells react to most harmless (self) antigens as well as dangerous 
pathogens. Besides activation of T and B cells, DCs also influence the differen-
tiation of CD4+ T cells, depending on the type of immune response required to 
eradicate the pathogen [17]. In particular the role of DCs in polarization towards 
Th1 effector T cells has been well studied, with DC-derived IL-12 being of para-
mount importance for this differentiation route [18, 19]. We and others have 
also shown that airway DCs are at the very heart of the sensitization process 
that leads to Th2 immunity in the lung [20, 21]. In a series of experiments, we 
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were able to demonstrate that myeloid dendritic cells (mDCs) are sufficient to 
induce Th2 sensitization in naïve mice [20, 22]. In these experiments, animals 
were sensitized to a model allergen (mostly OVA) via intratracheal injection of 
allergen-pulsed, bone marrow derived, DCs. Ten days later, mice were challenged 
with OVA aerosols on three consecutive days. The allergen challenge led to al-
lergen-specific Th2 cytokine synthesis, eosinophilic airway inflammation, goblet 
cell hyperplasia and bronchial hyperreactivity, all salient features of asthma (Fig-
ure 1). Not only adoptively transferred DCs but also endogenous (myeloid) DCs 
induce proper Th2 sensitization in response to inhaled antigen, providing that 
the antigen is capable of inducing the maturation of lung DCs [23, 24]. 
The subset of lung DCs presenting the inhaled antigen is also likely to influence 
the immunization process, either directly or indirectly. De Heer et al, showed a 
suppressive effect of plasmacytoid DCs (pDCs) on the outcome of airway immu-
nization, most likely via inhibiting myeloid DC function [25]. In the absence of 
pDCs, inhalation of harmless antigen led to stable Th2 immunity and features of 
asthma, while adoptive transfer of pDCs rendered mice tolerant to the antigen. 
These studies are supported by recent findings that the balance of particular sub-
sets of DCs presenting antigen in the draining lymph nodes of mice airways was 
dependent on the immunization protocol: predominantly pDCs were recovered 
under tolerizing conditions (OVA in the absence of adjuvant), while mDCs were 
isolated after an airway inflammation inducing regimen (OVA combined with 
cholera toxin ) [26]. Thus, the final outcome of an immune response is depending 
on the type of DC and/or activation status of the DC presenting the antigen. 
In humans, less is known about the precise role of DCs in the Th2 sensitization 
process at the basis of atopic asthma. Indirect evidence that points towards a role 
for DC-derived IL-12 in atopic sensitization is based on epidemiological studies, 
reporting an inverse correlation between endotoxin exposure at young age, a 
well-known IL-12 inducer, and atopic sensitization [15, 27]. More direct evidence 
was derived from studies examining the IL-12 production of PBMCs (including 
DCs) in atopic patients, which was shown to be subsequently lower compared 
to healthy individuals [28, 29]. Moreover, polymorphisms in the IL-12B gene 
promoter have been correlated with an enhanced severity of atopic asthma in 
children, presumably due to lower levels of IL-12 production by DCs [30-32]. 
Some of the most common allergens such as house dust mite and pollen allergens 
contain substances that clearly polarize DC function towards Th2 induction. In 
house dust mite, the proteolytic activity of the major allergen Der p 1 induces 
IL-10 production and CD86 expression, while suppressing IL-12 production in 
DCs obtained from house dust mite-allergic patients [33]. In pollen allergens, 
the plant phytoprostanes, closely related to mammalian prostaglandins, strongly 
suppress IL-12 secretion in DCs, leading to Th2 induction [34].
Altering DC function to prevent sensitization
The predominant influence of DCs on the critical decision between tolerance or 
Th1/Th2 adaptive immunity might be exploited to the benefit of preventing atopic 
Th2 sensitization in high risk individuals. Over the last years we have performed 
some proof of concept studies that this is a feasible strategy. In particular, we 
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have used an animal model of asthma where intratracheal injection of bone-
marrow derived DCs is used to prime for Th2 dependent eosinophilic airway 
infl ammation (fi gure 1 and [22]. In such a system, we can selectively modify DCs 
in vitro and subsequently observe what the eff ects of such modulation are on 
the process of DC-driven sensitization. As atopic asthma is associated with Th2-
dependent disease, deviation towards other pathways of CD4+ T cell development 
or suppressing of the Th2 response might be benefi cial.
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Altering the functional behavior of dendritic cells through bacterial products
As stated before, infectious pressure and associated levels of environmental en-
dotoxin at a young age profoundly influence the incidence of atopic asthma in 
later life. As DCs are the predominant cell type that steers adaptive immunity to 
allergens and also reacts to microbial stimuli we speculated that direct exposure 
to common microbial factors such as LPS might alter the potential of DCs to 
promote Th2 responses. When we exposed myeloid DCs to endotoxin and the 
model allergen OVA, the Th cell polarization process in vitro and in vivo was 
profoundly changed from a default Th2 pathway to a strong Th1 response. Not 
surprisingly, when mice were subsequently challenged with OVA aerosol, airway 
eosinophilia no longer developed [35]. These direct inhibitory effects of LPS ex-
posure on Th2 sensitization are in agreement with various other studies inves-
tigating the relationship between LPS exposure during intraperitoneal priming 
and eosinophilic airway inflammation [23, 36, 37]. They are new in the way that 
we now offer an explanation as to how LPS might work to induce suppression 
of asthma, i.e. by modeling the phenotype and function of DCs. Although in our 
system, we modified DCs with LPS in vitro, we believe that this is a reflection of 
what might happen in vivo. Indeed, recently our findings were corroborated by 
studies revealing that LPS modulation of atopic sensitization via the airways in 
murine models of eosinophilic airway inflammation were strongly dependent on 
TLR4 and MyD88 signaling, implicating that modulation of endogenous lung DC 
function is the mechanism by which high dose LPS suppresses Th2 development 
[23, 24]. An intriguing aspect of our study and other studies was the finding that 
the suppressive effect of LPS exposure on Th2 development and induction of 
Th1 development was independent of IL-12 production by DCs altogether [38]. 
One of the most plausible explanations for IL-12 independent Th1 development 
is rescue of Th1 differentiation by IL-27, which is produced by DCs upon LPS 
stimulation [39]. However, subsequent studies have revealed that IL-27 has also 
anti-inflammatory properties [40]. IL-23 might be another candidate, as it is pro-
duced by DCs and has been reported to drive IL-12 independent development of 
a highly pathogenic CD4+ T cell subset [41]. In addition to their fundamental role 
in T cell development, the Notch ligand families Delta and Jagged are also impli-
cated in DC-mediated CD4+ T cell polarization [42], with LPS increasing the cell-
surface expression of the Th1 favoring Delta-4 molecule on DCs. Future studies 
will address whether other microbial compounds such as β-glucans, CpG motifs 
or peptidoglycans, many of which also act upon members of the TLR family, also 
suppress sensitization by altering DC function. The ultimate goal of this strategy 
will be to find those compounds that act on endogenous DCs can be safely and 
reliably be administered and can exert their function in a non-toxic way.
Altering the functional behavior of dendritic cells through genetic modification
It remains a matter of debate whether IL-12 production capacity of APCs is fun-
damentally lower in atopics compared to healthy controls. IL-12 production is 
probably dependent upon the age of the individual, making comparisons be-
tween studies more difficult [28, 29, 43-45]. Despite the fact that LPS suppresses 
Th2 development in an IL-12-independent way, it is still possible that overexpres-
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sion of IL-12 is sufficient to prevent Th2 development. To prove this point, we 
have retrovirally overexpressed bioactive IL-12p70 in BM-DCs and see whether 
IL-12 overexpression would abolish the potential of these cells to induce Th2 
sensitization in the lungs [46]. To our surprise, we observed indeed that IL-12 
overexpression turned DCs into Th1 priming cells, even in the Th2 prone milieu 
of the lungs. These results were confirmed by another recent study that exam-
ined the feasibility of IL-12 transduced DC in prevention of eosinophilic airway 
inflammation [47]. 
As less is known about DC signals directing naïve CD4+ T cell differentiation to-
wards the type 2 subset compared to Th1 signals (e.g. IL-12), the strategies to 
directly inhibit Th2 development by DCs are limited. The cytokine IL-4 is criti-
cal for Th2 development, but is not produced by DCs. Recently, administration 
of plasmid DNA or a viral vector encoding for an IL-4R antagonist (A mutated 
form of IL-4 with binding capacity but lacking signaling capacity, IL-4Q/Y) could 
prevent eosinophilic airway inflammation in a murine asthma model [48, 49]. 
However, some preliminary experiments using DCs retrovirally expressing IL-4Q/
Y could not prevent antigen sensitization in our eosinophilic airway inflammation 
model (unpublished observations).
Significant ethical and practical problems will have to be solved before we can 
ever envisage a genetic strategy to prevent asthma. However, based upon our 
data in this mouse model we believe that genetic targeting of genes to DCs might 
be an efficient way of fundamentally altering Th priming in vivo. A potential ca-
veat that should be taken into account is Th1-mediated breakdown  of tolerance, 
as it was shown that mucosal tolerance to harmless antigen could be broken 
by administration of IL-12 [50, 51]. These findings suggest that, translated to a 
clinical setting, patients receiving Th1 inducing immunotherapy should be care-
fully monitored for breakdown of self-tolerance, which could eventually lead to 
autoimmunity.
Using DCs to revert existing Th2 responses : a novel form of im-
munotherapy ?
After the process of sensitization has occurred, it is hard to convert existing 
polarized pathogenic Th2 responses into protective Th1 or Tregs responses in 
an attempt to prevent the clinical manifestations of Th2 mediated diseases such 
as asthma, allergic rhinitis or atopic dermatitis (secondary prevention strategies). 
This is however clinically the most relevant question, as it would allow the 
secondary prevention of high risk sensitized children before any diseases have 
developed. In recent years, immunotherapy based on the unparalleled ability of 
DCs to activate and control the adaptive immune response has been pioneered, 
mainly in the field of cancer therapy and aimed at eliciting a tumor-specific 
immune response [52]. The techniques for generating large amounts of clinical 
grade DCs have become widely available, as are the techniques for (genetically) 
modifying the phenotype and degree of maturation of dendritic cells. In the field 
of cancer, the primary emphasis has been to generate DCs with a strong potential 
to induce CD4+ Th1 responses and cytotoxic CD8+ responses directed against 
the tumor. We have explored the ability of gene-modified DCs to modulate an 
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allergen-specific immune response, either by changing CD4+ T cell differentiation 
or suppressing Th2 development.
Counterbalancing Th2 responses by Th1 inducing DCs
The controversy about the relationship between IL-12 and allergic asthma (see 
before) does not exclude the possibility to employ Th1-inducing DCs for thera-
peutic purposes. Unfortunately, when we adoptively transferred IL-12 overex-
pressing DCs to already Th2 sensitized mice, to induce a counterregulatory anti-
gen-specific Th1 population, we could not prevent the occurrence of eosinophilic 
airway inflammation upon rechallenge of the mice with relevant allergen [46]. In 
other words, our secondary prevention strategy failed. In line with these results, 
it has been shown that adoptive transfer of antigen-specific Th1 cells does not 
suppress, or even enhances, Th2-mediated airway eosinophilia [16, 53, 54]. One 
study that did report a beneficial effect of Th1 cell transfer on eosinophilic air-
way inflammation saw only a decrease in the number of eosinophils in the BAL 
fluid compartment, not in tissue eosinophilia [55]. A mechanistic explanation was 
provided by Cohn et al, as it was shown that IFN-γ inhibits eosinophil migra-
tion to the airway lumen [56]. It should be emphasized though that all these 
studies transferred in vitro polarized Th1 cells, while in our DC-immunotherapy 
protocol naïve CD4+ T cell polarization took place in vivo. Recent evidence sug-
gests however, that in vivo differentiated antigen-specific Th1 cells have limited 
ability to inhibit Th2 cells development in vivo [57]. To summarize, despite the 
initial promising reports of IL-12 administration in murine models of asthma to 
prevent or treat asthma [58], the subsequent adverse side-effects noted in clini-
cal trials makes this approach not realistic [59]. Although we and the study of 
Ye [60] show that eosinophilic airway inflammation can be prevented through 
Th1-directed antigen sensitization, the subsequent lymphocytosis we and others 
observed [61] still represents a deviation of the normal state (no inflammation) 
and is likely to have also detrimental effects for the patient.
Direct suppression of Th2 responses
We have recently shown that conditional depletion of CD11c+ DCs from the air-
ways of mice was able to completely suppress Th2 mediated effector responses 
and cardinal features of asthma [62]. Therefore, altering the function of DCs 
might also directly suppress Th2 activation in an already sensitized host. In fact, 
the current standard therapy of asthma consists of inhaled steroids. A number of 
studies have already shown that inhaled and systemic corticosteroids reduce the 
number and function of airway DCs in vivo or ex vivo [63-65]. However, based on 
our knowledge of Th2 activation by DCs in asthmatic airways, we have attempted 
a more direct way of inhibiting Th2 activation by DCs.  
It is increasingly clear that the process of T cell activation involves not only co-
stimulatory molecules being expressed on DCs, but that there are also inhibitory 
molecules that have the potential to suppress or switch off naïve and/or activated 
T cells in an antigen specific manner [66]. Overexpression of these negative sig-
nals on DCs could be exploited as a strategy to suppress only antigen-specific T 
cell responses. The strategy of targeting activated T cells selectively has the clear 
advantage that the immune response to allergens or self antigens is abolished 
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instead of deviated, theoretically decreasing the risk of severe side-effects. As a 
nice illustration it was shown that DCs overexpressing the death receptor ligand 
FasL (CD178) and a specific antigen were able to kill selectively the activated an-
tigen specific T cells expressing Fas [67]. This led to a reduction in auto-immune 
disease [68]. With respect to asthma, it has been shown that intratracheal deliv-
ery of adenovirus encoding FasL could significantly suppress pulmonary immune 
responses [69]. However, this strategy has been disputed a lot as some recent 
reports have shown that DCs overexpressing FasL induce massive pulmonary 
inflammation, pleuritis and acute skin allograft rejection [70, 71].
In an attempt to devise a similar, less toxic way of eliminating antigen-specific 
Th2 responses, we have chosen to overexpress the ligands for the inhibitory re-
ceptor PD-1 on DCs. PD-1 is expressed on activated T and B cells and its inhibi-
tory function is illustrated by the fact mice deficient for PD-1 develop autoim-
mune diseases [72]. The ligands for PD-1 identified so far are PD-L1 (B7-H1) and 
PD-L2 (B7-DC), which show some homology to other B7 family members such 
as B7-1 and B7-2. Expression of PD-L2 is limited to activated macrophages and 
DCs, while PD-L1 is also expressed on non-hematopoietic cells [66, 72]. Unfor-
tunately, the efficacy of the inhibitory molecules PD-L1 and PD-L2 was limited 
in our DC-mediated model of eosinophilic airway inflammation, and these gene 
modified DCs were not able to abolish established Th2 priming (unpublished 
observations). Accumulating evidence suggests that the PD-L1/2-PD-1 ‘signal 2’ 
pathway is primarily important in peripheral tolerance, mediated by non-profes-
sional APCs, possibly to limit the extent of immunopathology. The expression 
pattern of PD-L1 is in agreement with this hypothesis, as it is not only expressed 
on cells of hematopoietic origin but also in other organs such as heart, lungs and 
placenta [47, 66]. Furthermore, it might be that this pathway is not as efficient as 
other similar costimulatory pathways with an inhibitory role such as the CTLA-4 
cascade, as mice deficient for CTLA-4 exhibit massive lymphoproliverative dis-
orders and die at 3-4 weeks of age [73]. PD-1 deficient mice also spontaneously 
develop autoimmune diseases, but more slowly and succumb after 5-6 months 
[72].
Another strategy one can exploit to suppress Th2 immune responses is based on 
a phenomenon termed ‘reverse signaling’, where molecules classically defined 
as ligands turn into receptors, transmitting signals into the cell from which they 
are expressed Reverse signaling has recently been described for DCs via CD80, 
CD86 as well as BTLA. [74-76]. We have obtained evidence that PD-L1 and/or 
PD-L2 can fulfill a similar role, as soluble PD-1 (the extracellular domain of PD-1 
fused to the constant domain of human IgG1) could inhibit CD4+ T cell activa-
tion in vitro. This inhibition was accompanied by an increased IL-10 production. 
Subsequent analysis of the mode of action has revealed that soluble PD-1 acts 
via PD-L1 and/or PD-L2 on DCs, which acquire a suppressive phenotype consist-
ing of downregulation of CD80 and CD86, in combination with enhanced IL-10 
production (manuscript submitted). It is currently not clear whether these immu-
nosuppressive DCs are directly responsible for suppressing T cell activation or 
generate inducible regulatory T cells (Tregs; discussed below). Irrespective of the 
mode of action, this phenomenon could be exploited for therapeutic purposes, 
as pulmonary DCs express high levels of PD-L1 and PD-L2 during eosinophilic 
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airway inflammation [62, 77, 78]. Indeed, we observed that soluble PD-1 had the 
capacity to suppress Th2 dependent eosinophilic airway inflammation.
The enzyme indoleamine 2,3- dioxygenase (IDO) is capable of inhibiting T cell re-
sponses, either by depletion of tryptophan or the production of inhibitory metab-
olites such as kynurenine, and thought to be involved in DC-mediated tolerance 
[79]. The therapeutic effects of CpG motifs, also seem to be mediated by induction 
of IDO enzyme activity in the lung [80]. We found that tolerogenic pDCs isolated 
from the lungs of tolerized mice produce high levels of IDO (unpublised obser-
vations) and we reasoned that this enzyme could endow these cells with their 
tolerogenic properties [25] Based on these findings, we have undertaken several 
attempts to generate  DCs overexpressing IDO. Unfortunately, despite IDO gene 
transcription and IDO protein production in transduced DCs, we did not succeed 
in inhibiting CD4+ T cell responses in vitro (unpublished observations). 
Indirect suppression via induction of regulatory T cells
A promising new strategy to develop immunotherapy against disorders ranging 
from cancer to allergies currently under intense scrutiny of immunologists is 
based on regulatory T cells (Tregs) As a thorough review of this subset of CD4+ T 
cells falls outside the scope of this review, we will provide a brief summary here 
(see [81] for a review). Two major populations have been described so far, the 
natural occurring regulatory T cells and inducible Tregs. The natural occurring 
Tregs cells represent 5‒10% of the CD4+ T lymphocytes in healthy adult mice and 
humans and are characterized by expression of CD25 in a naïve state, hence the 
designation CD4+CD25+, and express the transcription factor Foxp3. Inducible 
Tregs appear in vivo under regimens of antigen administration known to gener-
ate anergy/tolerance. The exact mechanisms of action of these regulatory T cell 
subsets are not understood in detail. Several mediators have been reported for 
CD4+CD25+ Tregs, including IL-10, TGF-ß, CTLA-4 and GITR, but this list is not be-
lieved to be complete. Inducible Tregs mainly exert their effect via secreted IL-10, 
although in some studies it has also been found that cell-cell contact is required, 
suggesting other effector mechanisms.
The specific interest to employ these cells for immunotherapy against atopic 
disorders was fuelled by recent discoveries that naturally occurring CD4+CD25+ 
regulatory T cells from allergic patients have limited ability to suppress activa-
tion of allergen-specific effector T cells compared to healthy controls [82]. In 
addition, tolerance induction to cow’s milk allergens was associated with an in-
creased frequency of circulating CD4+CD25+ regulatory T cells and a decreased in 
vitro response to a major allergen [83]. Another piece of evidence underscoring 
the importance of these naturally occurring regulatory T cells is the provided 
by the observation that humans suffering from the IPEX syndrome, caused by a 
mutation in the foxp3 gene, is not only associated with autoimmune disease but 
with allergy as well [84].
Furthermore, the proportion of allergen-specific induced regulatory T cells was 
reduced in atopic individuals compared to healthy controls [85]. These findings 
suggest that function and/or frequency of regulatory T cells are different in atop-
ics compared to healthy individuals.
Animal models of eosinophilic airway inflammation suggest a role for pulmonary 
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DCs in the induction of regulatory T cells [86, 87]. Similarly, we could also show 
that a specific subset of plasmacytoid DCs has the potential to capture airborne 
antigen and induce the formation of Tregs ex vivo [25].
Thus, engineering DCs in such a manner that they induce subsets of regulatory 
T cells might have great therapeutic potential, not only for allergic disorders but 
also for other pathologies characterized by unwanted immune responses.
The precise signals governing the induction of Tregs are currently unknown. It 
has been shown that antigen-specific tolerance as a result of a respiratory expo-
sure regime is mediated by pulmonary DCs that produce IL-10. These DCs subse-
quently induce IL-10 producing T cells in a B7RP-1-ICOS dependent manner [87]. 
Interestingly, in our hands, IL-12 producing DCs lead to increased production of 
IL-10 and IFN-γ by CD4+ T cells [46]. Although we did not formally show that in 
our assays these cytokines were simultaneously produced by the same cell, it was 
previously shown that IL-12 and strong polarization stimuli lead to IL-10/IFN-γ 
secreting CD4+ T cells [88]. These particular subset was also identified in vivo 
after infection with pathogens causing chronic inflammation and believed to pro-
tect against severe inflammatory pathology [89]. More recently, a CD4+ T cell sub-
set with a similar cytokine production phenotype but also expressing T-bet and 
Foxp3 was found to protect against airway hyperreactivity [90]. Moreover, this T 
cell subset with regulatory properties could only be induced by a particular DC 
subset expressing IL-12. It will be of interest to know whether IL-12 transduced 
DC can drive CD4+ T cell differentiation into the same regulatory subset. Surface 
molecules expressed by DCs might also induce the generation of Tregs. This was 
elegantly shown in a model of respiratory allergy where DCs transfected with 
the Notch ligand Jagged 1 was able to specifically induce antigen specific Tregs 
[91].
Using persistently immature DCs for tolerance induction
Induction of DC maturation by ligation of TLR receptors on DCs is a critical event 
in the decision between immunity or tolerance [92]. With elegant experiments 
using DCs that could conditionally express a viral antigen it was shown that an-
tigen expression under inflammatory conditions resulted in the generation of an 
effective immune response towards this virus, while under steady-state condi-
tions, antigen presentation leads to T cell tolerance, which could not be broken 
by subsequent infection with the virus [93]. Along similar lines, Brimnes and 
colleagues showed that inhalation of OVA protein alone leads to tolerance, while 
simultaneous exposure to OVA and influenza virus results in a immune response 
towards OVA as well as influenza [94]. Further evidence underscoring the impor-
tance of the maturation status of DCs was obtained by silencing SOCS1 expres-
sion in DCs, leading to increased antigen presentation and enhanced anti-tumor 
immunity [95]. Therefore, keeping DCs in a persistent immature state and using 
these for immunotherapeutic purposes can be seen as a strategy to induce T 
cell tolerance. Two tactics can be employed. First, antigens could be targeted to 
endogenous immature DCs, providing we know the receptors for specifically tar-
geting antigens to these cells. The feasibility of this approach was illustrated by 
specific targeting of antigen to murine DCs via conjugation of antigen to a mono-
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clonal directed against DEC-205, a C-type lectin. Targeting OVA antigen to DCs 
under non-infl ammatory conditions led to tolerance, and mice were unresponsive 
to subsequent OVA challenges in the presence of strong adjuvants [96]. This prin-
ciple of achieving tolerance via DC targeting is currently pursued for therapeutic 
purposes through identifi cation of the natural ligands for this (and other) lectins, 
followed by antigen conjugation. The diff erent approaches described above are 
summarized in fi gure 2. A second strategy would be to culture immature DCs ex 
vivo, pulse them with antigen and reinject those in a persistently immature form 
to mediate tolerance to the antigen. There have been several attempts at this 
strategy. Martin et al [97] used CD40 defi cient DCs, resisting T cell mediated DC 
maturation, to induce Tregs in vivo and these cells could suppress T cell mediated 
pathologies. Others have used a dominant negative inhibitor of NF-Kb signaling 
to keep DCs in an immature state to generate Tregs [98].
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Conditions for successful DC-mediated immunotherapy
Despite these exciting possibilities for DC based immunotherapy for a range of 
human diseases looming at the horizon, some basic questions need to be eluci-
dated before routine clinical use becomes a reality.
How can we control DC activation? 
The context in which antigen is presented to naïve T cells by DCs is of paramount 
importance for the class of immune response generated [17]. The discovery of 
pattern recognition receptors (PRRs), such as TLRs, provided a molecular mecha-
nism for the transition of immature, tolerizing, DCs into effective APCs. To tai-
lor a DC vaccine in such a way that it generates the desired immune response 
requires more detailed knowledge about these secondary signals. For example, 
which stimuli (or absence of stimuli) are required to induce tolerance against a 
particular allergen without inducing an immune response against self-antigens, 
resulting in autoimmunity? Conversely, for tumor eradication a robust immune 
response needs to be generated and inadequate innate signals may make an in-
dividual even more susceptible to further tumor growth by actively tolerizing the 
antigen-specific lymphocytes.
What is the optimal route and dose of administration of DC?
The optimal route of administration for immunotherapy for allergic disease has 
not been settled. In current practice, standard desensitization immunotherapy 
using allergen extracts is administered subcutaneously  or sublingually. Based on 
the findings in DC-immunotherapy  in cancer patients, it might similarly be prac-
tical to inject DCs subcutaneously or directly into the skin draining node using an 
echography-guided approach.  However, interfering with a mucosal disease such 
as asthma might also require the administration of tolerogenic DCs to the nasal 
or lung mucosa.  Preclinical experiments will have to be performed in the future 
in mouse models to address these points in greater detail.
What is the antigen-specificity and are the targets of regulatory T cells?
Although the presence of regulatory T cells has been confirmed in many disease 
models [99], less is known about the antigen specificity and targets of these cells. 
The naturally occurring CD4+CD25+ T cell population mainly seems to recognize 
an antigen repertoire of peripheral self-antigens [100, 101], but have also been 
implicated to control pathogen infections [102]. Inducible regulatory T cells, on 
the other hand, arise during antigen administration regimes known to induce tol-
erance/anergy [81], and antigen-specific clones have also been generated from 
lymphocytes isolated from B. pertussis infected lungs [103]. Besides the antigen 
specificity of the cell populations, its is also important to unravel their mecha-
nism of action. The effector molecules of induced Tregs identified so far, IL-10 
and TGF-ß, suggest that this subset is activated in an antigen-dependent manner, 
but suppresses immune responses in an antigen-independent fashion. Therefore, 
careful examination of the regulation of regulatory T cell activation and termina-
tion needs to be undertaken to avoid general immunosuppresion due to Treg-
inducing immunotherapy.
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Concluding remarks : early immunomodulatory intervention is 
the key to altering the natural history of asthma
Current asthma therapy is largely based on the use of inhaled corticosteroids 
[104], which are adequate and safe but concerns remain about their long-term 
use, particularly in children [105]. Although inhaled corticosteroids reduce eo-
sinophilic airway inflammation and provide symptomatic relief, it is unclear if 
they also modify airway remodeling [106-108]. Upon withdrawal of treatment, 
the symptoms recur, suggesting that they do not alter the natural history of asth-
ma and that the various structural changes in airway tissue, are of increasing 
importance in established disease. The only way to intervene with the natural 
history of asthma is to alter the aberrant Th2 response to inhaled allergens, and 
in this way halt ‘the atopic march’. Various strategies of immunotherapy have 
been employed, some of them involving regular subcutaneous injections of al-
lergen extracts or recombinant allergen, others using sublingual administration 
of allergens, in the hope of downregulating the allergen-specific Th2 response 
[109]. Many of these studies have been performed in adults with chronic, therapy 
resistant disease. Based on our current understanding of the pathology of estab-
lished asthma, and on our experience with DC driven immunotherapy, it can be 
concluded that immunotherapy will likely be of limited use for treatment at the 
chronic phase of the disease. Instead, immunotherapeutic interventions should 
be of greater benefit at an earlier stage, before onset of symptoms [110]. It is 
known that the lung undergoes profound changes during infancy driven by rap-
id growth and differentiation, establishing structure-function relationships that 
are central to respiratory health throughout the rest of life [111]. Accumulating 
evidence suggests that lung injury during this critical period may initiate devel-
opmental changes that are amplified during subsequent growth and eventually 
culminate in asthma. So, (immunotherapeutic) intervention at this early stage of 
disease development might have great impact on the final disease outcome. The 
key element of this strategy will be to predict which infants are most likely to 
progress towards adult asthma. Advances in susceptibly gene discovery will most 
certainly aid in identification of children that have a high risk to develop chronic 
allergic airway inflammation, together with large-scale prospective cohort stud-
ies, involving tracking of individual children over a period of years, from first 
manifestation of infant wheezing through to the development of persistent asth-
ma in adult life [112]. Together with increased understanding of DC biology, in 
particular in the area of CD4+ T cell polarization, this knowledge may ultimately 
result in DC-based vaccines to prevent atopic asthma.
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Summary
Asthma is a chronic disease of the lower airways, characterized by intermittent 
episodes of airway narrowing, causing symptoms of chest tightness, wheezing 
and shortness of breath. Although rarely life-threatening, the disease significant-
ly affects the quality of life and places a large economic burden on the healthcare 
system. Moreover, for yet unknown reasons, the disease is reaching epidemic 
proportions in the industrialized world.
Although the cause of asthma is complex and multifactorial, is it certain that the 
immune system provides a large contribution. The symptoms of asthma are cor-
related with inflammation of the lung tissue, as evidenced by the accumulation of 
cells of the immunesystem, such as eosinophils, mast cells, lymphocytes and den-
dritic cells. Mediators produced by these cells are also increased in the lungs of 
asthmatic patients. Several phases can be distinguished during the development 
of this disease Upon encounter with an allergen (any compound that can trigger 
a so-called allergic reaction), sentinel cells that line all tissues exposed to the 
outside world, termed dendritic cells (DCs) , take up the allergen and transport 
it to specialized organs of the body, lymph nodes. Here, DCs interact with CD4+ 
T lymphocytes that recognize the allergen, resulting in T cell activation. These 
T cells subsequently differentiate into a specialized subset of T cells, called Th2 
cells. These Th2 cells force another type of lymphocytes, B cells, to secrete al-
lergen-specific IgE that binds to mast cells. People susceptible to develop asthma 
are now said to be sensitized. Upon subsequent encounter with allergen during 
the so called challenge phase, this allergen binds to the IgE  bound to mast cells, 
which triggers the release of  all sorts of products responsible for immediate 
effect such as bronchoconstriction leading to airway narrowing and mucus pro-
duction, which plugs the airways. This immediate response is called the ‘early 
asthmatic reaction’ to allergen and is mainly mediated by mast cells. Moreover, 
local DCs can stimulate previously activated T cells which migrated to the site 
of inflammation. These stimulated Th2 cells in turn also secrete mediators re-
sponsible for characteristics ranging form mucus production to attracting and 
activating eosinophils. This phase occurs 3-6 hours after allergen challenge and 
is called the ‘late asthmatic reaction’. Repeated exposure to allergen leads to 
chronic inflammation and eventually leads to permanent alterations of the lung 
tissue. What probably was already deduced from the above mentioned sequence 
of events is the pivotal role of DCs and Th2 cells during the developmental as 
well established phases of the disease. Indeed, depletion of these cells in animal 
models of asthma completely abrogated the symptoms of this disease. 
Despite the wealth of information acquired in the last decades about the role 
of the immunologic component of the disease, current treatment is still rather 
crude and mainly consists of inhalation of corticosteroids, which non-specifically 
suppress the entire immune system, in combination with bronchodilators. Cor-
ticosteroids only suppress symptoms though, and do not cure the disease. Fur-
thermore, although current therapy is considered safe, some concerns remain 
about potential long-term use of corticosteriods in particular in the light of the 
chronic nature of the disease and the trend towards an earlier onset of therapy 
in children.
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In this thesis,  we investigated whether we could use dendritic cells to prevent de-
velopment of asthma or suppress established asthma, in an effort to more specifi-
cally target the immune pathways involved in airway inflammation. To that end, 
we used a previously established mouse model of asthma in which animals were 
sensitized to a model allergen by presentation of this allergen by DCs applied to 
the airways. In this way, we were able to deliver signals simultaneously with the 
allergen that modify the response of the allergen-specific T cells. In this thesis we 
have followed several strategies to modify the T cell response. 
In the context of asthma, T cells differentiate towards the so-called Th2 subset, as 
discussed above. However, another subset of T cells is the Th1 subset. This subset 
is involved in helping other cells of the immune system to fight off intracellular 
pathogens, e.g. viruses. Moreover, it was postulated that these subsets suppress 
each others’ development and function. Thus, Th1 cells suppress the formation 
and function of Th2 cells. Depending on the type of stimulus, DCs are potent in-
ducers of Th1 cells. If DCs are stimulated with Th1-inducing stimuli, DCs secrete 
soluble messengers molecules (cytokines) that act on T cells and drive Th1 differ-
entiation. A very important molecule in this regard is IL-12. To examine whether 
deviation towards a Th1 immune response protected against the development of 
asthma in mice, we incubated DCs with a compound derived from the cell wall of 
bacteria (LPS) know for its potent IL-12 production capacity by DCs. Indeed, as 
described in chapter 3, LPS stimulated DCs induce Th1 formation in a cell-cul-
ture system (in vitro) as well as in mice (in vivo), as judged by cytokine production 
patterns specific for Th1 cells. LPS stimulated DCs were also capable to reduce 
Th2-specific airway inflammation, with a reduction in Th2 cytokines, eosinophils 
and mucus production. Interestingly, production of IL-12 by LPS stimulated DCs 
was not necessary to reduce eosinophilic airway inflammation. It was suggested 
that endogenous cells could rescue IL-12 production, but repetition of the ex-
periments in mice deficient for IL-12 showed similar results. Thus, it can be con-
cluded that stimulating the formation of Th1 cells can suppress the development 
of Th2-dependent eosinophilic airway inflammation, but that IL-12 is not per se 
necessary for these suppressive effects.
However, as shown in chapter 4, IL-12 is sufficient to drive the Th1 differentia-
tion of naïve T cells. In this chapter, we transduced DCs with a retroviral vector 
harboring the genes encoding IL-12. In this way, DCs continuously produce high 
levels of IL-12. Analogous to LPS stimulated DCs, IL-12 transduced DCs have po-
tent Th1 skewing capabilities in vitro and efficiently inhibit the development of 
eosinophilic airway inflammation. The Th1 response in the lung was confirmed 
by quantitative analysis of expression levels in the lungs of a whole array of 
messenger molecules (cytokines and chemokines), which revealed an expression 
pattern consistent with previously published reported Th1 expression patterns. 
Unfortunately, injecting IL-12 producing DCs into pre-sensitized animals did not 
result in suppression of asthma symptoms but rather enhanced the disease.
To summarize, deviation of the immune response towards Th1was beneficial to 
suppress the development of asthma. However, inducing the formation of aller-
156
Su
m
m
ar
y
gen-specific Th1 cells in the presence allergen-specific Th2 cells worsened dis-
ease symptoms considerably, making this approach not suitable for treatment of 
established disease, which is the present situation in human patients. In addition, 
it can be questioned whether substituting one type of immune response (Th2) 
for another type (Th1)  is the most optimal treatment strategy.
To circumvent this problem, we also investigated an alternative strategy consist-
ing of direct suppression of allergen-specific Th2 lymphocytes. This strategy was 
based on a group of molecules collectively called ‘co-stimulators’. These mol-
ecules are expressed by DCs and together with antigen required to optimally 
activate T cells. However, recently new members of this family, called PD-L1 and 
PD-L2, have been discovered that possess inhibitory properties that inhibit T cell 
function instead of stimulating it. In this thesis, we examined whether overex-
pressing these molecules by DCs presenting a model allergen could inhibit T cell 
function in cell cultures as well as in our mouse model of asthma (chapter 5). The 
cell culture experiments showed no differences in T cell division, a marker for 
activation, when PD-L1 or PD-L2 overexpressing DCs were compared to mock-in-
fected DCs. However, levels of an important activation cytokine, IL-2, were lower. 
We next reasoned that expression levels of stimulatory co-stimulator molecules, 
notably CD80 and CD86, were too high to permit any inhibitory effect of  PD-L1 
or PD-L2. Therefore, we repeated the cell-culture experiments with DCs lack-
ing CD80 and CD86. However, even in the absence of these potent stimulatory 
molecules, PD-L1 or PD-L2 were not capable of inhibiting T cell division. Still, 
the consistent observation that PD-L1 and PD-L2 decrease IL-2 production by T 
cells suggested a suboptimal activation of T cells. To examine whether this would 
result in a suboptimal immune response in vivo, we sensitized mice in our asthma 
model with DCs overexpressing PD-L1 or PD-L2 and measured lung inflamma-
tion. We did not detect a significantly lower inflammation, indicating that despite 
the decreased IL-2 production in vitro, T cells were sufficiently activated in vivo 
to cause airway inflammation. 
Finally, we attempted to exploit for therapeutic purposes a phenomenon we ob-
served when we added a soluble form of the receptor for PD-L1 and PD-L2, PD-1, 
to DC-T cell cultures. When soluble PD-1 was present, T cells divided less and 
produced less IL-2, but the amount of the suppressive cytokine IL-10 in the cul-
ture was increased.. Subsequent dissection of the cell type involved demonstrat-
ed that soluble PD-1 acted upon DCs, which acquired a suppressive phenotype, 
secreting IL-10 and downregulating costimulatory molecules. This indicates the 
occurrence of a phenomenon  known as reverse signaling, where ligands (PD-L1 
and/or PD-L2) turn into receptors, and has also been described for homologous 
costimulatory ligands and their receptors such as CTLA-4 and CD28. Analysis of 
PD-L1 and PD-L2 expression on DCs isolated from asthmatic mice showed high 
expression of these ligands, prompting us to investigate the therapeutic effect of 
soluble PD-1 in our mouse model of asthma. We observed a slight decrease in 
the number of eosinophils obtained from lung fluid, and decreased levels of pro-
totypic Th2 messenger molecules, but this decrease is not sufficient to warrant 
therapeutic purposes (chapter 6).
In conclusion,  the concept of DC mediated immunotherapy directed against 
asthma still holds potential, as judged from chapters 3 to 6. However, some re-
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quirements need to be fulfilled before asthma immunotherapy becomes reality. 
First and foremost, the results presented in chapter 4 indicate that the timing of 
immunological intervention is an important parameter, i.e. the earlier the better. 
In this regard, it is currently not possibly to accurately predict which atopic chil-
dren progress from episodes of wheezing into full blown asthma and thus may 
qualify for immunotherapy. Longitudinal  cohort studies following up children 
from birth up into their teens are now underway and may yield prognostic tools 
that could help to better identify children at risk. Secondly, from chapters 3 and 
4 it is evident that although substituting a Th2 response with a Th1 response in-
hibits the development of allergic airway inflammation, it still represents a devia-
tion from the normal, non-inflamed, situation in the lung. The recent discovery of 
the involvement of regulatory T cells (Tregs) in allergic diseases might therefore 
offer new therapeutic strategies. Tregs are a subset of CD4+ T cells that suppress 
other cells of the immunesystem. It has been reported  that lung DCs are able 
to deliver signals that support the formation and activation of these cells that 
subsequently inhibit lung inflammation. However, before this approach can be 
applied in a clinical setting, more data is required about the DC-mediated signals 
that result in Treg formation/activation. Furthermore, the precise mechanism of 
Treg activation and target cells need to be elucidated, to avoid potentially dan-
gerous general immunesuppression. Providing that we can fill these specific gaps 
in our current knowledge, DCs based immunotherapy ultimately may become 
reality for an array of immunological disorders, including asthma. 
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Samenvatting
Astma is een chronische ontsteking van de luchtwegen die wordt gekarakteri-
seerd door periodieke luchtwegvernauwing resulterend in een drukkend gevoel 
op de borst, piepende ademhaling en benauwdheid. Ondanks dat deze ziekte 
zelden levensbedreigend is, kan de kwaliteit van leven ernstig worden aangetast 
en zijn de directe en indirecte kosten groot. Bovendien neemt de ziekte epide-
mische vormen aan in de westerse wereld. 
De precieze oorzaak van astma is complex en niet precies bekend. Wel is het 
zeker dat het immuunsysteem een grote bijdrage levert. De symptomen van ast-
ma correleren met ontstekingen in de longen, zoals kan worden afgeleid aan 
de ophoping van ontstekingscellen zoals eosinofielen, mestcellen, lymfocyten 
en dendritische cellen. Stoffen geproduceerd door deze cellen komen ook in 
verhoogde mate in de longen van astma patiënten voor. Verscheidende fasen 
kunnen worden onderscheiden in het verloop van de ziekte. Als de longen in 
contact komen met een allergeen (elke stof die een zogenoemde allergische re-
actie kan veroorzaken) wordt dit opgenomen door ‘schildwacht’ cellen die zich 
bevinden in alle weefsels die in contact staan met de buitenwereld. Deze cellen 
worden dendritische cellen (DCs) genoemd. Vervolgens transporteren DCs het 
allergeen naar gespecialiseerde organen van het lichaam, de lymfeklieren. Hier 
komen deze DCs in contact met CD4+ T lymfocyten die het allergeen herkennen 
wat leidt tot T cel activatie. Deze geactiveerde T cellen differentiëren vervolgens 
in een speciale subset van T cellen, de Th2 cellen. Stoffen geproduceerd door 
deze T cellen zetten een ander type lymfocyten, B cellen, aan tot de productie 
van allergeen-specifiek IgE dat bindt aan mest cellen. Vanaf dit moment spreekt 
men van sensibilisatie voor een specifiek allergeen. Bij ieder volgend contact met 
allergeen bindt dit aan het IgE op mestcellen. Hierdoor scheiden de mestcellen 
allerhande stoffen uit die verantwoordelijk zijn voor directe effecten in de longen 
zoals luchtwegvernauwing en slijm productie dat de luchtwegen verstopt. Deze 
eerste reactie op allergeen wordt de ‘vroege astmatische reactie’ genoemd en 
wordt voornamelijk veroorzaakt door mest cellen. Ook kunnen lokaal aanwezige 
DCs geactiveerde Th2 cellen stimuleren die naar de plek van de ontsteking zijn 
gemigreerd. Deze gestimuleerde T cellen produceren op hun beurt allerlei me-
diatoren verantwoordelijk voor allerhande ontstekingsprocessen, variërend van 
slijm productie tot het aantrekken en activeren van eosinofielen. Deze fase vindt 
3-6 uur na allergeen blootstelling plaats en wordt de ‘late astmatische reactie’ 
genoemd. Herhaalde blootstelling aan allergenen leidt tot chronische ontstek-
ing en uiteindelijk tot permanente veranderingen van het longweefsel. Wat kan 
worden afgeleid uit het bovenstaande is dat DCs en Th2 cellen een essentiële rol 
spelen in zowel ziekte ontwikkeling als het in stand houden van de symptomen. 
Dit wordt bevestigd in diermodellen van astma, waarbij deletie van deze cellen 
leidt tot het compleet verdwijnen van de ziekte symptomen.
Ondanks alle kennis die gedurende de laatste jaren is vergaard over de rol van 
het immuunsysteem in deze ziekte, is de huidige behandeling niet echt verfijnd en 
bestaat voornamelijk uit inhalatie van corticosteroïden, die op een niet-specifieke 
wijze het gehele immuun systeem onderdrukken, in combinatie met luchtwegver-
wijderaars. Door deze behandelwijze worden echter alleen de symptomen best-
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reden en niet de onderliggende oorzaken. Verder bestaan er, alhoewel de huidige 
therapie als veilig wordt beschouwd, zorgen over de lange-termijn effecten van 
langdurig steroïden gebruik. Dit vooral in het licht van de chronische aard van de 
ziekte en de trend om behandeling op steeds jongere leeftijd te beginnen.
In dit proefschrift is onderzochte of dendritische cellen gebruikt konden worden 
om het ontstaan van astma te voorkomen of bestaand astma te onderdrukken en 
daardoor op meer specifieke wijze te interveniëren in de immunologische proces-
sen betrokken bij de ontsteking in de longen. Om dit te realiseren is er gebruik 
gemaakt van een bestaand muizenmodel van astma waarin dieren worden gesen-
sibiliseerd tegen een model allergeen dat wordt gepresenteerd door DCs geïnjec-
teerd in de luchtwegen. Op deze wijze waren we in staat om de DCs, tegelijkertijd 
met het allergeen, specifieke signalen te laten afgeven die de respons van al-
lergeen-specifieke T cellen beïnvloeden. In dit proefschrift werden verschillende 
strategieën gevolgd teneinde de T cel respons te beïnvloeden.
In context van astma differentiëren T cellen naar de bovengenoemde Th2 subset. 
Echter, er bestaat nog een andere subset van T lymfocyten, de Th1 cellen. Deze 
subset is betrokken bij de afweer tegen intracellulaire ziekteverwekkers, b.v. vi-
russen. Er zijn bewijzen dat deze subsets elkaars formatie en functie afremmen. 
Dus, Th1 cellen onderdrukken de vorming en functie van Th2 cellen. DCs zijn, 
afhankelijk van het type stimulus, zeer goed in staat om T cellen richting Th1 te 
laten differentiëren. Blootstelling van DCs aan zogenaamde. Th1 stimuli leidt tot 
de secretie van boodschapper molekulen (cytokines) welke T cel differentiatie 
sturen richting de Th1 subset. Een belangrijke molecuul in dit verband is IL-12. 
Om te onderzoeken of een Th1 respons beschermt tegen de ontwikkeling van 
astma in muizen stelden we DCs bloot aan een celwand component van bacteriën 
(LPS) waarvan bekend is dat deze IL-12 produktie van DCs stimuleert. Inderdaad, 
zoals beschreven in hoofdstuk 3, kon uit het cytokine profiel worden afgeleid 
dat LPS-gestimuleerde DCs Th1 cellen induceerden in zowel een  laboratorium 
celkweek systeem (in vitro) alsmede in muizen (in vivo). LPS gestimuleerde DCs 
waren ook in staat om Th2-specifieke luchtwegontsteking te verminderen, met 
een vermindering van Th2 cytokinen, het aantal eosinofielen en slijmproductie. 
Interessant genoeg bleek dat IL-12 hiervoor niet nodig was. Hierop werd gesugg-
ereerd dat endogene cellen (van de muis zelf) de benodigde IL-12 produceerden, 
maar herhaling van de experimenten in muizen die geen IL-12 produceerden 
gaf dezelfde resultaten. Samenvattend kan hieruit geconcludeerd worden dat het 
stimuleren van de vorming van Th1 cellen de ontwikkeling van Th2-afhankelijke 
luchtwegontsteking kan voorkomen maar dat IL-12 hiervoor niet per se nodig 
is.
Echter, uit de resultaten beschreven in hoofdstuk 4 bleek dat IL-12 alleen vol-
doende is om de T cel ontwikkeling richting Th1 te sturen. Daartoe maakten 
we gebruik van een proces dat transductie wordt genoemd; het inbrengen van 
een gen in een cel door middel van een  (kreupel) virus.  In dit hoofdstuk trans-
duceerden we DCs met een retrovirale vector die genen coderend voor IL-12 bev-
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atte. Op deze manier produceerden DCs continu grote hoeveelheden IL-12. IL-12 
getransduceerde DCs waren, net als LPS gestimuleerde DCs, sterke Th1 inducers 
in vitro en remden de ontwikkeling van eosinofiele luchtwegontsteking. De Th1-
gemedieerde respons in de longen werd bevestigd door kwantitatieve analyse 
van de expressie niveaus van een reeks boodschapper moleculen (cytokinen en 
chemokinen) die typisch zijn voor een Th1 respons. Helaas bleken IL-12 produ-
cerende DCs niet in staat astma af te remmen als de muizen al gesensibiliseerd 
waren, maar werden de symptomen hierdoor alleen maar verergerd.
Samenvattend kan gezegd worden dat sturing van de immuunrespons richting 
Th1 in staat was om de vorming van astma te voorkomen, maar dat de vorming 
van allergeen-specifieke  Th1 cellen in de aanwezigheid van allergeen-specifieke 
Th2 cellen de ziekte verergerde. Hierdoor is deze strategie niet bruikbaar om 
bestaand astma te behandelen. Daarnaast kan men zich afvragen of het vervan-
gen van het ene type immuun respons (Th2)  door het andere (Th1) de meest 
ideale strategie is.
Om dit probleem te omzeilen is ook onderzocht of direkte afremming van aller-
geen-specifieke Th2 lymfocyten een mogelijkheid was om astma te voorkomen 
of te verminderen. Deze benadering was gebaseerd op een groep moleculen die 
‘co-stimulators’genoemd worden. Deze moleculen worden (onder andere) tot 
expressie gebracht door DCs  en zijn samen met het allergeen nodig voor een 
optimale activatie van T cellen. Echter, recentelijk zijn nieuwe leden van deze 
familie, PD-L1 en PD-L2, ontdekt die T cel activering afremmen in plaats van 
stimuleren. In dit proefschrift is onderzocht of overexpressie van deze molecu-
len door DCs die een model allergeen presenteerden aan T cellen leidde tot ver-
minderde T cel activatie, zowel in vitro alsmede in ons muizemodel van astma 
(hoofdstuk 5). Vergelijking van deze DCs met controle DCs liet geen verschillen 
zien in T cel deling (karakterisitiek voor T cel activatie). Echter, de hoeveelheden 
van een belangrijk activatie cytokine, IL-2, waren lager. Vervolgens redeneerden 
we dat expressie niveaus van positieve co-stimulators, met name CD80 en CD86, 
zodanig waren dat een eventueel remmend effect van PD-L1 en/of PD-L2 niet 
waarneembaar was.Hierop werden de celkweek experimenten herhaald met DCs 
die CD80 en CD86 misten. Maar zelfs in de afwezigheid van deze potente T cel 
stimulatoren waren PD-L1 en PD-L2 niet in staat om T cel deling te remmen. Ech-
ter, de consistent lagere IL-2 productie duidde op een suboptimale T cel activatie. 
Om te onderzoeken of dit ook leidde tot een suboptimale immuun respons in vivo 
werden muizen in ons astmamodel gesensibiliseerd met DCs die PD-L1 of PD-L2 
tot overexpressie brachten en vervolgens werd de mate van luchtwegontstek-
ing geanalyseerd.  Er was geen sprake van verminderderde ontsteking, waaruit 
geconcludeerd kan worden dat ondanks de lagere IL-2 productie in vitro T cellen 
in vivo voldoende waren geactiveerd om luchtweg inflammatie te veroorzaken.
Tenslotte werd er een poging ondernomen om astma af te remmen met behulp 
van de niet-membraan gebonden vorm (‘vrij’) van PD-1. Wanneer vrij PD1, de 
receptor voor PD-L1 en PD-L2 werd toegevoegd aan DC-T cel kweken deelden 
T cellen minder en produceerden minder IL-2, maar was er meer van het rem-
mende cytokine IL-10 aanwezig in de kweek. Uit vervolgonderzoek bleek dat 
vrij PD-1 deze effecten veroorzaakte via DCs, welke na incubatie met vrij PD-
1 een remmend karakter kregen bestaande uit verminderde expressie van co-
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stimulator moleculen en productie van IL-10. Dit duidt op het optreden van een 
fenomeen dat bekend staat als ‘reverse signaling’, waarbij liganden (PD-L1 en/of 
PD-L2) veranderen in receptoren en dat ook beschreven is voor homologe recep-
tor-ligand paren zoals CTLA-4 en CD28. Uit analyse van DCs geïsoleerd uit de 
longen van muizen met eosinofiele (astma) luchtwegontsteking bleek dat PD-L1 
en PD-L2 hoog tot expressie kwamen,waarop het effect van vrij PD-1 op astma 
in ons muizemodel werd onderzocht. Een lichte afname in het aantal eosinofielen 
in long spoelvloeistof werd gemeten, evenals verminderde hoeveelheden karak-
teristieke Th2 cytokines, maar deze vermindering lijkt echter onvoldoende voor 
therapeutische doeleinden (hoofdstuk 6). 
Concluderend bezit het concept van immunotherapie tegen astma met behulp 
van DCs potentieel, zoals kan worden afgeleid van hoofdstuk 3 t/m 6. Echter, 
er zal aan enkele voorwaarden voldaan moeten worden voordat astma immuno-
therapie realiteit wordt. Allereerst blijkt uit de resultaten van hoofdstuk 4 dat de 
timing van interventie een belangrijke parameter is; hoe vroeger hoe beter. In 
dit opzicht is het een probleem dat op het moment niet accuraat voorspeld kan 
worden welke allergische kinderen uiteindelijk astma ontwikkelen en daardoor 
in aanmerking komen voor immunotherapie. Er lopen momenteel longitudinale 
cohort studies die kinderen volgen vanaf de geboorte tot in de tienerjaren en die 
mogelijk leiden tot hulpmiddelen waarmee beter voorspeld kan worden welke 
kinderen uiteindelijk astma ontwikkelen. Ten tweede wordt uit hoofdstuk 3 en 4 
duidelijk dat ondanks dat vervanging van een Th2 respons door een Th1 respons 
de ontwikkeling van astma kan afremmen er nog steeds sprake is van een im-
muunrespons, wat een afwijking van de normale situatie (geen immuunrespons) 
inhoudt. De recent ontdekking dat regulatoire T cellen (Tregs) ook een rol spelen 
bij allergieën kan en aanknopingspunt zijn voor nieuwe behandelings mogeli-
jkheden. Tregs zijn een subset van CD4+ T cellen die andere cellen van het im-
muunsysteem onderdrukken. Er zijn aanwijzingen dat DCs uit de longen in staat 
zijn om het ontstaan en activatie van deze Tregs te bevorderen en dat deze cellen 
vervolgens luchtwegontsteking afremmen. Voordat deze strategie echter toege-
past kan worden in de kliniek moet er eerst meer bekend zijn over de precieze DC 
signalen die betrokken zijn bij Treg formatie/activatie. Verder moet er ook meer 
bekend zijn over de omstandigheden waarin deze cellen geactiveerd worden en 
welke het doelwit zijn van deze Treg cellen, om potentieel gevaarlijk niet-speci-
fieke onderdrukking van het immuunsysteem te voorkomen. Vooropgesteld dat 
we deze hiaten in onze kennis kunnen opvullen zou immunotherapie met behulp 
van DCs uiteindelijk realiteit kunnen worden voor een reeks van ziekten waarbij 
het immuunsysteem verstoord is, waaronder astma.
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7-AAD  7 aminoactinomycin
Ag   antigen
ALN   axillar lymph nodes
APC  antigen-presenting cell
APC   allophycocyanin
Ag   antigen
AICD   activation induced cell death
BAL   broncho alveolar lavage
BHR   bronchial hyperreactivity
BSA  bovine serum albumin
BM   bone marrow
CD   cluster of differentiation
CFSE   carboxy fluorescein diacetate succinimidylester
CM   culture medium
d   day
DC   dendritic cell
EDTA   ethylene-diamine-tetraacetic acid
ELISA  enzyme-linked immuno sorbent assay
FACS   fluorescence activated cell sorter
FSC   forward scatter
FITC   fluorescein isothiocyanate
Flt-3L   Flt-3 ligand
FCS   fetal calf serum
GFP   green fluorescent protein
GM-CSF  granulocyte-macrophage colony stimulating factor
h   hour
ICAM   intracellular adhesion molecule
IFN   interferon
IL  interleukin
i.p.   intraperitoneal
IP-10    interferon inducible protein-10
i.t.   intratracheal
i.v.   intravenous
LN   lymph node
LPS   lipopolysaccharide
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MACS   magnet activated cell sorting
mAb   monoclonal antibody
MHC   major histocompatibility complex
MLN   mediastinal lymph nodes
NK   natural killer cell
NKT   natural killer T cell
NF-kB   nuclear factor kB
OVA   Ovalbumin
PAMP   pathogen-associated molecular pattern
PAS   periodic acid-Schiff
PBS   phosphate-buffered saline
pDC   plasmacytoid DC
PE   phycoerythrin
PECy5   phycoerythrin-cychrome 5
PI   propidium iodide 
PRI   proliferation index
PRR   pattern-recognition receptor
RPMI   Roswell Park Memorial Institute medium
Sav   streptavidin
sCD40L  soluble CD40 ligand
SEM   standard error of the mean
STAT   Signal Transducers and Activators of Transcription
TCR   T cell receptor
Th   T helper cell
TLR   Toll-like receptor
TNF   tumor necrosis factor
Treg   regulatory T cell
WT   wild type
Het ‘boek-
je’ is af. Wat rest is 
het dankwoord. Niet het moei-
lijkste gedeelte zou je denken. Echter, de 
wetenschap dat dit het meest gelezen stukje is 
èn dat je niemand wil vergeten maken het schrij-
ven van een dankwoord niet zo makkelijk als het lijkt. 
Laat ik een poging wagen…
Allereerst professor Hoogsteden, die mij in de gelegenheid 
heeft gesteld om onderzoek te doen op de afdeling Longziekten 
waarvan hier het resultaat.
Daarnaast natuurlijk Bart Lambrecht, mijn co-promoter en begeleider op 
het lab. Beste Bart, ondanks de wat moeizame start van mijn promotie is het 
uiteindelijk toch gelukt, niet in het minst doordat je me altijd weer enthousi-
ast wist te maken als ik weer eens sceptisch en cynisch naar mijn data keek. En 
als dat nog niet genoeg was, wist je altijd wel weer uit je hoofd een referentie op 
te noemen waarin precies stond waarom je gelijk had…. Dit, gecombineerd met je 
ongeëvenaarde neus voor data die het nader uitzoeken waard zijn zullen een goede 
professor van je maken. Heel veel succes, DC minnend Nederland (en België) zullen nog 
veel van je horen! 
De overige leden van de lees-en promotiecommissie: prof.dr. Osterhaus, prof.dr. Drexhage, 
prof. dr. De Jongste, prof.dr. Thielemans, dr. Braakman en prof. dr. Coyle wil ik bedanken 
voor het beoordelen van mijn mansucript en/of te opponeren.
Promoveren doe je nooit alleen en dat geldt zeker ook voor de praktische zaken. Daarom is 
hier natuurlijk ook een plaatsje ingeruimd voor alle collega’s en oud-collega’s van Longziekten. 
Dat ik nu promoveer op dendritische cellen was aan het begin van mijn promotie helemaal niet 
de bedoeling! Jan-Bas, bedankt voor je begeleiding in het begin, maar ook voor je positivisme en 
relativeringsvermogen na mijn ‘valse start’. Dat heeft er zeker toe bijgedragen dat ik gebleven ben. 
Victor, ook jij bent al enige tijd geleden vertrokken. Bedankt voor de hulp met de vele secties en DC 
injecties en veel succes met je eigen promotie in de VS. Ook Sophia, alias ‘Dr Love’ werkt niet meer 
‘op de long’. Jammer, dat scheelt een  hoop lol en maakt het vinden van de longziekten groep in het 
bedrijfsrestaurant er ook niet makkelijker op.
Maar er zijn nog veel collega’s overgebleven en zelfs vele bijgekomen. 
Lous, Brigit, Hamida, Hendrik-Jan, Bianca, Leonie, Karolina, Nanda, Alex, Corine, Annabrita, Hermelijn, 
Marco, Tanja en Ivette. Bedankt voor alle hulp, adviezen (gewenst of ongewenst), de koffi  epauze ‘discus-
sies’ en niet te vergeten voor alle mooie labuitjes die er in de jaren geweest zijn. Enkele mensen wil ik 
nog in het bijzonder bedanken. Daniëlle, voor het doen van vele ELISAs, en later, de FACS sorteringen 
en de hlp met DNA cloneringen. Femke, voor het vullen van ontelbare qPCR welletjes (zonder fouten!) 
en voor al het (soms ondankbare) viruswerk. Gelukkig werkt het eindelijk! Monique, altijd lachend 
deed jij (weer) stapels ELISAs en anders was je niet te beroerd om te helpen met een sectie of weer 
wat longetjes te snijden. Zonder jou was het boekje half zo dik, ontzettend bedankt. Thomas ben ik 
dank verschuldigd voor al zijn hulp met het opzetten van -en meehelpen bij- wéér een experiment-
der-experimenten (‘heb jij de tickets voor Stockholm al geboekt?’) en niet te vergeten voor het feit 
dat je altijd voor kanonnenvoer wilde spelen na weer een mislukt experiment (half 5 bij de tank 
in Neuville?). Tot slot mijn roomies. Mirjam, bedankt voor alle vrolijkheid en gezelligheid 
(vooral ’s ochtends vroeg) en natuurlijk voor het feit dat je mannelijke kamergeno-
ten hun dagelijkse portie fruit krijgen. Joost, vanaf het 
prille begin al kamergenoten. On-
danks dat ik jou, Bep 
en Truus 
wat betreft 
onderzoeksonderwerp 
al snel gedag zei, heb ik heel veel van je 
geleerd wat betreft de fi jne kneepjes van het 
labwerk en was je daarnaast gewoon een super 
kamergenoot. Succes met je eigen laatste loodjes.
Not all my PhD time was spent in Rotterdam. I per-
formed the initial virus experiments at Millenium Pharma-
ceuticals in Boston. First of all, thanks to Tony Coyle for giv-
ing me the opportunity to work in his department for 3 months. 
I would also like to thank all the people in his department who took 
time to help me out, in particular Jane Tian and Steve Manning.
At the end of my PhD I had another chance to ‘escape’ Rotterdam, this time 
to master the art of Flexiventing in (not inconvenient) Perth in the lab of Peter 
Sly. I learned a lot about this technique, but I would also like to mention the 
eff ort you all at ICHR did to make us feel home, not only me but also Marieke. 
Thanks.
Gelukkig is het niet alleen werk wat de klok slaat. Zo was daar ook het ‘kliekje’ oud-
Wageningers waar regelmatig een biertje mee gedronken werd of een goeie fi lm be-
zocht (de ‘13th warrior’ is voor iedereen een aanrader). Met name Josien en Marieke M. 
bedankt, met wie het als (nu oud-) collega’s altijd goed klagen was hoe zwaar het leven 
van een AIO wel niet was (ach en wee). Bedankt allemaal.
Arne, Bram, Sander, Floris, Friso, Rutger, Wouter en Ad, alias Quark, een constante factor 
sinds Wageningen. Bedankt voor alle interesse, adviezen maar vooral de afl eiding van het 
werk. Three down, one to go..
Ruud en Hetty, bedankt voor de belangstelling voor mijn onderzoek en niet te vergeten die 
overheerlijke Indische rijsttafels in Rhoon.
Lieve Kristien, ondanks dat we in sommige opzichten elkaars tegenpolen zijn kan ik me geen 
betere zus wensen. Jij èn Marc bedankt voor de feestjes, skivakanties, KvK-avonden, kortom al 
die niet-curriculaire activiteiten die het leven zo leuk maken.
Lieve papa en mama, bedankt voor alle liefde, steun en vertrouwen (vooral in 4 VWO), anders 
hadden jullie nu geen exemplaar van dit ‘boekje’ ontvangen. Ik weet ‘t, het is een cliché, maar 
clichés zijn waar! 
Liefde is... 
... begrip  als ik weer eens zat te mokken over een mislukt experiment of met mijn gedachten
   er niet bij was
... zeggen dat promoveren wèl een knappe prestatie is
... niet boos worden als het een uurtje (of 2) later wordt door uitgelopen experimenten.
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